ASE Patent Due Diligence US8283155B2

APEX STANDARDS ENTERPRISE
Pseudo Claim Charting for Invalidity Checks

Patent: US8283155B2*
Filed: 2005-05-09
Issued: 2012-10-09
Original Patent Holder: (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC
Inventor(s): Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi

Title: Point-of-care fluidic systems and uses thereof

Abstract: This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications.

* References: Unified Patents, Prior Art published on Theranos patents now asserted by Fortress/Softbank against medical diagnostic companies (May 7, 2020), as well as, the Open Covid Pledge.

Disclaimer: Pseudo Claim Charting (PCC) provides aggressive mapping between a target patent's claim elements and other documents (potential technical standard contents or prior arts), therefore allowing for a top-down, apriori due diligence, with which, stakeholders can assess standard essentiality (potential strengths) or invalidity (potential weaknesses) quickly and effectively. PCC may relieve partial burden of proof but is NOT a litigation-ready work product.

Click on respective references to view claim charts.

Ground	References	Title	Term Nuances	Challenged Claims
Ground	References	Title	Term Nuances	1	2	3	8	9	10	11	12	13	14	16	17	18	19	22	23	30	31	32	37	38	39	40	41	42	43	45	48	49
1	US5130238A (Lawrence T. Malek, 1992)	Enhanced nucleic acid amplification process	▪ nucleic acid, nucleic acid reagents ≈ said nucleic acid								X	X															X	X
2	US5854033A (Paul M. Lizardi, 1998)	Rolling circle replication reporter systems	▪ nucleic acid ≈ nucleic acid								X	X															X	X
3	US5455166A (George T. Walker, 1995)	Strand displacement amplification	▪ nucleic acid, nucleic acid reagents ≈ stranded nucleic acid, nucleic acid fragment								X	X															X	X
4	US5942443A (John Wallace Parce, 1999)	High throughput screening assay systems in microscale fluidic devices	▪ analyte present ≈ said first component																X													X
5	US5797898A (John T. Santini, 1998)	Microchip drug delivery devices	▪ nucleic acid ≈ nucleic acid								X	X															X	X
6	US20010051766A1 (Robert Gazdzinski, 2001)	Endoscopic smart probe and method	▪ analyte present ≈ said first housing																X													X
7	US5885470A (John Wallace Parce, 1999)	Controlled fluid transport in microfabricated polymeric substrates	▪ 3 orders ≈ second planar substrate ▪ analyte present ≈ said polymeric material										X						X										X			X
8	US5270184A (George T. Walker, 1993)	Nucleic acid target generation	▪ nucleic acid, nucleic acid reagents ≈ stranded nucleic acid, nucleic acid fragment								X	X															X	X
9	US5674698A (David A. Zarling, 1997)	Up-converting reporters for biological and other assays using laser excitation techniques	▪ nucleic acid ≈ nucleic acid								X	X															X	X
10	US6440725B1 (Farzad Pourahmadi, 2002)	Integrated fluid manipulation cartridge	▪ nucleic acid ≈ nucleic acid								X	X															X	X
11	US6174675B1 (Calvin Y. H. Chow, 2001)	Electrical current for controlling fluid parameters in microchannels	▪ nucleic acid, nucleic acid reagents ≈ nucleic acid amplification reaction ▪ care location ≈ electrical power supply								X	X															X	X
12	US20040053290A1 (Robert Terbrueggen, 2004)	Devices and methods for biochip multiplexing	▪ nucleic acid, nucleic acid reagents ≈ nucleic acid amplification reaction ▪ board calibration ≈ printed circuit board								X	X															X	X
13	US6340588B1 (Michael P. Nova, 2002)	Matrices with memories	▪ nucleic acid ≈ nucleic acid								X	X															X	X
14	US6551838B2 (John T. Santini, 2003)	Microfabricated devices for the storage and selective exposure of chemicals and devices	▪ nucleic acid ≈ nucleic acid								X	X															X	X
15	US20050054078A1 (Cary Miller, 2005)	Immunoassay device with improved sample closure	▪ bodily fluid ≈ sample collection device	X				X										X		X				X						X	X
16	US5648211A (Melinda S. Fraiser, 1997)	Strand displacement amplification using thermophilic enzymes	▪ nucleic acid, nucleic acid reagents ≈ stranded nucleic acid, nucleic acid fragment								X	X															X	X
17	US6544732B1 (Mark S. Chee, 2003)	Encoding and decoding of array sensors utilizing nanocrystals	▪ nucleic acid ≈ nucleic acid								X	X															X	X
18	US20040005582A1 (Edward Shipwash, 2004)	Biospecific desorption microflow systems and methods for studying biospecific interactions and their modulators	▪ assay assembly ≈ amino acid sequence	X										X				X		X											X
19	US6591124B2 (Faiz Feisal Sherman, 2003)	Portable interstitial fluid monitoring system	▪ optical signal ≈ optical signal ▪ communication assembly ≈ said main body	X											X	X				X
20	US6361958B1 (Chan-Long Shieh, 2002)	Biochannel assay for hybridization with biomaterial	▪ nucleic acid, nucleic acid reagents ≈ said nucleic acid								X	X															X	X
21	US5939291A (Zvi Loewy, 1999)	Microfluidic method for nucleic acid amplification	▪ detection assembly ≈ target nucleic acids	X																X
22	US5527670A (Christopher J. Stanley, 1996)	Electrochemical denaturation of double-stranded nucleic acid	▪ nucleic acid, nucleic acid reagents ≈ stranded nucleic acid, said nucleic acid								X	X															X	X
23	US20030061687A1 (Carl Hansen, 2003)	High throughput screening of crystallization materials	▪ nucleic acid reagents ≈ first control line								X	X															X	X
24	US20020143437A1 (Kalyan Handique, 2002)	Methods and systems for control of microfluidic devices	▪ executable commands ≈ host computer system ▪ optical signal ≈ optical signal												X	X
25	US20020034757A1 (Roger Cubicciotti, 2002)	Single-molecule selection methods and compositions therefrom	▪ nucleic acid ≈ nucleic acid								X	X															X	X
26	US20040096959A1 (Matthias Stiene, 2004)	Analyte measurement	▪ communication assembly, detection method, detection assembly, detection method includes collecting signals ≈ electrically conductive material ▪ fluid movement ≈ selective fluid communication ▪ bodily fluid ≈ bodily fluid	X				X							X		X	X		X				X						X	X
27	US20050009101A1 (Gary Blackburn, 2005)	Microfluidic devices comprising biochannels	▪ optical signal ≈ optical signal												X	X
28	US6368275B1 (John W. Sliwa, 2002)	Method and apparatus for diagnostic medical information gathering, hyperthermia treatment, or directed gene therapy	▪ dilution chamber ≈ to receive signals ▪ therapeutic agent ≈ therapeutic agent																											X
29	US6156181A (John Wallace Parce, 2000)	Controlled fluid transport microfabricated polymeric substrates	▪ analyte present ≈ said polymeric material																X													X
30	US6245057B1 (Ulrich Sieben, 2001)	Device for treating malignant, tumorous tissue areas	▪ bodily fluid ≈ bodily fluid	X				X										X		X				X						X	X
31	US20020132226A1 (Vijay Nair, 2002)	Ingestible electronic capsule	▪ bodily fluid ≈ outer shell housing	X				X										X		X				X						X	X
32	US6887202B2 (John F. Currie, 2005)	Systems and methods for monitoring health and delivering drugs transdermally	▪ nucleic acid ≈ nucleic acid								X	X															X	X
33	US5976896A (Amit Kumar, 1999)	Immunoassays in capillary tubes	▪ analyte present ≈ analyte present																X													X
34	US6471916B1 (David Noblett, 2002)	Apparatus and method for calibration of a microarray scanning system	▪ test device, detection method ≈ optical detection device	X			X					X			X		X			X			X					X
35	US6352854B1 (Michael P. Nova, 2002)	Remotely programmable matrices with memories	▪ nucleic acid ≈ nucleic acid								X	X															X	X
36	US6482593B2 (David R. Walt, 2002)	Fiber optic biosensor for selectively detecting oligonucleotide species in a mixed fluid sample	▪ nucleic acid, nucleic acid reagents ≈ said nucleic acid ▪ sample collection unit ≈ second end face, first end face	X				X			X	X								X				X			X	X
37	US5687716A (Peter Kaufmann, 1997)	Selective differentiating diagnostic process based on broad data bases	▪ bodily fluid ≈ bodily fluid	X				X										X		X				X						X	X
38	US20030104590A1 ( John Santini, 2003)	Microfabricated devices for the storage and selective exposure of chemicals and devices	▪ nucleic acid ≈ nucleic acid								X	X															X	X
39	US6372428B1 (Michael P. Nova, 2002)	Remotely programmable matrices with memories	▪ detection method, controller having computer ≈ optical storage medium ▪ nucleic acid, nucleic acid reagents ≈ stranded nucleic acid	X							X	X			X		X										X	X
40	JP2003166910A (Keisuke Kamisaka, 2003)	送液機構及び該送液機構を備える分析装置	▪ optical signal ≈ の内部												X	X
41	CN2559986Y (温龙平, 2003)	集成微流体和微阵列探针的微芯片	▪ bodily fluid ≈ 微流体	X				X										X		X				X						X	X
42	JP2005010179A (Hideji Tajima, 2005)	容器	▪ communication assembly ≈ 少なくとも１ ▪ optical signal ≈ 放射状 ▪ detection assembly ≈ 受光部	X									X		X	X	X			X									X
43	JPH08211071A (Hideji Tajima, 1996)	自動分析装置及びその方法	▪ test device, detection method includes collecting signals ≈ 定位置 ▪ optical signal ≈ 放射状	X			X					X			X	X	X			X			X					X
44	EP0684315A1 (Melinda S. Fraiser, 1995)	Strand displacement amplification using thermophilic enzymes	▪ nucleic acid, nucleic acid reagents ≈ nucleic acid fragment, stranded nucleic acid, about 50 ° C								X	X															X	X
45	JP2003329696A (Takeshi Kono, 2003)	化学発光酵素免疫測定装置	▪ reader assembly, assay assembly ≈ 移動自在	X	X				X	X				X				X		X	X				X	X					X
46	JPH1157560A (Masaru Nitta, 1999)	液体散布車	▪ detection method, detection assembly ≈ 検出信号 ▪ way communication system ≈ 検出装置 ▪ dilution chamber ≈ 水平面	X											X		X			X										X
47	CN1526074A (乔斯坦・霍尔特伦德, 2004)	检测系统	▪ analyte present ≈ 检测试剂 ▪ assay assembly containing reactants ≈ 其中一种 ▪ board calibration ≈ 的并且	X						X									X	X						X						X
48	EP1203959A1 (Akira Kiguchi, 2002)	Analyzing cartridge and liquid feed control device	▪ test device, nucleic acid reagents, analyte present ≈ hydrophobic porous membrane	X			X				X	X							X	X			X				X	X				X
49	EP0723146A1 (designation of the inventor has not yet been filed The, 1996)	Up-converting reporters for biological and other assays using laser excitation techniques	▪ assay assembly containing reactants ≈ second electrical signal	X																X
50	JPH0727700A (Kakin Jiyo, 1995)	光学式成分濃度測定装置および方法	▪ detection method, detection assembly ≈ 検出手段, 受光部 ▪ test device ≈ 照射部	X			X					X			X		X			X			X					X
51	JP2004358261A (Cass A Hanson, 2004)	体液の抽出及びその抽出物中の分析物の監視のための装置、システム、及び方法	▪ bodily fluid ≈ 使い捨てカートリッジ ▪ communication assembly ≈ 少なくとも１	X				X										X		X				X						X	X
52	JP2003322653A (Seiji Imai, 2003)	プローブ固定支持体及びプローブ固定担体	▪ communication assembly ≈ 前記基	X																X
53	JP2003315348A (Tatsutoshi Imaoka, 2003)	検体処理システム及びそれを用いた検体検査自動化システム	▪ 3 orders ≈ 遠心分離										X																X
54	JPH10267888A (Yoshito Ikariyama, 1998)	バイオセンサ	▪ bodily fluid ≈ 過酸化水素 ▪ test device ≈ のパルス ▪ therapeutic agent ≈ 電極等	X			X	X				X						X		X			X	X				X		X	X
55	EP0564254A1 (Vincent A. Durante, 1993)	Polycyclic aromatic ring cleavage (parc) process	▪ dilution chamber ≈ Group VIII metals																											X
56	EP0478319A1 (Koji c/o Intellectual Property Div. Hashimoto, 1992)	Gene detection method	▪ nucleic acid, nucleic acid reagents ≈ said nucleic acid ▪ detection method ≈ detection method ▪ optical signal ≈ optical signal	X							X	X			X	X	X										X	X
57	CN1192567C (卡里·霍尼曼, 2005)	基于功率频谱密度估计的数据速率确定	▪ dilution chamber ≈ 包括下述																											X
58	JP2005030983A (Yoshihiro Kataoka, 2005)	測定装置	▪ programmable processor ≈ メモリ ▪ test device ≈ 試験片	X			X					X								X			X					X
59	CN1572320A (W·程, 2005)	利用药代动力学和药效模型进行红细胞生成素给药的方法	▪ detection assembly ≈ 或多个	X																X
60	JP2004333452A (Takashi Eto, 2004)	糖化タンパク質測定用試験片	▪ assay assembly containing reactants ≈ 酵素反応, １２〜	X																X
61	JP2004317498A (Yasuyuki Numajiri, 2004)	生化学反応カートリッジ及びその使用方法	▪ dilution chamber ≈ チャンバ内																											X
62	CN1499949A (M・斯蒂尼, 2004)	分析物测量	▪ analyte present ≈ 电化学传感器, 分析物的浓度 ▪ way communication system, bodily fluid ≈ 流体连通, 装置流体 ▪ board calibration ≈ 有效地形	X			X	X			X	X	X				X	X	X	X			X	X			X	X	X	X
63	JP2004028589A (Hisao Inami, 2004)	分析チップ及び分析装置	▪ communication assembly ≈ 前記基	X																X
64	JP2003222611A (Masakazu Baba, 2003)	分離装置、分離方法および分離装置の製造方法	▪ detection method ≈ 有する基板	X											X		X
65	JP2003207454A (Shunichi Hayamizu, 2003)	透過光検出装置	▪ detection assembly ≈ 光検出装置, 受光部 ▪ test device ≈ 照射部	X			X					X								X			X					X
66	CN1416528A (查德·斯蒂芬·格普哈特, 2003)	医疗诊断系统	▪ optical signal ≈ 电极之间 ▪ therapeutic agent ≈ 利用第一 ▪ reader assembly ≈ 网络接	X	X			X	X	X			X		X	X	X			X	X			X	X	X			X	X
67	JP2003057244A (Takehito Ito, 2003)	記録媒体およびこの記録媒体を用いた血糖測定システム	▪ turn effects ≈ 電源部と	X																X
68	JP2002282217A (Kazutoshi Tokunaga, 2002)	測定装置及びそれを含む測定結果管理システム	▪ detection method includes collecting signals ≈ バーコードリーダ														X
69	EP1202057A2 (Hans G. Kloepfer, 2002)	Solid state microcuvette using dry films	▪ therapeutic agent ≈ blood glucose level ▪ sample collection unit, analyte present ≈ red blood cells	X				X											X	X				X								X
70	JP2002044007A (Nobuhiro Takeda, 2002)	携帯電話機	▪ detection method, detection assembly ≈ 検出信号	X											X		X			X
71	JP2002010990A (Arkady Glukhovsky, 2002)	組織の電気的特性の計測	▪ test device ≈ インピーダン ▪ assay assembly containing reactants ≈ カップ状 ▪ optical signal ≈ の内部	X			X					X			X	X				X			X					X
72	JP2001165752A (Toshiyuki Ikeda, 2001)	血清量測定装置および測定方法	▪ detection method, detection assembly ≈ 検出手段	X											X		X			X
73	JP2000314719A (Akihiro Arai, 2000)	電気泳動チップ	▪ optical signal ≈ の内部												X	X
74	CN1262606A (D·D·坎宁安, 2000)	采集诊断测试用血的方法和设备	▪ way communication system, bodily fluid ≈ 流体连通 ▪ analyte present ≈ 分析物数 ▪ 3 orders ≈ 的位置	X				X					X					X	X	X				X					X	X	X	X
75	EP1002229A1 (Ron Blonder, 2000)	Electrochemical and photochemical electrodes and their use	▪ optical signal ≈ optical signal												X	X
76	CN1253625A (R·S·杜布罗, 2000)	改进了通道几何结构的微型流体装置	▪ nucleic acid reagents ≈ 基丙烯酸甲酯 ▪ programmable processor ≈ 将第一 ▪ therapeutic agent ≈ 二氧化	X				X			X	X						X		X				X			X	X		X	X
77	EP0962773A1 (Mark Howard Jones, 1999)	Electrochemical based assay processes instrument and labels	▪ care location ≈ electrical power supply ▪ nucleic acid ≈ nucleic acid								X	X															X	X
78	JPH10305016A (Toru Yamakita, 1998)	行動情報提供システム	▪ detection method, detection assembly ≈ 検出手段	X											X		X			X
79	JPH10239240A (Tomoharu Kajiyama, 1998)	自動ｄｎａプローブ装置	▪ detection assembly ≈ 光検出 ▪ s dosage ≈ 的結合	X																X
80	JPH1072628A (Harry W Ii Miller, 1998)	エアバッグ用インフレーターの再利用	▪ sample collection unit ≈ 金属部品	X				X												X				X
81	JPH09281078A (Yoshinori Mishina, 1997)	Ｄｎａ塩基配列決定装置	▪ effect trending ≈ なるＤＮＡ ▪ detection method, detection assembly ≈ 検出手段, 光検出	X		X									X		X			X		X
82	JPH09253056A (Masayuki Takahashi, 1997)	患者監視装置及び患者監視システム	▪ programmable processor ≈ メモリ	X																X
83	JPH09244055A (Masayasu Eto, 1997)	液晶表示装置	▪ detection method ≈ する合金	X											X		X
84	JPH09192218A (Toshiko Fujii, 1997)	血糖値管理システム	▪ communication assembly ≈ 少なくとも１ ▪ detection assembly ≈ 光検出	X																X
85	JPH09113511A (Shigeru Doi, 1997)	グリコアルブミン測定用乾式試験片	▪ test device ≈ 試験片	X			X					X								X			X					X
86	CN1146017A (神原秀记, 1997)	毛细管阵列电泳系统	▪ analyte present ≈ 一个毛细管 ▪ way communication system ≈ 一个激励 ▪ therapeutic agent ≈ 光照射	X				X											X	X				X								X
87	JPH0968533A (Masaki Yamaguchi, 1997)	薬品投与量を表示可能な生化学物質測定装置	▪ communication assembly ≈ 少なくとも１ ▪ detection method, detection assembly ≈ 検出手段	X											X		X			X
88	EP0734017A1 (Gary Gibson, 1996)	Storage device	▪ detection method, board calibration ≈ constant current source	X											X		X
89	JPH07196314A (Minoru Hanazaki, 1995)	チューブ状合成無機微粒子	▪ nucleic acid reagents ≈ ヒドロキシアパタイト, １０００ ▪ communication assembly ≈ 少なくとも１ ▪ therapeutic agent ≈ ストロン	X							X	X								X							X	X
90	JPH07151101A (Kazuo Sugimura, 1995)	ダイヤフラム接触面が渦巻状の容器	▪ detection method ≈ スタート	X											X		X
91	JPH07120393A (Yoshio Kawai, 1995)	蛍光検出法	▪ detection assembly ≈ 光検出	X																X
92	EP0652600A1 (Koji Eriguchi, 1995)	Aggregate of semiconductor micro-needles and method of manufacturing the same, and semiconductor apparatus and method of manufacturing the same	▪ optical signal ≈ optical signal												X	X
93	JPH07103959A (Kisaburo Deguchi, 1995)	クロマトグラム解析方法およびクロマトグラフ装置およびこれらに用いられるデータ処理装置	▪ programmable processor ≈ メモリ	X																X
94	EP0640828A1 (Russell G. Higuchi, 1995)	Monitoring multiple reactions simultaneously and analyzing same	▪ nucleic acid, nucleic acid reagents ≈ nucleic acid amplification reaction ▪ sample collection unit ≈ excitation light source	X				X			X	X								X				X			X	X
95	EP0631137A2 (Edward W. Stark, 1994)	Glucose related measurement method and apparatus	▪ assay assembly containing reactants ≈ second electrical signal	X																X
96	EP0576602A1 (James E Aysta, 1994)	A device and a method for separating liquid samples.	▪ nucleic acid ≈ nucleic acid								X	X															X	X
97	EP0571225A2 (Edwin B. Merrick, 1993)	Measurement device and method of calibration	▪ optical signal ≈ optical signal												X	X

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US5130238A Filed: 1989-08-23 Issued: 1992-07-14 Enhanced nucleic acid amplification process (Original Assignee) CANGENE CORP (Current Assignee) CANGENE CORP Lawrence T. Malek, Cheryl Davey, Graham Henderson, Roy Sooknanan
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (said nucleic acid) reagents immobilized within the assay assembly.	US5130238A CLAIM 14. A process according to claim 13, wherein step (D) comprises detecting said nucleic acid (nucleic acid, nucleic acid reagents) product using a nucleic acid probe.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (said nucleic acid) reagents for said plurality of analytes.	US5130238A CLAIM 14. A process according to claim 13, wherein step (D) comprises detecting said nucleic acid (nucleic acid, nucleic acid reagents) product using a nucleic acid probe.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (said nucleic acid) reagents immobilized within the assay assembly.	US5130238A CLAIM 14. A process according to claim 13, wherein step (D) comprises detecting said nucleic acid (nucleic acid, nucleic acid reagents) product using a nucleic acid probe.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (said nucleic acid) reagents for said plurality of analytes.	US5130238A CLAIM 14. A process according to claim 13, wherein step (D) comprises detecting said nucleic acid (nucleic acid, nucleic acid reagents) product using a nucleic acid probe.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US5854033A Filed: 1995-11-21 Issued: 1998-12-29 Rolling circle replication reporter systems (Original Assignee) Yale University (Current Assignee) Yale University Paul M. Lizardi
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US5854033A CLAIM 1. A method of amplifying nucleic acid (nucleic acid) sequences, the method comprising, (a) mixing a rolling circle replication primer with one or more amplification target circles(ATC), to produce a primer-ATC mixture, and incubating the primer-ATC mixture under conditions that promote hybridization between the amplification target circles and the rolling circle replication primer in the primer-ATC mixture, wherein the amplification target circles each comprise a single-stranded, circular DNA molecule comprising a primer complement portion, and wherein the primer complement portion is complementary to the rolling circle replication primer, wherein at least one of the amplification target circles is tethered to a specific binding molecule so that the amplification target circle can rotate freely, (b) mixing DNA polymerase with the primer-ATC mixture, to produce a polymerase-ATC mixture, and incubating the polymerase-ATC mixture under conditions that promote replication of the amplification target circles, wherein relication of the amplification target circles results in the formation of tandem sequence DNA, and, simultaneous with, or following, step (b), (c) mixing RNA polymerase with the polymerase-ATC mixture, and incubating the polymerase-ATC mixture under conditions that promote transcription of the tandem sequence DNA, wherein transcription of the tandem sequence DNA results in the formation of transcript RNA.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US5854033A CLAIM 1. A method of amplifying nucleic acid (nucleic acid) sequences, the method comprising, (a) mixing a rolling circle replication primer with one or more amplification target circles(ATC), to produce a primer-ATC mixture, and incubating the primer-ATC mixture under conditions that promote hybridization between the amplification target circles and the rolling circle replication primer in the primer-ATC mixture, wherein the amplification target circles each comprise a single-stranded, circular DNA molecule comprising a primer complement portion, and wherein the primer complement portion is complementary to the rolling circle replication primer, wherein at least one of the amplification target circles is tethered to a specific binding molecule so that the amplification target circle can rotate freely, (b) mixing DNA polymerase with the primer-ATC mixture, to produce a polymerase-ATC mixture, and incubating the polymerase-ATC mixture under conditions that promote replication of the amplification target circles, wherein relication of the amplification target circles results in the formation of tandem sequence DNA, and, simultaneous with, or following, step (b), (c) mixing RNA polymerase with the polymerase-ATC mixture, and incubating the polymerase-ATC mixture under conditions that promote transcription of the tandem sequence DNA, wherein transcription of the tandem sequence DNA results in the formation of transcript RNA.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US5854033A CLAIM 1. A method of amplifying nucleic acid (nucleic acid) sequences, the method comprising, (a) mixing a rolling circle replication primer with one or more amplification target circles(ATC), to produce a primer-ATC mixture, and incubating the primer-ATC mixture under conditions that promote hybridization between the amplification target circles and the rolling circle replication primer in the primer-ATC mixture, wherein the amplification target circles each comprise a single-stranded, circular DNA molecule comprising a primer complement portion, and wherein the primer complement portion is complementary to the rolling circle replication primer, wherein at least one of the amplification target circles is tethered to a specific binding molecule so that the amplification target circle can rotate freely, (b) mixing DNA polymerase with the primer-ATC mixture, to produce a polymerase-ATC mixture, and incubating the polymerase-ATC mixture under conditions that promote replication of the amplification target circles, wherein relication of the amplification target circles results in the formation of tandem sequence DNA, and, simultaneous with, or following, step (b), (c) mixing RNA polymerase with the polymerase-ATC mixture, and incubating the polymerase-ATC mixture under conditions that promote transcription of the tandem sequence DNA, wherein transcription of the tandem sequence DNA results in the formation of transcript RNA.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US5854033A CLAIM 1. A method of amplifying nucleic acid (nucleic acid) sequences, the method comprising, (a) mixing a rolling circle replication primer with one or more amplification target circles(ATC), to produce a primer-ATC mixture, and incubating the primer-ATC mixture under conditions that promote hybridization between the amplification target circles and the rolling circle replication primer in the primer-ATC mixture, wherein the amplification target circles each comprise a single-stranded, circular DNA molecule comprising a primer complement portion, and wherein the primer complement portion is complementary to the rolling circle replication primer, wherein at least one of the amplification target circles is tethered to a specific binding molecule so that the amplification target circle can rotate freely, (b) mixing DNA polymerase with the primer-ATC mixture, to produce a polymerase-ATC mixture, and incubating the polymerase-ATC mixture under conditions that promote replication of the amplification target circles, wherein relication of the amplification target circles results in the formation of tandem sequence DNA, and, simultaneous with, or following, step (b), (c) mixing RNA polymerase with the polymerase-ATC mixture, and incubating the polymerase-ATC mixture under conditions that promote transcription of the tandem sequence DNA, wherein transcription of the tandem sequence DNA results in the formation of transcript RNA.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US5455166A Filed: 1992-01-09 Issued: 1995-10-03 Strand displacement amplification (Original Assignee) Becton Dickinson and Co (Current Assignee) Becton Dickinson and Co George T. Walker
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (stranded nucleic acid, nucleic acid fragment) reagents immobilized within the assay assembly.	US5455166A CLAIM 1. A method for amplifying a target nucleic acid sequence comprising: a) providing a single stranded nucleic acid (nucleic acid, nucleic acid reagents) fragment containing the target nucleic acid sequence, the fragment having a 5' end and a 3' end; b) binding an oligonucleotide primer to the 3' end of the fragment such that the primer forms a 5' single stranded overhang, the primer comprising a 3' end complementary to the 3' end of the fragment and a 5' end comprising a recognition sequence for a restriction endonuclease which does not cut the target nucleic acid sequence; c) extending the primer on the fragment in the presence of i) a DNA polymerase lacking 5'-3' exonuclease activity, ii) deoxynucleoside triphosphates, iii) at least one α-thio substituted deoxynucleoside triphosphate, and iv) a restriction endonuclease selected from the group consisting of HincII, HindII, AvaI, Fnu4HI, Tth111I, NciI, BstXI, BsmI, BsrI, BsaI, NIaIV, NspI, PflMI, HphI, AlwI, FokI, DpnI, MspI and AccI, thereby producing a double stranded first reaction product comprising the primer, a first newly synthesized strand and a hemimodified restriction endonuclease recognition sequence; d) nicking the double stranded hemimodified restriction endonuclease recognition sequence with the restriction endonuclease; e) extending from the nick using the polymerase, thereby displacing the first newly synthesized strand from the first reaction product and generating a second newly synthesized strand, and; f) repeating the nicking, extending and displacing steps such that the target sequence is amplified.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (stranded nucleic acid, nucleic acid fragment) reagents for said plurality of analytes.	US5455166A CLAIM 1. A method for amplifying a target nucleic acid sequence comprising: a) providing a single stranded nucleic acid (nucleic acid, nucleic acid reagents) fragment containing the target nucleic acid sequence, the fragment having a 5' end and a 3' end; b) binding an oligonucleotide primer to the 3' end of the fragment such that the primer forms a 5' single stranded overhang, the primer comprising a 3' end complementary to the 3' end of the fragment and a 5' end comprising a recognition sequence for a restriction endonuclease which does not cut the target nucleic acid sequence; c) extending the primer on the fragment in the presence of i) a DNA polymerase lacking 5'-3' exonuclease activity, ii) deoxynucleoside triphosphates, iii) at least one α-thio substituted deoxynucleoside triphosphate, and iv) a restriction endonuclease selected from the group consisting of HincII, HindII, AvaI, Fnu4HI, Tth111I, NciI, BstXI, BsmI, BsrI, BsaI, NIaIV, NspI, PflMI, HphI, AlwI, FokI, DpnI, MspI and AccI, thereby producing a double stranded first reaction product comprising the primer, a first newly synthesized strand and a hemimodified restriction endonuclease recognition sequence; d) nicking the double stranded hemimodified restriction endonuclease recognition sequence with the restriction endonuclease; e) extending from the nick using the polymerase, thereby displacing the first newly synthesized strand from the first reaction product and generating a second newly synthesized strand, and; f) repeating the nicking, extending and displacing steps such that the target sequence is amplified.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (stranded nucleic acid, nucleic acid fragment) reagents immobilized within the assay assembly.	US5455166A CLAIM 1. A method for amplifying a target nucleic acid sequence comprising: a) providing a single stranded nucleic acid (nucleic acid, nucleic acid reagents) fragment containing the target nucleic acid sequence, the fragment having a 5' end and a 3' end; b) binding an oligonucleotide primer to the 3' end of the fragment such that the primer forms a 5' single stranded overhang, the primer comprising a 3' end complementary to the 3' end of the fragment and a 5' end comprising a recognition sequence for a restriction endonuclease which does not cut the target nucleic acid sequence; c) extending the primer on the fragment in the presence of i) a DNA polymerase lacking 5'-3' exonuclease activity, ii) deoxynucleoside triphosphates, iii) at least one α-thio substituted deoxynucleoside triphosphate, and iv) a restriction endonuclease selected from the group consisting of HincII, HindII, AvaI, Fnu4HI, Tth111I, NciI, BstXI, BsmI, BsrI, BsaI, NIaIV, NspI, PflMI, HphI, AlwI, FokI, DpnI, MspI and AccI, thereby producing a double stranded first reaction product comprising the primer, a first newly synthesized strand and a hemimodified restriction endonuclease recognition sequence; d) nicking the double stranded hemimodified restriction endonuclease recognition sequence with the restriction endonuclease; e) extending from the nick using the polymerase, thereby displacing the first newly synthesized strand from the first reaction product and generating a second newly synthesized strand, and; f) repeating the nicking, extending and displacing steps such that the target sequence is amplified.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (stranded nucleic acid, nucleic acid fragment) reagents for said plurality of analytes.	US5455166A CLAIM 1. A method for amplifying a target nucleic acid sequence comprising: a) providing a single stranded nucleic acid (nucleic acid, nucleic acid reagents) fragment containing the target nucleic acid sequence, the fragment having a 5' end and a 3' end; b) binding an oligonucleotide primer to the 3' end of the fragment such that the primer forms a 5' single stranded overhang, the primer comprising a 3' end complementary to the 3' end of the fragment and a 5' end comprising a recognition sequence for a restriction endonuclease which does not cut the target nucleic acid sequence; c) extending the primer on the fragment in the presence of i) a DNA polymerase lacking 5'-3' exonuclease activity, ii) deoxynucleoside triphosphates, iii) at least one α-thio substituted deoxynucleoside triphosphate, and iv) a restriction endonuclease selected from the group consisting of HincII, HindII, AvaI, Fnu4HI, Tth111I, NciI, BstXI, BsmI, BsrI, BsaI, NIaIV, NspI, PflMI, HphI, AlwI, FokI, DpnI, MspI and AccI, thereby producing a double stranded first reaction product comprising the primer, a first newly synthesized strand and a hemimodified restriction endonuclease recognition sequence; d) nicking the double stranded hemimodified restriction endonuclease recognition sequence with the restriction endonuclease; e) extending from the nick using the polymerase, thereby displacing the first newly synthesized strand from the first reaction product and generating a second newly synthesized strand, and; f) repeating the nicking, extending and displacing steps such that the target sequence is amplified.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US5942443A Filed: 1996-06-28 Issued: 1999-08-24 High throughput screening assay systems in microscale fluidic devices (Original Assignee) Caliper Technologies Corp (Current Assignee) Caliper Life Sciences Inc John Wallace Parce, Anne R. Kopf-Sill, Luc J. Bousse
US8283155B2 CLAIM 23. The method of claim 22 further comprising quantifying the amount of said analyte present (said first component) in said sample.	US5942443A CLAIM 28. The method of claim 27, wherein said first component (analyte present) of a biochemical system comprises an enzyme and said indicator compound comprises a substrate for said enzyme, wherein action of said enzyme on said substrate produces a detectable signal.
US8283155B2 CLAIM 49. The method of claim 48 further comprising quantifying the amount of said analyte present (said first component) in said sample.	US5942443A CLAIM 28. The method of claim 27, wherein said first component (analyte present) of a biochemical system comprises an enzyme and said indicator compound comprises a substrate for said enzyme, wherein action of said enzyme on said substrate produces a detectable signal.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US5797898A Filed: 1996-07-02 Issued: 1998-08-25 Microchip drug delivery devices (Original Assignee) Massachusetts Institute of Technology (Current Assignee) Massachusetts Institute of Technology John T. Santini, Jr., Michael J. Cima, Robert S. Langer
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US5797898A CLAIM 18. The method of claim 17 wherein the molecules are a drug selected from the group consisting of nucleic acid (nucleic acid) s, proteins, amino acids, polysaccharides, and organic or synthetic molecules.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US5797898A CLAIM 18. The method of claim 17 wherein the molecules are a drug selected from the group consisting of nucleic acid (nucleic acid) s, proteins, amino acids, polysaccharides, and organic or synthetic molecules.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US5797898A CLAIM 18. The method of claim 17 wherein the molecules are a drug selected from the group consisting of nucleic acid (nucleic acid) s, proteins, amino acids, polysaccharides, and organic or synthetic molecules.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US5797898A CLAIM 18. The method of claim 17 wherein the molecules are a drug selected from the group consisting of nucleic acid (nucleic acid) s, proteins, amino acids, polysaccharides, and organic or synthetic molecules.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US20010051766A1 Filed: 2001-03-26 Issued: 2001-12-13 Endoscopic smart probe and method (Original Assignee) Gazdzinski Robert F. (Current Assignee) West View Research LLC Robert Gazdzinski
US8283155B2 CLAIM 23. The method of claim 22 further comprising quantifying the amount of said analyte present (said first housing) in said sample.	US20010051766A1 CLAIM 10 . A probe for autonomously operating within a living body, comprising: a first probe housing element, and a second probe housing element disposed proximate to said first housing (analyte present) element, wherein said second probe element is adapted to move substantially independently of said first probe housing element.
US8283155B2 CLAIM 49. The method of claim 48 further comprising quantifying the amount of said analyte present (said first housing) in said sample.	US20010051766A1 CLAIM 10 . A probe for autonomously operating within a living body, comprising: a first probe housing element, and a second probe housing element disposed proximate to said first housing (analyte present) element, wherein said second probe element is adapted to move substantially independently of said first probe housing element.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US5885470A Filed: 1997-04-14 Issued: 1999-03-23 Controlled fluid transport in microfabricated polymeric substrates (Original Assignee) Caliper Technologies Corp (Current Assignee) Caliper Life Sciences Inc John Wallace Parce, Michael R. Knapp, Calvin Y. H. Chow, Luc Bousse
US8283155B2 CLAIM 14. The system of claim 13 wherein the system is configured to detect a plurality of analytes that generate distinct signals, wherein the intensities of said distinct signals vary over a range of 3 orders (second planar substrate) of magnitude.	US5885470A CLAIM 5. The microfluidic system of claim 1, wherein said polymeric body comprises: a first planar, polymeric substrate, having at least a first surface, said at least first and second intersecting channels being disposed in said surface; and a second planar substrate (3 orders) overlaying said first planar polymeric substrate, and sealably covering said at least first and second intersecting channels.
US8283155B2 CLAIM 23. The method of claim 22 further comprising quantifying the amount of said analyte present (said polymeric material) in said sample.	US5885470A CLAIM 9. The microfluidic system of claim 8, wherein said polymeric material (analyte present) comprises a fluorocarbon polymer, and said charged compound comprises a fluorinated buffer modifier.
US8283155B2 CLAIM 43. The system of claim 42 wherein the system is configured to detect a plurality of analytes that generate distinct signals, wherein the intensities of said distinct signals vary over a range of 3 orders (second planar substrate) of magnitude.	US5885470A CLAIM 5. The microfluidic system of claim 1, wherein said polymeric body comprises: a first planar, polymeric substrate, having at least a first surface, said at least first and second intersecting channels being disposed in said surface; and a second planar substrate (3 orders) overlaying said first planar polymeric substrate, and sealably covering said at least first and second intersecting channels.
US8283155B2 CLAIM 49. The method of claim 48 further comprising quantifying the amount of said analyte present (said polymeric material) in said sample.	US5885470A CLAIM 9. The microfluidic system of claim 8, wherein said polymeric material (analyte present) comprises a fluorocarbon polymer, and said charged compound comprises a fluorinated buffer modifier.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US5270184A Filed: 1991-11-19 Issued: 1993-12-14 Nucleic acid target generation (Original Assignee) Becton Dickinson and Co (Current Assignee) Becton Dickinson and Co George T. Walker, Michael C. Little, James G. Nadeau
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (stranded nucleic acid, nucleic acid fragment) reagents immobilized within the assay assembly.	US5270184A CLAIM 1. A method for generating an amplifying a nucleic acid fragment (nucleic acid, nucleic acid reagents) which comprises: (a) specifically hybridizing a first primer 5' to target nucleic acid sequence, the first primer containing a restriction enzyme recognition sequence 5' to a target binding region, (b) simultaneously with (a), hybridizing a second primer 5' to the first primer, (c) extending the first and second primer so that the first primer extension product is displaced from the target nucleic acid sequence by extension of the second primer, (d) making the first primer extension product double stranded by synthesizing a complementary strand, and (e) amplifying the first primer extension product in an amplification reaction in which the restriction enzyme recognition site of the double stranded nucleic acid (nucleic acid, nucleic acid reagents) fragment is nicked by a restriction enzyme.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (stranded nucleic acid, nucleic acid fragment) reagents for said plurality of analytes.	US5270184A CLAIM 1. A method for generating an amplifying a nucleic acid fragment (nucleic acid, nucleic acid reagents) which comprises: (a) specifically hybridizing a first primer 5' to target nucleic acid sequence, the first primer containing a restriction enzyme recognition sequence 5' to a target binding region, (b) simultaneously with (a), hybridizing a second primer 5' to the first primer, (c) extending the first and second primer so that the first primer extension product is displaced from the target nucleic acid sequence by extension of the second primer, (d) making the first primer extension product double stranded by synthesizing a complementary strand, and (e) amplifying the first primer extension product in an amplification reaction in which the restriction enzyme recognition site of the double stranded nucleic acid (nucleic acid, nucleic acid reagents) fragment is nicked by a restriction enzyme.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (stranded nucleic acid, nucleic acid fragment) reagents immobilized within the assay assembly.	US5270184A CLAIM 1. A method for generating an amplifying a nucleic acid fragment (nucleic acid, nucleic acid reagents) which comprises: (a) specifically hybridizing a first primer 5' to target nucleic acid sequence, the first primer containing a restriction enzyme recognition sequence 5' to a target binding region, (b) simultaneously with (a), hybridizing a second primer 5' to the first primer, (c) extending the first and second primer so that the first primer extension product is displaced from the target nucleic acid sequence by extension of the second primer, (d) making the first primer extension product double stranded by synthesizing a complementary strand, and (e) amplifying the first primer extension product in an amplification reaction in which the restriction enzyme recognition site of the double stranded nucleic acid (nucleic acid, nucleic acid reagents) fragment is nicked by a restriction enzyme.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (stranded nucleic acid, nucleic acid fragment) reagents for said plurality of analytes.	US5270184A CLAIM 1. A method for generating an amplifying a nucleic acid fragment (nucleic acid, nucleic acid reagents) which comprises: (a) specifically hybridizing a first primer 5' to target nucleic acid sequence, the first primer containing a restriction enzyme recognition sequence 5' to a target binding region, (b) simultaneously with (a), hybridizing a second primer 5' to the first primer, (c) extending the first and second primer so that the first primer extension product is displaced from the target nucleic acid sequence by extension of the second primer, (d) making the first primer extension product double stranded by synthesizing a complementary strand, and (e) amplifying the first primer extension product in an amplification reaction in which the restriction enzyme recognition site of the double stranded nucleic acid (nucleic acid, nucleic acid reagents) fragment is nicked by a restriction enzyme.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US5674698A Filed: 1995-03-30 Issued: 1997-10-07 Up-converting reporters for biological and other assays using laser excitation techniques (Original Assignee) SRI International (Current Assignee) SRI International ; Sarnoff Corp David A. Zarling, Michel J. Rossi, Norman A. Peppers, James Kane, Gregory W. Faris, Mark J. Dyer, Steve Y. Ng, Luke V. Schneider
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US5674698A CLAIM 33. The method of claim 32, wherein binding component-target complexes are localized to the contact surface by a method selected from the group consisting of: magnetic localization of magnetic beads to said contact surface, wherein said binding component-target complexes are localized on the magnetic beads relative to unbound labeled binding component; gravitational sedimentation of binding component-target complexes from unbound labelled binding component, wherein said sedimented binding component-target complexes are localized on the contact surface relative to unbound labeled binding component; filtration over a contact surface wherein said binding component-target complexes are localized on the contact surface relative to unbound labeled binding component; antibody capture; affinity adsorption; and nucleic acid (nucleic acid) hybridization.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US5674698A CLAIM 33. The method of claim 32, wherein binding component-target complexes are localized to the contact surface by a method selected from the group consisting of: magnetic localization of magnetic beads to said contact surface, wherein said binding component-target complexes are localized on the magnetic beads relative to unbound labeled binding component; gravitational sedimentation of binding component-target complexes from unbound labelled binding component, wherein said sedimented binding component-target complexes are localized on the contact surface relative to unbound labeled binding component; filtration over a contact surface wherein said binding component-target complexes are localized on the contact surface relative to unbound labeled binding component; antibody capture; affinity adsorption; and nucleic acid (nucleic acid) hybridization.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US5674698A CLAIM 33. The method of claim 32, wherein binding component-target complexes are localized to the contact surface by a method selected from the group consisting of: magnetic localization of magnetic beads to said contact surface, wherein said binding component-target complexes are localized on the magnetic beads relative to unbound labeled binding component; gravitational sedimentation of binding component-target complexes from unbound labelled binding component, wherein said sedimented binding component-target complexes are localized on the contact surface relative to unbound labeled binding component; filtration over a contact surface wherein said binding component-target complexes are localized on the contact surface relative to unbound labeled binding component; antibody capture; affinity adsorption; and nucleic acid (nucleic acid) hybridization.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US5674698A CLAIM 33. The method of claim 32, wherein binding component-target complexes are localized to the contact surface by a method selected from the group consisting of: magnetic localization of magnetic beads to said contact surface, wherein said binding component-target complexes are localized on the magnetic beads relative to unbound labeled binding component; gravitational sedimentation of binding component-target complexes from unbound labelled binding component, wherein said sedimented binding component-target complexes are localized on the contact surface relative to unbound labeled binding component; filtration over a contact surface wherein said binding component-target complexes are localized on the contact surface relative to unbound labeled binding component; antibody capture; affinity adsorption; and nucleic acid (nucleic acid) hybridization.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US6440725B1 Filed: 1999-06-25 Issued: 2002-08-27 Integrated fluid manipulation cartridge (Original Assignee) Cepheid Inc (Current Assignee) Cepheid Inc Farzad Pourahmadi, William A. McMillan, Jesus Ching, Ronald Chang, Lee A. Christel, Gregory T. A. Kovacs, M. Allen Northrup, Kurt E. Petersen
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US6440725B1 CLAIM 37. A device for separating nucleic acid (nucleic acid) from a fluid sample and for holding the nucleic acid for an amplification reaction, the device comprising: a) a cartridge having: i) a first flow path including: an extraction chamber containing at least one solid support for capturing the nucleic acid; and a waste chamber, downstream of the extraction chamber, for receiving waste fluid; ii) a second flow path for eluting the captured nucleic acid from the extraction chamber, wherein the second flow path passes through the extraction chamber and diverges from the first flow path after passing through the extraction chamber; and iii) at least one flow controller for directing the waste fluid into the waste chamber and for directing the eluted nucleic acid into the second flow path; and b) a reaction vessel coupled to the cartridge for receiving the eluted nucleic acid, the reaction vessel having a reaction chamber for holding the nucleic acid for the amplification reaction, and the reaction vessel being coupled to the cartridge such that the vessel protrudes from the body of the cartridge.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US6440725B1 CLAIM 37. A device for separating nucleic acid (nucleic acid) from a fluid sample and for holding the nucleic acid for an amplification reaction, the device comprising: a) a cartridge having: i) a first flow path including: an extraction chamber containing at least one solid support for capturing the nucleic acid; and a waste chamber, downstream of the extraction chamber, for receiving waste fluid; ii) a second flow path for eluting the captured nucleic acid from the extraction chamber, wherein the second flow path passes through the extraction chamber and diverges from the first flow path after passing through the extraction chamber; and iii) at least one flow controller for directing the waste fluid into the waste chamber and for directing the eluted nucleic acid into the second flow path; and b) a reaction vessel coupled to the cartridge for receiving the eluted nucleic acid, the reaction vessel having a reaction chamber for holding the nucleic acid for the amplification reaction, and the reaction vessel being coupled to the cartridge such that the vessel protrudes from the body of the cartridge.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US6440725B1 CLAIM 37. A device for separating nucleic acid (nucleic acid) from a fluid sample and for holding the nucleic acid for an amplification reaction, the device comprising: a) a cartridge having: i) a first flow path including: an extraction chamber containing at least one solid support for capturing the nucleic acid; and a waste chamber, downstream of the extraction chamber, for receiving waste fluid; ii) a second flow path for eluting the captured nucleic acid from the extraction chamber, wherein the second flow path passes through the extraction chamber and diverges from the first flow path after passing through the extraction chamber; and iii) at least one flow controller for directing the waste fluid into the waste chamber and for directing the eluted nucleic acid into the second flow path; and b) a reaction vessel coupled to the cartridge for receiving the eluted nucleic acid, the reaction vessel having a reaction chamber for holding the nucleic acid for the amplification reaction, and the reaction vessel being coupled to the cartridge such that the vessel protrudes from the body of the cartridge.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US6440725B1 CLAIM 37. A device for separating nucleic acid (nucleic acid) from a fluid sample and for holding the nucleic acid for an amplification reaction, the device comprising: a) a cartridge having: i) a first flow path including: an extraction chamber containing at least one solid support for capturing the nucleic acid; and a waste chamber, downstream of the extraction chamber, for receiving waste fluid; ii) a second flow path for eluting the captured nucleic acid from the extraction chamber, wherein the second flow path passes through the extraction chamber and diverges from the first flow path after passing through the extraction chamber; and iii) at least one flow controller for directing the waste fluid into the waste chamber and for directing the eluted nucleic acid into the second flow path; and b) a reaction vessel coupled to the cartridge for receiving the eluted nucleic acid, the reaction vessel having a reaction chamber for holding the nucleic acid for the amplification reaction, and the reaction vessel being coupled to the cartridge such that the vessel protrudes from the body of the cartridge.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US6174675B1 Filed: 1998-08-27 Issued: 2001-01-16 Electrical current for controlling fluid parameters in microchannels (Original Assignee) Caliper Technologies Corp (Current Assignee) Caliper Life Sciences Inc Calvin Y. H. Chow, Anne R. Kopf-Sill, John Wallace Parce
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid amplification reaction) reagents immobilized within the assay assembly.	US6174675B1 CLAIM 24. The system of claim 1 , wherein the first portion of the first channel comprises reagents for carrying out a nucleic acid amplification reaction (nucleic acid, nucleic acid reagents) .
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid amplification reaction) reagents for said plurality of analytes.	US6174675B1 CLAIM 24. The system of claim 1 , wherein the first portion of the first channel comprises reagents for carrying out a nucleic acid amplification reaction (nucleic acid, nucleic acid reagents) .
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid amplification reaction) reagents immobilized within the assay assembly.	US6174675B1 CLAIM 24. The system of claim 1 , wherein the first portion of the first channel comprises reagents for carrying out a nucleic acid amplification reaction (nucleic acid, nucleic acid reagents) .
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid amplification reaction) reagents for said plurality of analytes.	US6174675B1 CLAIM 24. The system of claim 1 , wherein the first portion of the first channel comprises reagents for carrying out a nucleic acid amplification reaction (nucleic acid, nucleic acid reagents) .

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US20040053290A1 Filed: 2003-04-11 Issued: 2004-03-18 Devices and methods for biochip multiplexing (Original Assignee) Clinical Micro Sensors Inc (Current Assignee) Clinical Micro Sensors Inc Robert Terbrueggen, Gary Blackburn, Marc Chason, Xunhu Dai, Manes Eliacin, Piotr Grodzinski, Bruce Irvine, Jon Kayyem, Keryn Lian, Robin Liu, Shawn O'Rourke, Edward Sheldon, Frederic Zenhausern
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid amplification reaction) reagents immobilized within the assay assembly.	US20040053290A1 CLAIM 5 . A biochip cartridge as in claim 1 wherein said reaction mixture is the product of an isothermal nucleic acid amplification reaction (nucleic acid, nucleic acid reagents) .
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid amplification reaction) reagents for said plurality of analytes.	US20040053290A1 CLAIM 5 . A biochip cartridge as in claim 1 wherein said reaction mixture is the product of an isothermal nucleic acid amplification reaction (nucleic acid, nucleic acid reagents) .
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid amplification reaction) reagents immobilized within the assay assembly.	US20040053290A1 CLAIM 5 . A biochip cartridge as in claim 1 wherein said reaction mixture is the product of an isothermal nucleic acid amplification reaction (nucleic acid, nucleic acid reagents) .
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid amplification reaction) reagents for said plurality of analytes.	US20040053290A1 CLAIM 5 . A biochip cartridge as in claim 1 wherein said reaction mixture is the product of an isothermal nucleic acid amplification reaction (nucleic acid, nucleic acid reagents) .

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US6340588B1 Filed: 1998-09-22 Issued: 2002-01-22 Matrices with memories (Original Assignee) Discovery Partners International Inc (Current Assignee) IRORI TECHNOLOGIES Inc Michael P. Nova, Hanan Potash
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US6340588B1 CLAIM 12. The library of claim 1 , wherein the molecules or biological particles are selected from the group consisting of monomers, nucleotides, amino acids, small molecules, antigens, antibodies, ligands, proteins, nucleic acid (nucleic acid) s, phage and viral particles, and cells.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US6340588B1 CLAIM 12. The library of claim 1 , wherein the molecules or biological particles are selected from the group consisting of monomers, nucleotides, amino acids, small molecules, antigens, antibodies, ligands, proteins, nucleic acid (nucleic acid) s, phage and viral particles, and cells.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US6340588B1 CLAIM 12. The library of claim 1 , wherein the molecules or biological particles are selected from the group consisting of monomers, nucleotides, amino acids, small molecules, antigens, antibodies, ligands, proteins, nucleic acid (nucleic acid) s, phage and viral particles, and cells.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US6340588B1 CLAIM 12. The library of claim 1 , wherein the molecules or biological particles are selected from the group consisting of monomers, nucleotides, amino acids, small molecules, antigens, antibodies, ligands, proteins, nucleic acid (nucleic acid) s, phage and viral particles, and cells.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US6551838B2 Filed: 2001-03-02 Issued: 2003-04-22 Microfabricated devices for the storage and selective exposure of chemicals and devices (Original Assignee) MicroChips Inc (Current Assignee) MICROCHIPS BIOTECH Inc John T. Santini, Jr., Norman F. Sheppard, Jr., Chung Chang Young, Robert S. Langer
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US6551838B2 CLAIM 10. The microchip device of claim 9 wherein the reacting component is selected from the group consisting of proteins, enzymes, nucleic acid (nucleic acid) s, and polysaccharides.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US6551838B2 CLAIM 10. The microchip device of claim 9 wherein the reacting component is selected from the group consisting of proteins, enzymes, nucleic acid (nucleic acid) s, and polysaccharides.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US6551838B2 CLAIM 10. The microchip device of claim 9 wherein the reacting component is selected from the group consisting of proteins, enzymes, nucleic acid (nucleic acid) s, and polysaccharides.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US6551838B2 CLAIM 10. The microchip device of claim 9 wherein the reacting component is selected from the group consisting of proteins, enzymes, nucleic acid (nucleic acid) s, and polysaccharides.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US20050054078A1 Filed: 2003-09-10 Issued: 2005-03-10 Immunoassay device with improved sample closure (Original Assignee) iStat Corp (Current Assignee) Abbott Point of Care Inc Cary Miller, Andy Maczuszenko
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid (sample collection device) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	US20050054078A1 CLAIM 1 . A method of sealing a fluid sample collection device (bodily fluid) , comprising: loading a fluid sample collection device with a fluid sample, said device comprising a housing having at least one substantially planar surface that includes an orifice in fluid communication with an internal fluid sample holding chamber which terminates at an internal capillary stop; and slidably moving a sealing element over at least a portion of said substantially planar surface in a way that displaces any excess fluid sample away from the orifice, seals the fluid sample within said holding chamber, and inhibits the fluid sample from prematurely breaking through the internal capillary stop.
US8283155B2 CLAIM 9. The system of claim 1 wherein the sample collection unit collects a sample of bodily fluid (sample collection device) which is less than about 500 uL.	US20050054078A1 CLAIM 1 . A method of sealing a fluid sample collection device (bodily fluid) , comprising: loading a fluid sample collection device with a fluid sample, said device comprising a housing having at least one substantially planar surface that includes an orifice in fluid communication with an internal fluid sample holding chamber which terminates at an internal capillary stop; and slidably moving a sealing element over at least a portion of said substantially planar surface in a way that displaces any excess fluid sample away from the orifice, seals the fluid sample within said holding chamber, and inhibits the fluid sample from prematurely breaking through the internal capillary stop.
US8283155B2 CLAIM 22. A method for detecting an analyte in a bodily fluid (sample collection device) of a subject, comprising: a) providing a system of claim 1 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	US20050054078A1 CLAIM 1 . A method of sealing a fluid sample collection device (bodily fluid) , comprising: loading a fluid sample collection device with a fluid sample, said device comprising a housing having at least one substantially planar surface that includes an orifice in fluid communication with an internal fluid sample holding chamber which terminates at an internal capillary stop; and slidably moving a sealing element over at least a portion of said substantially planar surface in a way that displaces any excess fluid sample away from the orifice, seals the fluid sample within said holding chamber, and inhibits the fluid sample from prematurely breaking through the internal capillary stop.
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid (sample collection device) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	US20050054078A1 CLAIM 1 . A method of sealing a fluid sample collection device (bodily fluid) , comprising: loading a fluid sample collection device with a fluid sample, said device comprising a housing having at least one substantially planar surface that includes an orifice in fluid communication with an internal fluid sample holding chamber which terminates at an internal capillary stop; and slidably moving a sealing element over at least a portion of said substantially planar surface in a way that displaces any excess fluid sample away from the orifice, seals the fluid sample within said holding chamber, and inhibits the fluid sample from prematurely breaking through the internal capillary stop.
US8283155B2 CLAIM 38. The system of claim 30 wherein the sample collection unit collects a sample of bodily fluid (sample collection device) which is less than about 500 uL.	US20050054078A1 CLAIM 1 . A method of sealing a fluid sample collection device (bodily fluid) , comprising: loading a fluid sample collection device with a fluid sample, said device comprising a housing having at least one substantially planar surface that includes an orifice in fluid communication with an internal fluid sample holding chamber which terminates at an internal capillary stop; and slidably moving a sealing element over at least a portion of said substantially planar surface in a way that displaces any excess fluid sample away from the orifice, seals the fluid sample within said holding chamber, and inhibits the fluid sample from prematurely breaking through the internal capillary stop.
US8283155B2 CLAIM 45. The system of claim 30 further comprising a dilution chamber containing a diluents for diluting the sample of bodily fluid (sample collection device) according to said protocol transmitted by the external device and received by the reader assembly.	US20050054078A1 CLAIM 1 . A method of sealing a fluid sample collection device (bodily fluid) , comprising: loading a fluid sample collection device with a fluid sample, said device comprising a housing having at least one substantially planar surface that includes an orifice in fluid communication with an internal fluid sample holding chamber which terminates at an internal capillary stop; and slidably moving a sealing element over at least a portion of said substantially planar surface in a way that displaces any excess fluid sample away from the orifice, seals the fluid sample within said holding chamber, and inhibits the fluid sample from prematurely breaking through the internal capillary stop.
US8283155B2 CLAIM 48. A method for detecting an analyte in a bodily fluid (sample collection device) of a subject, comprising: a) providing a system of claim 30 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	US20050054078A1 CLAIM 1 . A method of sealing a fluid sample collection device (bodily fluid) , comprising: loading a fluid sample collection device with a fluid sample, said device comprising a housing having at least one substantially planar surface that includes an orifice in fluid communication with an internal fluid sample holding chamber which terminates at an internal capillary stop; and slidably moving a sealing element over at least a portion of said substantially planar surface in a way that displaces any excess fluid sample away from the orifice, seals the fluid sample within said holding chamber, and inhibits the fluid sample from prematurely breaking through the internal capillary stop.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US5648211A Filed: 1994-04-18 Issued: 1997-07-15 Strand displacement amplification using thermophilic enzymes (Original Assignee) Becton Dickinson and Co (Current Assignee) Becton Dickinson and Co Melinda S. Fraiser, Catherine A. Spargo, George Terrance Walker, Mark Van Cleve, David James Wright, Michael C. Little
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (stranded nucleic acid, nucleic acid fragment) reagents immobilized within the assay assembly.	US5648211A CLAIM 1. A method for amplifying a target sequence comprising: A) providing a single stranded nucleic acid (nucleic acid, nucleic acid reagents) fragment containing the target sequence, the fragment having a 5' end and a 3' end; B) binding an amplification primer for SDA to the 3' end of the fragment such that the primer forms a 5' single stranded overhang, the amplification primer comprising a recognition/cleavage site for a thermophilic restriction endonuclease which does not cut the target nucleic acid sequence, and; C) amplifying the target sequence at 50° C.-60° C. in a reaction comprising the steps of i) extending the amplification primer on the fragment in the presence of a) a thermophilic DNA polymerase having a temperature optimum for polymerizing activity of 65° C.-75° C., the polymerase having strand displacing activity and lacking 5'-3' exonuclease activity, b) deoxynucleoside triphosphates, c) at least one derivatized deoxynucleoside triphosphate, and d) a thermophilic restriction endonuclease which nicks the recognition/cleavage site when the site is hemimodified by incorporation of the derivatized deoxynucleoside triphosphate, the endonuclease having a temperature optimum for cleavage of double-stranded DNA of 50° C.-65° C., thereby producing a first double stranded product comprising the amplification primer, a first newly synthesized strand complementary to the target sequence, and a double stranded hemimodified restriction endonuclease recognition/cleavage site; ii) nicking the double stranded hemimodified restriction endonuclease recognition/cleavage site with the restriction endonuclease; iii) extending from the nick using the DNA polymerase, thereby displacing the first newly synthesized strand from the fragment and generating a second extension product comprising a second newly synthesized strand, and; iv) repeating the nicking, extending and displacing steps such that the target sequence is amplified.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (stranded nucleic acid, nucleic acid fragment) reagents for said plurality of analytes.	US5648211A CLAIM 1. A method for amplifying a target sequence comprising: A) providing a single stranded nucleic acid (nucleic acid, nucleic acid reagents) fragment containing the target sequence, the fragment having a 5' end and a 3' end; B) binding an amplification primer for SDA to the 3' end of the fragment such that the primer forms a 5' single stranded overhang, the amplification primer comprising a recognition/cleavage site for a thermophilic restriction endonuclease which does not cut the target nucleic acid sequence, and; C) amplifying the target sequence at 50° C.-60° C. in a reaction comprising the steps of i) extending the amplification primer on the fragment in the presence of a) a thermophilic DNA polymerase having a temperature optimum for polymerizing activity of 65° C.-75° C., the polymerase having strand displacing activity and lacking 5'-3' exonuclease activity, b) deoxynucleoside triphosphates, c) at least one derivatized deoxynucleoside triphosphate, and d) a thermophilic restriction endonuclease which nicks the recognition/cleavage site when the site is hemimodified by incorporation of the derivatized deoxynucleoside triphosphate, the endonuclease having a temperature optimum for cleavage of double-stranded DNA of 50° C.-65° C., thereby producing a first double stranded product comprising the amplification primer, a first newly synthesized strand complementary to the target sequence, and a double stranded hemimodified restriction endonuclease recognition/cleavage site; ii) nicking the double stranded hemimodified restriction endonuclease recognition/cleavage site with the restriction endonuclease; iii) extending from the nick using the DNA polymerase, thereby displacing the first newly synthesized strand from the fragment and generating a second extension product comprising a second newly synthesized strand, and; iv) repeating the nicking, extending and displacing steps such that the target sequence is amplified.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (stranded nucleic acid, nucleic acid fragment) reagents immobilized within the assay assembly.	US5648211A CLAIM 1. A method for amplifying a target sequence comprising: A) providing a single stranded nucleic acid (nucleic acid, nucleic acid reagents) fragment containing the target sequence, the fragment having a 5' end and a 3' end; B) binding an amplification primer for SDA to the 3' end of the fragment such that the primer forms a 5' single stranded overhang, the amplification primer comprising a recognition/cleavage site for a thermophilic restriction endonuclease which does not cut the target nucleic acid sequence, and; C) amplifying the target sequence at 50° C.-60° C. in a reaction comprising the steps of i) extending the amplification primer on the fragment in the presence of a) a thermophilic DNA polymerase having a temperature optimum for polymerizing activity of 65° C.-75° C., the polymerase having strand displacing activity and lacking 5'-3' exonuclease activity, b) deoxynucleoside triphosphates, c) at least one derivatized deoxynucleoside triphosphate, and d) a thermophilic restriction endonuclease which nicks the recognition/cleavage site when the site is hemimodified by incorporation of the derivatized deoxynucleoside triphosphate, the endonuclease having a temperature optimum for cleavage of double-stranded DNA of 50° C.-65° C., thereby producing a first double stranded product comprising the amplification primer, a first newly synthesized strand complementary to the target sequence, and a double stranded hemimodified restriction endonuclease recognition/cleavage site; ii) nicking the double stranded hemimodified restriction endonuclease recognition/cleavage site with the restriction endonuclease; iii) extending from the nick using the DNA polymerase, thereby displacing the first newly synthesized strand from the fragment and generating a second extension product comprising a second newly synthesized strand, and; iv) repeating the nicking, extending and displacing steps such that the target sequence is amplified.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (stranded nucleic acid, nucleic acid fragment) reagents for said plurality of analytes.	US5648211A CLAIM 1. A method for amplifying a target sequence comprising: A) providing a single stranded nucleic acid (nucleic acid, nucleic acid reagents) fragment containing the target sequence, the fragment having a 5' end and a 3' end; B) binding an amplification primer for SDA to the 3' end of the fragment such that the primer forms a 5' single stranded overhang, the amplification primer comprising a recognition/cleavage site for a thermophilic restriction endonuclease which does not cut the target nucleic acid sequence, and; C) amplifying the target sequence at 50° C.-60° C. in a reaction comprising the steps of i) extending the amplification primer on the fragment in the presence of a) a thermophilic DNA polymerase having a temperature optimum for polymerizing activity of 65° C.-75° C., the polymerase having strand displacing activity and lacking 5'-3' exonuclease activity, b) deoxynucleoside triphosphates, c) at least one derivatized deoxynucleoside triphosphate, and d) a thermophilic restriction endonuclease which nicks the recognition/cleavage site when the site is hemimodified by incorporation of the derivatized deoxynucleoside triphosphate, the endonuclease having a temperature optimum for cleavage of double-stranded DNA of 50° C.-65° C., thereby producing a first double stranded product comprising the amplification primer, a first newly synthesized strand complementary to the target sequence, and a double stranded hemimodified restriction endonuclease recognition/cleavage site; ii) nicking the double stranded hemimodified restriction endonuclease recognition/cleavage site with the restriction endonuclease; iii) extending from the nick using the DNA polymerase, thereby displacing the first newly synthesized strand from the fragment and generating a second extension product comprising a second newly synthesized strand, and; iv) repeating the nicking, extending and displacing steps such that the target sequence is amplified.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US6544732B1 Filed: 1999-05-20 Issued: 2003-04-08 Encoding and decoding of array sensors utilizing nanocrystals (Original Assignee) Illumina Inc (Current Assignee) Illumina Inc Mark S. Chee, Steven M. Barnard, Chanfeng Zhao
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US6544732B1 CLAIM 9. A composition according to claim 8 wherein said bioactive agents comprise nucleic acid (nucleic acid) s.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US6544732B1 CLAIM 9. A composition according to claim 8 wherein said bioactive agents comprise nucleic acid (nucleic acid) s.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US6544732B1 CLAIM 9. A composition according to claim 8 wherein said bioactive agents comprise nucleic acid (nucleic acid) s.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US6544732B1 CLAIM 9. A composition according to claim 8 wherein said bioactive agents comprise nucleic acid (nucleic acid) s.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US20040005582A1 Filed: 2002-12-19 Issued: 2004-01-08 Biospecific desorption microflow systems and methods for studying biospecific interactions and their modulators (Original Assignee) NanoBioDynamics Inc (Current Assignee) NanoBioDynamics Inc Edward Shipwash
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly (amino acid sequence) containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	US20040005582A1 CLAIM 1 . A microfluidic biospecific desorption assay method for characterizing the binding site of a protein, said method comprising: (1) establishing a buffer flow through a microchannel in fluidic contact with an immobilized binding complex comprising a first immobilized binding pair member and a second labeled binding pair member; wherein one of the first or second members is the protein or a fragment of the protein; and wherein the protein or protein fragment is bound to the other binding pair member via the binding site; (2) introducing a polypeptide into the buffer flow; wherein the polypeptide has an amino acid subsequence of the protein; (3) detecting the desorption of the label following introduction of the polypeptide; and repeating steps (2) and (3) for each of a plurality of polypeptides of differing amino acid sequence (assay assembly) s, wherein at least one of the polypeptides comprises the binding site; whereby the polypeptide comprising the binding site is identified and the binding site is thereby localized to a portion of the protein having the amino acid sequence of the polypeptide comprising the binding site.
US8283155B2 CLAIM 16. The system of claim 1 wherein the assay assembly (amino acid sequence) is configured to run a plurality of types of assays.	US20040005582A1 CLAIM 1 . A microfluidic biospecific desorption assay method for characterizing the binding site of a protein, said method comprising: (1) establishing a buffer flow through a microchannel in fluidic contact with an immobilized binding complex comprising a first immobilized binding pair member and a second labeled binding pair member; wherein one of the first or second members is the protein or a fragment of the protein; and wherein the protein or protein fragment is bound to the other binding pair member via the binding site; (2) introducing a polypeptide into the buffer flow; wherein the polypeptide has an amino acid subsequence of the protein; (3) detecting the desorption of the label following introduction of the polypeptide; and repeating steps (2) and (3) for each of a plurality of polypeptides of differing amino acid sequence (assay assembly) s, wherein at least one of the polypeptides comprises the binding site; whereby the polypeptide comprising the binding site is identified and the binding site is thereby localized to a portion of the protein having the amino acid sequence of the polypeptide comprising the binding site.
US8283155B2 CLAIM 22. A method for detecting an analyte in a bodily fluid of a subject, comprising: a) providing a system of claim 1 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly (amino acid sequence) to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	US20040005582A1 CLAIM 1 . A microfluidic biospecific desorption assay method for characterizing the binding site of a protein, said method comprising: (1) establishing a buffer flow through a microchannel in fluidic contact with an immobilized binding complex comprising a first immobilized binding pair member and a second labeled binding pair member; wherein one of the first or second members is the protein or a fragment of the protein; and wherein the protein or protein fragment is bound to the other binding pair member via the binding site; (2) introducing a polypeptide into the buffer flow; wherein the polypeptide has an amino acid subsequence of the protein; (3) detecting the desorption of the label following introduction of the polypeptide; and repeating steps (2) and (3) for each of a plurality of polypeptides of differing amino acid sequence (assay assembly) s, wherein at least one of the polypeptides comprises the binding site; whereby the polypeptide comprising the binding site is identified and the binding site is thereby localized to a portion of the protein having the amino acid sequence of the polypeptide comprising the binding site.
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly (amino acid sequence) configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	US20040005582A1 CLAIM 1 . A microfluidic biospecific desorption assay method for characterizing the binding site of a protein, said method comprising: (1) establishing a buffer flow through a microchannel in fluidic contact with an immobilized binding complex comprising a first immobilized binding pair member and a second labeled binding pair member; wherein one of the first or second members is the protein or a fragment of the protein; and wherein the protein or protein fragment is bound to the other binding pair member via the binding site; (2) introducing a polypeptide into the buffer flow; wherein the polypeptide has an amino acid subsequence of the protein; (3) detecting the desorption of the label following introduction of the polypeptide; and repeating steps (2) and (3) for each of a plurality of polypeptides of differing amino acid sequence (assay assembly) s, wherein at least one of the polypeptides comprises the binding site; whereby the polypeptide comprising the binding site is identified and the binding site is thereby localized to a portion of the protein having the amino acid sequence of the polypeptide comprising the binding site.
US8283155B2 CLAIM 48. A method for detecting an analyte in a bodily fluid of a subject, comprising: a) providing a system of claim 30 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly (amino acid sequence) to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	US20040005582A1 CLAIM 1 . A microfluidic biospecific desorption assay method for characterizing the binding site of a protein, said method comprising: (1) establishing a buffer flow through a microchannel in fluidic contact with an immobilized binding complex comprising a first immobilized binding pair member and a second labeled binding pair member; wherein one of the first or second members is the protein or a fragment of the protein; and wherein the protein or protein fragment is bound to the other binding pair member via the binding site; (2) introducing a polypeptide into the buffer flow; wherein the polypeptide has an amino acid subsequence of the protein; (3) detecting the desorption of the label following introduction of the polypeptide; and repeating steps (2) and (3) for each of a plurality of polypeptides of differing amino acid sequence (assay assembly) s, wherein at least one of the polypeptides comprises the binding site; whereby the polypeptide comprising the binding site is identified and the binding site is thereby localized to a portion of the protein having the amino acid sequence of the polypeptide comprising the binding site.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US6591124B2 Filed: 2001-05-11 Issued: 2003-07-08 Portable interstitial fluid monitoring system (Original Assignee) Procter and Gamble Co (Current Assignee) Corium Inc Faiz Feisal Sherman, Francisco Arias, Vladimir Gartstein, Grover David Owens, Milan Marcel Jevtitch, Chow Chi Huang
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly (said main body) to said external device.	US6591124B2 CLAIM 8. A fluid sampling apparatus, comprising: (a) an attachable/detachable portion that includes a plurality of microneedles, a reservoir, an optical sensor pad, and an optical window; and (b) a main body portion that includes a receptacle to receive said attachable/detachable portion such that, when in position, the optical window faces said main body (communication assembly) portion and the plurality of microneedles are accessible; a light source and light detector; and a manually-operated control actuator mounted on a surface of said main body portion that causes fluid to flow proximal to said plurality of microneedles; wherein said reservoir receives fluid that flows through said plurality of microneedles upon manual operation of said control actuator, and said optical sensor pad exhibits a change in a physical property that is detected by said light detector as said light source shines light upon said optical sensor pad.
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method further comprises detecting an optical signal (optical signal) from the sample.	US6591124B2 CLAIM 20. The replaceable cartridge as recited in claim 19 , wherein said second signal comprises one of: (a) an electrical signal, (b) an acoustic signal, (c) a magnetic signal, or (d) an electromagnetic signal having a wavelength so as to be one of: (i) an optical signal (optical signal) , (ii) a microwave signal, or (iii) a radio-frequency signal.
US8283155B2 CLAIM 18. The system of claim 17 wherein the optical signal (optical signal) is a chemiluminscent signal.	US6591124B2 CLAIM 20. The replaceable cartridge as recited in claim 19 , wherein said second signal comprises one of: (a) an electrical signal, (b) an acoustic signal, (c) a magnetic signal, or (d) an electromagnetic signal having a wavelength so as to be one of: (i) an optical signal (optical signal) , (ii) a microwave signal, or (iii) a radio-frequency signal.
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly (said main body) to said external device.	US6591124B2 CLAIM 8. A fluid sampling apparatus, comprising: (a) an attachable/detachable portion that includes a plurality of microneedles, a reservoir, an optical sensor pad, and an optical window; and (b) a main body portion that includes a receptacle to receive said attachable/detachable portion such that, when in position, the optical window faces said main body (communication assembly) portion and the plurality of microneedles are accessible; a light source and light detector; and a manually-operated control actuator mounted on a surface of said main body portion that causes fluid to flow proximal to said plurality of microneedles; wherein said reservoir receives fluid that flows through said plurality of microneedles upon manual operation of said control actuator, and said optical sensor pad exhibits a change in a physical property that is detected by said light detector as said light source shines light upon said optical sensor pad.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US6361958B1 Filed: 1999-11-12 Issued: 2002-03-26 Biochannel assay for hybridization with biomaterial (Original Assignee) Motorola Solutions Inc (Current Assignee) Osmetech Technology Inc Chan-Long Shieh, Barbara Foley, Huinan Yu, Vi-en Choong
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (said nucleic acid) reagents immobilized within the assay assembly.	US6361958B1 CLAIM 15. A microfluidic device according to claim 14 wherein said nucleic acid (nucleic acid, nucleic acid reagents) is a DNA.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (said nucleic acid) reagents for said plurality of analytes.	US6361958B1 CLAIM 15. A microfluidic device according to claim 14 wherein said nucleic acid (nucleic acid, nucleic acid reagents) is a DNA.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (said nucleic acid) reagents immobilized within the assay assembly.	US6361958B1 CLAIM 15. A microfluidic device according to claim 14 wherein said nucleic acid (nucleic acid, nucleic acid reagents) is a DNA.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (said nucleic acid) reagents for said plurality of analytes.	US6361958B1 CLAIM 15. A microfluidic device according to claim 14 wherein said nucleic acid (nucleic acid, nucleic acid reagents) is a DNA.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US5939291A Filed: 1996-06-14 Issued: 1999-08-17 Microfluidic method for nucleic acid amplification (Original Assignee) Sarnoff Corp (Current Assignee) Sarnoff Corp Zvi Loewy, Rajan Kumar
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly (target nucleic acids) for detecting said signal which is transmitted via said communication assembly to said external device.	US5939291A CLAIM 1. An amplification device for target nucleic acids (detection assembly) comprising a reaction chamber and at least one supply chamber, wherein amplicons complementary to a target nucleic acid segment of the target nucleic acid are generated in a reaction chamber within the device and form duplex amplicons between complementary amplicons, and wherein denaturation of the duplex amplicons is effected in the reaction chamber by a chemical denaturant or an electrostatic process wherein the device further comprises: an electric field generating device effective to create a field at a reaction chamber of the device such that the strands of amplicons in that chamber separate, wherein the amplicons are each formed from first primer and a second primer, where the first primers have one charge and the second primers have the opposite charge.
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly (target nucleic acids) for detecting said signal which is transmitted via said communication assembly to said external device.	US5939291A CLAIM 1. An amplification device for target nucleic acids (detection assembly) comprising a reaction chamber and at least one supply chamber, wherein amplicons complementary to a target nucleic acid segment of the target nucleic acid are generated in a reaction chamber within the device and form duplex amplicons between complementary amplicons, and wherein denaturation of the duplex amplicons is effected in the reaction chamber by a chemical denaturant or an electrostatic process wherein the device further comprises: an electric field generating device effective to create a field at a reaction chamber of the device such that the strands of amplicons in that chamber separate, wherein the amplicons are each formed from first primer and a second primer, where the first primers have one charge and the second primers have the opposite charge.

US8283155B2

Filed: 2005-05-09 Issued: 2012-10-09

Point-of-care fluidic systems and uses thereof

(Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC

Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi

US5939291A

Filed: 1996-06-14 Issued: 1999-08-17

Microfluidic method for nucleic acid amplification

(Original Assignee) Sarnoff Corp (Current Assignee) Sarnoff Corp

Zvi Loewy, Rajan Kumar

US8283155B2
CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly (target nucleic acids) for detecting said signal which is transmitted via said communication assembly to said external device.

US5939291A
CLAIM 1. An amplification device for target nucleic acids (detection assembly) comprising a reaction chamber and at least one supply chamber, wherein amplicons complementary to a target nucleic acid segment of the target nucleic acid are generated in a reaction chamber within the device and form duplex amplicons between complementary amplicons, and wherein denaturation of the duplex amplicons is effected in the reaction chamber by a chemical denaturant or an electrostatic process wherein the device further comprises: an electric field generating device effective to create a field at a reaction chamber of the device such that the strands of amplicons in that chamber separate, wherein the amplicons are each formed from first primer and a second primer, where the first primers have one charge and the second primers have the opposite charge.

US8283155B2
CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly (target nucleic acids) for detecting said signal which is transmitted via said communication assembly to said external device.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US5527670A Filed: 1994-08-09 Issued: 1996-06-18 Electrochemical denaturation of double-stranded nucleic acid (Original Assignee) Sagentia Ltd (Current Assignee) Affymetrix Inc Christopher J. Stanley
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (stranded nucleic acid, said nucleic acid) reagents immobilized within the assay assembly.	US5527670A CLAIM 1. A process for denaturing double-stranded nucleic acid comprising the steps of: applying a voltage to a solution containing said nucleic acid (nucleic acid, nucleic acid reagents) with an electrode; and converting at least a proportion of said nucleic acid to a wholly or partially single stranded form so as to produce single-stranded nucleic acid in said solution not bound to said electrode, which single-stranded nucleic acid is capable of renaturation to double-stranded form.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (stranded nucleic acid, said nucleic acid) reagents for said plurality of analytes.	US5527670A CLAIM 1. A process for denaturing double-stranded nucleic acid comprising the steps of: applying a voltage to a solution containing said nucleic acid (nucleic acid, nucleic acid reagents) with an electrode; and converting at least a proportion of said nucleic acid to a wholly or partially single stranded form so as to produce single-stranded nucleic acid in said solution not bound to said electrode, which single-stranded nucleic acid is capable of renaturation to double-stranded form.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (stranded nucleic acid, said nucleic acid) reagents immobilized within the assay assembly.	US5527670A CLAIM 1. A process for denaturing double-stranded nucleic acid comprising the steps of: applying a voltage to a solution containing said nucleic acid (nucleic acid, nucleic acid reagents) with an electrode; and converting at least a proportion of said nucleic acid to a wholly or partially single stranded form so as to produce single-stranded nucleic acid in said solution not bound to said electrode, which single-stranded nucleic acid is capable of renaturation to double-stranded form.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (stranded nucleic acid, said nucleic acid) reagents for said plurality of analytes.	US5527670A CLAIM 1. A process for denaturing double-stranded nucleic acid comprising the steps of: applying a voltage to a solution containing said nucleic acid (nucleic acid, nucleic acid reagents) with an electrode; and converting at least a proportion of said nucleic acid to a wholly or partially single stranded form so as to produce single-stranded nucleic acid in said solution not bound to said electrode, which single-stranded nucleic acid is capable of renaturation to double-stranded form.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US20030061687A1 Filed: 2002-04-05 Issued: 2003-04-03 High throughput screening of crystallization materials (Original Assignee) California Institute of Technology (Current Assignee) California Institute of Technology ; University of California Carl Hansen, Stephen Quake, James Berger
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid reagents (first control line) immobilized within the assay assembly.	US20030061687A1 CLAIM 14 . The microfluidic structure of claim 13 further comprising: a first valve controlling fluidic communication through the first flow channel portion, the first valve defined by a first control line (nucleic acid reagents) crossing over the first flow channel portion, a first elastomer membrane between the first control line and the first flow channel portion actuable into the first flow channel portion; and a second valve controlling fluidic communication through the second flow channel portion, the second valve defined by a second control line crossing over the second flow channel portion, a second elastomer membrane between the second control line and the second flow channel portion actuable into the second flow channel portion, the first and second valves independently actuable to first allow diffusion between the target material solution and the crystallizing agent to form a crystal, and then to allow diffusion of the cryogen.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents (first control line) for said plurality of analytes.	US20030061687A1 CLAIM 14 . The microfluidic structure of claim 13 further comprising: a first valve controlling fluidic communication through the first flow channel portion, the first valve defined by a first control line (nucleic acid reagents) crossing over the first flow channel portion, a first elastomer membrane between the first control line and the first flow channel portion actuable into the first flow channel portion; and a second valve controlling fluidic communication through the second flow channel portion, the second valve defined by a second control line crossing over the second flow channel portion, a second elastomer membrane between the second control line and the second flow channel portion actuable into the second flow channel portion, the first and second valves independently actuable to first allow diffusion between the target material solution and the crystallizing agent to form a crystal, and then to allow diffusion of the cryogen.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid reagents (first control line) immobilized within the assay assembly.	US20030061687A1 CLAIM 14 . The microfluidic structure of claim 13 further comprising: a first valve controlling fluidic communication through the first flow channel portion, the first valve defined by a first control line (nucleic acid reagents) crossing over the first flow channel portion, a first elastomer membrane between the first control line and the first flow channel portion actuable into the first flow channel portion; and a second valve controlling fluidic communication through the second flow channel portion, the second valve defined by a second control line crossing over the second flow channel portion, a second elastomer membrane between the second control line and the second flow channel portion actuable into the second flow channel portion, the first and second valves independently actuable to first allow diffusion between the target material solution and the crystallizing agent to form a crystal, and then to allow diffusion of the cryogen.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents (first control line) for said plurality of analytes.	US20030061687A1 CLAIM 14 . The microfluidic structure of claim 13 further comprising: a first valve controlling fluidic communication through the first flow channel portion, the first valve defined by a first control line (nucleic acid reagents) crossing over the first flow channel portion, a first elastomer membrane between the first control line and the first flow channel portion actuable into the first flow channel portion; and a second valve controlling fluidic communication through the second flow channel portion, the second valve defined by a second control line crossing over the second flow channel portion, a second elastomer membrane between the second control line and the second flow channel portion actuable into the second flow channel portion, the first and second valves independently actuable to first allow diffusion between the target material solution and the crystallizing agent to form a crystal, and then to allow diffusion of the cryogen.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US20020143437A1 Filed: 2001-03-28 Issued: 2002-10-03 Methods and systems for control of microfluidic devices (Original Assignee) HandyLab Inc (Current Assignee) HandyLab Inc Kalyan Handique, Karthik Ganesan, Sundaresh Brahmasandra
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method further comprises detecting an optical signal (optical signal) from the sample.	US20020143437A1 CLAIM 2 . The method of claim 1 wherein the control signals comprise electrical and optical signal (optical signal) s.
US8283155B2 CLAIM 18. The system of claim 17 wherein the optical signal (optical signal) is a chemiluminscent signal.	US20020143437A1 CLAIM 2 . The method of claim 1 wherein the control signals comprise electrical and optical signal (optical signal) s.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US20020034757A1 Filed: 2001-07-17 Issued: 2002-03-21 Single-molecule selection methods and compositions therefrom (Original Assignee) Cubicciotti Roger S. Roger Cubicciotti
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US20020034757A1 CLAIM 6 . The synthetic heteropolymer of claim 1 wherein the second defined sequence segment is capable of specifically recognizing a second selected nonoligonucleotide molecule or a selected nucleic acid (nucleic acid) sequence.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US20020034757A1 CLAIM 6 . The synthetic heteropolymer of claim 1 wherein the second defined sequence segment is capable of specifically recognizing a second selected nonoligonucleotide molecule or a selected nucleic acid (nucleic acid) sequence.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US20020034757A1 CLAIM 6 . The synthetic heteropolymer of claim 1 wherein the second defined sequence segment is capable of specifically recognizing a second selected nonoligonucleotide molecule or a selected nucleic acid (nucleic acid) sequence.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US20020034757A1 CLAIM 6 . The synthetic heteropolymer of claim 1 wherein the second defined sequence segment is capable of specifically recognizing a second selected nonoligonucleotide molecule or a selected nucleic acid (nucleic acid) sequence.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US20040096959A1 Filed: 2003-12-29 Issued: 2004-05-20 Analyte measurement (Original Assignee) LifeScan Scotland Ltd (Current Assignee) Lifescan IP Holdings LLC Matthias Stiene, Tanja Richter, John Allen, Jerome McAleer
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid (bodily fluid) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method (electrically conductive material) for detecting said signal, and wherein said reader further comprises a detection assembly (electrically conductive material) for detecting said signal which is transmitted via said communication assembly (electrically conductive material) to said external device.	US20040096959A1 CLAIM 17 . A device for measuring the concentration of an analyte in a bodily fluid (bodily fluid) , comprising skin penetration means, said penetration means being sufficiently short so as to penetrate only the cutaneous layer of skin without penetrating the sub-cutaneous layer, and a support member, said support member comprising an analyte sensing site and a microchannel for conducting said body fluid from said penetration member to said analyte sensing site. US20040096959A1 CLAIM 82 . A method of making a device for measuring the concentration of a substance in a liquid comprising forming a first channel in a substrate material, fitting said channel at least partially with an electrically conductive material (communication assembly, detection method, detection assembly, detection method includes collecting signals) , and forming a second channel so as to intersect said first channel, thereby forming two conductive portions on respective opposite sides of the second channel.
US8283155B2 CLAIM 9. The system of claim 1 wherein the sample collection unit collects a sample of bodily fluid (bodily fluid) which is less than about 500 uL.	US20040096959A1 CLAIM 17 . A device for measuring the concentration of an analyte in a bodily fluid (bodily fluid) , comprising skin penetration means, said penetration means being sufficiently short so as to penetrate only the cutaneous layer of skin without penetrating the sub-cutaneous layer, and a support member, said support member comprising an analyte sensing site and a microchannel for conducting said body fluid from said penetration member to said analyte sensing site.
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method (electrically conductive material) further comprises detecting an optical signal from the sample.	US20040096959A1 CLAIM 82 . A method of making a device for measuring the concentration of a substance in a liquid comprising forming a first channel in a substrate material, fitting said channel at least partially with an electrically conductive material (communication assembly, detection method, detection assembly, detection method includes collecting signals) , and forming a second channel so as to intersect said first channel, thereby forming two conductive portions on respective opposite sides of the second channel.
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method (electrically conductive material) includes collecting signals from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	US20040096959A1 CLAIM 82 . A method of making a device for measuring the concentration of a substance in a liquid comprising forming a first channel in a substrate material, fitting said channel at least partially with an electrically conductive material (communication assembly, detection method, detection assembly, detection method includes collecting signals) , and forming a second channel so as to intersect said first channel, thereby forming two conductive portions on respective opposite sides of the second channel.
US8283155B2 CLAIM 22. A method for detecting an analyte in a bodily fluid (bodily fluid) of a subject, comprising: a) providing a system of claim 1 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	US20040096959A1 CLAIM 17 . A device for measuring the concentration of an analyte in a bodily fluid (bodily fluid) , comprising skin penetration means, said penetration means being sufficiently short so as to penetrate only the cutaneous layer of skin without penetrating the sub-cutaneous layer, and a support member, said support member comprising an analyte sensing site and a microchannel for conducting said body fluid from said penetration member to said analyte sensing site.
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid (bodily fluid) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly (electrically conductive material) for detecting said signal which is transmitted via said communication assembly (electrically conductive material) to said external device.	US20040096959A1 CLAIM 17 . A device for measuring the concentration of an analyte in a bodily fluid (bodily fluid) , comprising skin penetration means, said penetration means being sufficiently short so as to penetrate only the cutaneous layer of skin without penetrating the sub-cutaneous layer, and a support member, said support member comprising an analyte sensing site and a microchannel for conducting said body fluid from said penetration member to said analyte sensing site. US20040096959A1 CLAIM 82 . A method of making a device for measuring the concentration of a substance in a liquid comprising forming a first channel in a substrate material, fitting said channel at least partially with an electrically conductive material (communication assembly, detection method, detection assembly, detection method includes collecting signals) , and forming a second channel so as to intersect said first channel, thereby forming two conductive portions on respective opposite sides of the second channel.
US8283155B2 CLAIM 38. The system of claim 30 wherein the sample collection unit collects a sample of bodily fluid (bodily fluid) which is less than about 500 uL.	US20040096959A1 CLAIM 17 . A device for measuring the concentration of an analyte in a bodily fluid (bodily fluid) , comprising skin penetration means, said penetration means being sufficiently short so as to penetrate only the cutaneous layer of skin without penetrating the sub-cutaneous layer, and a support member, said support member comprising an analyte sensing site and a microchannel for conducting said body fluid from said penetration member to said analyte sensing site.
US8283155B2 CLAIM 45. The system of claim 30 further comprising a dilution chamber containing a diluents for diluting the sample of bodily fluid (bodily fluid) according to said protocol transmitted by the external device and received by the reader assembly.	US20040096959A1 CLAIM 17 . A device for measuring the concentration of an analyte in a bodily fluid (bodily fluid) , comprising skin penetration means, said penetration means being sufficiently short so as to penetrate only the cutaneous layer of skin without penetrating the sub-cutaneous layer, and a support member, said support member comprising an analyte sensing site and a microchannel for conducting said body fluid from said penetration member to said analyte sensing site.
US8283155B2 CLAIM 48. A method for detecting an analyte in a bodily fluid (bodily fluid) of a subject, comprising: a) providing a system of claim 30 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	US20040096959A1 CLAIM 17 . A device for measuring the concentration of an analyte in a bodily fluid (bodily fluid) , comprising skin penetration means, said penetration means being sufficiently short so as to penetrate only the cutaneous layer of skin without penetrating the sub-cutaneous layer, and a support member, said support member comprising an analyte sensing site and a microchannel for conducting said body fluid from said penetration member to said analyte sensing site.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US20050009101A1 Filed: 2004-07-07 Issued: 2005-01-13 Microfluidic devices comprising biochannels (Original Assignee) Motorola Solutions Inc (Current Assignee) Motorola Solutions Inc Gary Blackburn
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method further comprises detecting an optical signal (optical signal) from the sample.	US20050009101A1 CLAIM 11 . A microfluidic device according to claim 1 , further comprising an optical signal (optical signal) detector.
US8283155B2 CLAIM 18. The system of claim 17 wherein the optical signal (optical signal) is a chemiluminscent signal.	US20050009101A1 CLAIM 11 . A microfluidic device according to claim 1 , further comprising an optical signal (optical signal) detector.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US6368275B1 Filed: 1999-10-07 Issued: 2002-04-09 Method and apparatus for diagnostic medical information gathering, hyperthermia treatment, or directed gene therapy (Original Assignee) Acuson Corp (Current Assignee) Acuson Corp ; Siemens Medical Solutions USA Inc John W. Sliwa, William R. Dreschel
US8283155B2 CLAIM 45. The system of claim 30 further comprising a dilution chamber (to receive signals) containing a diluents for diluting the sample of bodily fluid according to said protocol transmitted by the external device and received by the reader assembly.	US6368275B1 CLAIM 14. A medical diagnostic ultrasound system for observing a physiological property of a body, the system comprising: a transducer operable to transmit energy into the body; a plurality of micro-instrument particles having an observable property responsive to the ultrasonic energy, the observable property varying as a function of the physiological property of the body; and a receive beamformer operable to receive signals (dilution chamber) responsive to the micro-instrument particles along a scan line.

US6368275B1

Filed: 1999-10-07 Issued: 2002-04-09

Method and apparatus for diagnostic medical information gathering, hyperthermia treatment, or directed gene therapy

(Original Assignee) Acuson Corp (Current Assignee) Acuson Corp ; Siemens Medical Solutions USA Inc

John W. Sliwa, William R. Dreschel

US8283155B2
CLAIM 45. The system of claim 30 further comprising a dilution chamber (to receive signals) containing a diluents for diluting the sample of bodily fluid according to said protocol transmitted by the external device and received by the reader assembly.

US6368275B1
CLAIM 14. A medical diagnostic ultrasound system for observing a physiological property of a body, the system comprising: a transducer operable to transmit energy into the body; a plurality of micro-instrument particles having an observable property responsive to the ultrasonic energy, the observable property varying as a function of the physiological property of the body; and a receive beamformer operable to receive signals (dilution chamber) responsive to the micro-instrument particles along a scan line.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US6156181A Filed: 1998-10-26 Issued: 2000-12-05 Controlled fluid transport microfabricated polymeric substrates (Original Assignee) Caliper Technologies Corp (Current Assignee) Caliper Life Sciences Inc John Wallace Parce, Michael R. Knapp, Calvin Y. H. Chow, Luc Bousse
US8283155B2 CLAIM 23. The method of claim 22 further comprising quantifying the amount of said analyte present (said polymeric material) in said sample.	US6156181A CLAIM 9. The microfluidic device of claim 1, wherein said polymeric material (analyte present) is selected from: polydimethylsiloxane (PDMS), polyurethane, polyvinylchloride (PVC), polystyrene, polysulfone, polycarbonate, polymethylmethacrylate (PMMA), and polytetrafluoroethylene.
US8283155B2 CLAIM 49. The method of claim 48 further comprising quantifying the amount of said analyte present (said polymeric material) in said sample.	US6156181A CLAIM 9. The microfluidic device of claim 1, wherein said polymeric material (analyte present) is selected from: polydimethylsiloxane (PDMS), polyurethane, polyvinylchloride (PVC), polystyrene, polysulfone, polycarbonate, polymethylmethacrylate (PMMA), and polytetrafluoroethylene.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US6245057B1 Filed: 1999-10-22 Issued: 2001-06-12 Device for treating malignant, tumorous tissue areas (Original Assignee) TDK-Micronas GmbH (Current Assignee) TDK-Micronas GmbH Ulrich Sieben, Bernhard Wolf
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid (bodily fluid) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	US6245057B1 CLAIM 1. A device ( 1 , 1 a , 1 b , 1 c , 1 d ) for treating malignant, tumorous tissue areas, comprising at least one measuring sensor ( 9 ) for determining chemical or physical signal patterns in an immediate vicinity of a tumorous tissue area, a control unit, and at least one treatment assembly having at least one active agent supply container ( 4 ), a dosing element with dosing control, and an active agent release element ( 6 ) for chemically influencing and/or treatment electrodes for physically influencing the tumorous tissue area to be treated, wherein the sensor(s)( 9 ), the active agent release element( 6 ) and/or the treatment electrodes ( 3 ) are connected to the control unit for controlling a physical and/or chemical treatment of the tumorous tissue area as a function of measured values of the tumor cells with continuous follow-up dosing of the active agent to be applied, wherein the device is constructed in a form of a swallowable capsule or a dragée and has a sheath ( 11 ) which at least covers the sensor(s)( 9 ), the sheath being removable at least over a certain area under the influence of bodily fluid (bodily fluid) , wherein the control unit and a sensor for detecting release parameters are designed with a threshold value switch for activating the active agent release element and/or the electrodes when a predetermined target value is exceeded, and wherein at least one heat resistor ( 18 ) is provided within the active agent supply container ( 4 ) for heating up and release of the active agent.
US8283155B2 CLAIM 9. The system of claim 1 wherein the sample collection unit collects a sample of bodily fluid (bodily fluid) which is less than about 500 uL.	US6245057B1 CLAIM 1. A device ( 1 , 1 a , 1 b , 1 c , 1 d ) for treating malignant, tumorous tissue areas, comprising at least one measuring sensor ( 9 ) for determining chemical or physical signal patterns in an immediate vicinity of a tumorous tissue area, a control unit, and at least one treatment assembly having at least one active agent supply container ( 4 ), a dosing element with dosing control, and an active agent release element ( 6 ) for chemically influencing and/or treatment electrodes for physically influencing the tumorous tissue area to be treated, wherein the sensor(s)( 9 ), the active agent release element( 6 ) and/or the treatment electrodes ( 3 ) are connected to the control unit for controlling a physical and/or chemical treatment of the tumorous tissue area as a function of measured values of the tumor cells with continuous follow-up dosing of the active agent to be applied, wherein the device is constructed in a form of a swallowable capsule or a dragée and has a sheath ( 11 ) which at least covers the sensor(s)( 9 ), the sheath being removable at least over a certain area under the influence of bodily fluid (bodily fluid) , wherein the control unit and a sensor for detecting release parameters are designed with a threshold value switch for activating the active agent release element and/or the electrodes when a predetermined target value is exceeded, and wherein at least one heat resistor ( 18 ) is provided within the active agent supply container ( 4 ) for heating up and release of the active agent.
US8283155B2 CLAIM 22. A method for detecting an analyte in a bodily fluid (bodily fluid) of a subject, comprising: a) providing a system of claim 1 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	US6245057B1 CLAIM 1. A device ( 1 , 1 a , 1 b , 1 c , 1 d ) for treating malignant, tumorous tissue areas, comprising at least one measuring sensor ( 9 ) for determining chemical or physical signal patterns in an immediate vicinity of a tumorous tissue area, a control unit, and at least one treatment assembly having at least one active agent supply container ( 4 ), a dosing element with dosing control, and an active agent release element ( 6 ) for chemically influencing and/or treatment electrodes for physically influencing the tumorous tissue area to be treated, wherein the sensor(s)( 9 ), the active agent release element( 6 ) and/or the treatment electrodes ( 3 ) are connected to the control unit for controlling a physical and/or chemical treatment of the tumorous tissue area as a function of measured values of the tumor cells with continuous follow-up dosing of the active agent to be applied, wherein the device is constructed in a form of a swallowable capsule or a dragée and has a sheath ( 11 ) which at least covers the sensor(s)( 9 ), the sheath being removable at least over a certain area under the influence of bodily fluid (bodily fluid) , wherein the control unit and a sensor for detecting release parameters are designed with a threshold value switch for activating the active agent release element and/or the electrodes when a predetermined target value is exceeded, and wherein at least one heat resistor ( 18 ) is provided within the active agent supply container ( 4 ) for heating up and release of the active agent.
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid (bodily fluid) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	US6245057B1 CLAIM 1. A device ( 1 , 1 a , 1 b , 1 c , 1 d ) for treating malignant, tumorous tissue areas, comprising at least one measuring sensor ( 9 ) for determining chemical or physical signal patterns in an immediate vicinity of a tumorous tissue area, a control unit, and at least one treatment assembly having at least one active agent supply container ( 4 ), a dosing element with dosing control, and an active agent release element ( 6 ) for chemically influencing and/or treatment electrodes for physically influencing the tumorous tissue area to be treated, wherein the sensor(s)( 9 ), the active agent release element( 6 ) and/or the treatment electrodes ( 3 ) are connected to the control unit for controlling a physical and/or chemical treatment of the tumorous tissue area as a function of measured values of the tumor cells with continuous follow-up dosing of the active agent to be applied, wherein the device is constructed in a form of a swallowable capsule or a dragée and has a sheath ( 11 ) which at least covers the sensor(s)( 9 ), the sheath being removable at least over a certain area under the influence of bodily fluid (bodily fluid) , wherein the control unit and a sensor for detecting release parameters are designed with a threshold value switch for activating the active agent release element and/or the electrodes when a predetermined target value is exceeded, and wherein at least one heat resistor ( 18 ) is provided within the active agent supply container ( 4 ) for heating up and release of the active agent.
US8283155B2 CLAIM 38. The system of claim 30 wherein the sample collection unit collects a sample of bodily fluid (bodily fluid) which is less than about 500 uL.	US6245057B1 CLAIM 1. A device ( 1 , 1 a , 1 b , 1 c , 1 d ) for treating malignant, tumorous tissue areas, comprising at least one measuring sensor ( 9 ) for determining chemical or physical signal patterns in an immediate vicinity of a tumorous tissue area, a control unit, and at least one treatment assembly having at least one active agent supply container ( 4 ), a dosing element with dosing control, and an active agent release element ( 6 ) for chemically influencing and/or treatment electrodes for physically influencing the tumorous tissue area to be treated, wherein the sensor(s)( 9 ), the active agent release element( 6 ) and/or the treatment electrodes ( 3 ) are connected to the control unit for controlling a physical and/or chemical treatment of the tumorous tissue area as a function of measured values of the tumor cells with continuous follow-up dosing of the active agent to be applied, wherein the device is constructed in a form of a swallowable capsule or a dragée and has a sheath ( 11 ) which at least covers the sensor(s)( 9 ), the sheath being removable at least over a certain area under the influence of bodily fluid (bodily fluid) , wherein the control unit and a sensor for detecting release parameters are designed with a threshold value switch for activating the active agent release element and/or the electrodes when a predetermined target value is exceeded, and wherein at least one heat resistor ( 18 ) is provided within the active agent supply container ( 4 ) for heating up and release of the active agent.
US8283155B2 CLAIM 45. The system of claim 30 further comprising a dilution chamber containing a diluents for diluting the sample of bodily fluid (bodily fluid) according to said protocol transmitted by the external device and received by the reader assembly.	US6245057B1 CLAIM 1. A device ( 1 , 1 a , 1 b , 1 c , 1 d ) for treating malignant, tumorous tissue areas, comprising at least one measuring sensor ( 9 ) for determining chemical or physical signal patterns in an immediate vicinity of a tumorous tissue area, a control unit, and at least one treatment assembly having at least one active agent supply container ( 4 ), a dosing element with dosing control, and an active agent release element ( 6 ) for chemically influencing and/or treatment electrodes for physically influencing the tumorous tissue area to be treated, wherein the sensor(s)( 9 ), the active agent release element( 6 ) and/or the treatment electrodes ( 3 ) are connected to the control unit for controlling a physical and/or chemical treatment of the tumorous tissue area as a function of measured values of the tumor cells with continuous follow-up dosing of the active agent to be applied, wherein the device is constructed in a form of a swallowable capsule or a dragée and has a sheath ( 11 ) which at least covers the sensor(s)( 9 ), the sheath being removable at least over a certain area under the influence of bodily fluid (bodily fluid) , wherein the control unit and a sensor for detecting release parameters are designed with a threshold value switch for activating the active agent release element and/or the electrodes when a predetermined target value is exceeded, and wherein at least one heat resistor ( 18 ) is provided within the active agent supply container ( 4 ) for heating up and release of the active agent.
US8283155B2 CLAIM 48. A method for detecting an analyte in a bodily fluid (bodily fluid) of a subject, comprising: a) providing a system of claim 30 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	US6245057B1 CLAIM 1. A device ( 1 , 1 a , 1 b , 1 c , 1 d ) for treating malignant, tumorous tissue areas, comprising at least one measuring sensor ( 9 ) for determining chemical or physical signal patterns in an immediate vicinity of a tumorous tissue area, a control unit, and at least one treatment assembly having at least one active agent supply container ( 4 ), a dosing element with dosing control, and an active agent release element ( 6 ) for chemically influencing and/or treatment electrodes for physically influencing the tumorous tissue area to be treated, wherein the sensor(s)( 9 ), the active agent release element( 6 ) and/or the treatment electrodes ( 3 ) are connected to the control unit for controlling a physical and/or chemical treatment of the tumorous tissue area as a function of measured values of the tumor cells with continuous follow-up dosing of the active agent to be applied, wherein the device is constructed in a form of a swallowable capsule or a dragée and has a sheath ( 11 ) which at least covers the sensor(s)( 9 ), the sheath being removable at least over a certain area under the influence of bodily fluid (bodily fluid) , wherein the control unit and a sensor for detecting release parameters are designed with a threshold value switch for activating the active agent release element and/or the electrodes when a predetermined target value is exceeded, and wherein at least one heat resistor ( 18 ) is provided within the active agent supply container ( 4 ) for heating up and release of the active agent.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US20020132226A1 Filed: 2002-05-06 Issued: 2002-09-19 Ingestible electronic capsule (Original Assignee) Motorola Solutions Inc (Current Assignee) Motorola Solutions Inc Vijay Nair, Piotr Grodzinski, Nada El-Zein, Herbert Goronkin
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid (outer shell housing) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	US20020132226A1 CLAIM 1 . An ingestible capsule for determining medical information in the body of a human or an animal comprising: a non-digestible outer shell that is configured to pass through an alimentary canal in the body of a human or an animal, the non-digestible outer shell housing (bodily fluid) within; a bio-sensing circuit; a driver circuit in electronic communication with the bio-sensing circuit; and a transducer circuit in electronic communication with the driver circuit.
US8283155B2 CLAIM 9. The system of claim 1 wherein the sample collection unit collects a sample of bodily fluid (outer shell housing) which is less than about 500 uL.	US20020132226A1 CLAIM 1 . An ingestible capsule for determining medical information in the body of a human or an animal comprising: a non-digestible outer shell that is configured to pass through an alimentary canal in the body of a human or an animal, the non-digestible outer shell housing (bodily fluid) within; a bio-sensing circuit; a driver circuit in electronic communication with the bio-sensing circuit; and a transducer circuit in electronic communication with the driver circuit.
US8283155B2 CLAIM 22. A method for detecting an analyte in a bodily fluid (outer shell housing) of a subject, comprising: a) providing a system of claim 1 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	US20020132226A1 CLAIM 1 . An ingestible capsule for determining medical information in the body of a human or an animal comprising: a non-digestible outer shell that is configured to pass through an alimentary canal in the body of a human or an animal, the non-digestible outer shell housing (bodily fluid) within; a bio-sensing circuit; a driver circuit in electronic communication with the bio-sensing circuit; and a transducer circuit in electronic communication with the driver circuit.
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid (outer shell housing) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	US20020132226A1 CLAIM 1 . An ingestible capsule for determining medical information in the body of a human or an animal comprising: a non-digestible outer shell that is configured to pass through an alimentary canal in the body of a human or an animal, the non-digestible outer shell housing (bodily fluid) within; a bio-sensing circuit; a driver circuit in electronic communication with the bio-sensing circuit; and a transducer circuit in electronic communication with the driver circuit.
US8283155B2 CLAIM 38. The system of claim 30 wherein the sample collection unit collects a sample of bodily fluid (outer shell housing) which is less than about 500 uL.	US20020132226A1 CLAIM 1 . An ingestible capsule for determining medical information in the body of a human or an animal comprising: a non-digestible outer shell that is configured to pass through an alimentary canal in the body of a human or an animal, the non-digestible outer shell housing (bodily fluid) within; a bio-sensing circuit; a driver circuit in electronic communication with the bio-sensing circuit; and a transducer circuit in electronic communication with the driver circuit.
US8283155B2 CLAIM 45. The system of claim 30 further comprising a dilution chamber containing a diluents for diluting the sample of bodily fluid (outer shell housing) according to said protocol transmitted by the external device and received by the reader assembly.	US20020132226A1 CLAIM 1 . An ingestible capsule for determining medical information in the body of a human or an animal comprising: a non-digestible outer shell that is configured to pass through an alimentary canal in the body of a human or an animal, the non-digestible outer shell housing (bodily fluid) within; a bio-sensing circuit; a driver circuit in electronic communication with the bio-sensing circuit; and a transducer circuit in electronic communication with the driver circuit.
US8283155B2 CLAIM 48. A method for detecting an analyte in a bodily fluid (outer shell housing) of a subject, comprising: a) providing a system of claim 30 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	US20020132226A1 CLAIM 1 . An ingestible capsule for determining medical information in the body of a human or an animal comprising: a non-digestible outer shell that is configured to pass through an alimentary canal in the body of a human or an animal, the non-digestible outer shell housing (bodily fluid) within; a bio-sensing circuit; a driver circuit in electronic communication with the bio-sensing circuit; and a transducer circuit in electronic communication with the driver circuit.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US6887202B2 Filed: 2001-05-30 Issued: 2005-05-03 Systems and methods for monitoring health and delivering drugs transdermally (Original Assignee) Science Applications International Corp SAIC; Georgetown University (Current Assignee) Georgetown University ; Leidos Inc John F. Currie, Makarand Paranjape, Carl C. Peck, Robert White, Thomas W. Schneider
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US6887202B2 CLAIM 6. The transdermal sampling system according to claim 1 , wherein the at least one specific-binding molecule is a hybridizable nucleic acid (nucleic acid) which specifically binds the at least one analyte.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US6887202B2 CLAIM 6. The transdermal sampling system according to claim 1 , wherein the at least one specific-binding molecule is a hybridizable nucleic acid (nucleic acid) which specifically binds the at least one analyte.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US6887202B2 CLAIM 6. The transdermal sampling system according to claim 1 , wherein the at least one specific-binding molecule is a hybridizable nucleic acid (nucleic acid) which specifically binds the at least one analyte.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US6887202B2 CLAIM 6. The transdermal sampling system according to claim 1 , wherein the at least one specific-binding molecule is a hybridizable nucleic acid (nucleic acid) which specifically binds the at least one analyte.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US5976896A Filed: 1996-07-29 Issued: 1999-11-02 Immunoassays in capillary tubes (Original Assignee) Idexx Laboratories Inc (Current Assignee) Idexx Laboratories Inc Amit Kumar, Larry Sheldon Jang, Danton Kai-Yu Leung, Richard Michele Rocco, Mark Charles Platshon
US8283155B2 CLAIM 23. The method of claim 22 further comprising quantifying the amount of said analyte present (analyte present) in said sample.	US5976896A CLAIM 8. The process of claim 1, wherein the detected fluorescence is used to determine the amount of analyte present (analyte present) .
US8283155B2 CLAIM 49. The method of claim 48 further comprising quantifying the amount of said analyte present (analyte present) in said sample.	US5976896A CLAIM 8. The process of claim 1, wherein the detected fluorescence is used to determine the amount of analyte present (analyte present) .

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US6471916B1 Filed: 1999-11-09 Issued: 2002-10-29 Apparatus and method for calibration of a microarray scanning system (Original Assignee) Packard Instrument Co Inc (Current Assignee) General Scanning Inc ; Packard Instrument Co Inc David Noblett
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (optical detection device) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method (optical detection device) for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	US6471916B1 CLAIM 6. The microarray scanning system of claim 1 wherein said means for detecting comprises at least one member of the group consisting of a photomultiplier tube, an avalanche photodiode, and a solid state optical detection device (test device, detection method) .
US8283155B2 CLAIM 8. The system of claim 1 wherein the test device (optical detection device) further comprises a microneedle useful for collecting the sample.	US6471916B1 CLAIM 6. The microarray scanning system of claim 1 wherein said means for detecting comprises at least one member of the group consisting of a photomultiplier tube, an avalanche photodiode, and a solid state optical detection device (test device, detection method) .
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device (optical detection device) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents for said plurality of analytes.	US6471916B1 CLAIM 6. The microarray scanning system of claim 1 wherein said means for detecting comprises at least one member of the group consisting of a photomultiplier tube, an avalanche photodiode, and a solid state optical detection device (test device, detection method) .
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method (optical detection device) further comprises detecting an optical signal from the sample.	US6471916B1 CLAIM 6. The microarray scanning system of claim 1 wherein said means for detecting comprises at least one member of the group consisting of a photomultiplier tube, an avalanche photodiode, and a solid state optical detection device (test device, detection method) .
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method (optical detection device) includes collecting signals from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	US6471916B1 CLAIM 6. The microarray scanning system of claim 1 wherein said means for detecting comprises at least one member of the group consisting of a photomultiplier tube, an avalanche photodiode, and a solid state optical detection device (test device, detection method) .
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (optical detection device) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	US6471916B1 CLAIM 6. The microarray scanning system of claim 1 wherein said means for detecting comprises at least one member of the group consisting of a photomultiplier tube, an avalanche photodiode, and a solid state optical detection device (test device, detection method) .
US8283155B2 CLAIM 37. The system of claim 30 wherein the test device (optical detection device) further comprises a microneedle useful for collecting the sample.	US6471916B1 CLAIM 6. The microarray scanning system of claim 1 wherein said means for detecting comprises at least one member of the group consisting of a photomultiplier tube, an avalanche photodiode, and a solid state optical detection device (test device, detection method) .
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device (optical detection device) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents for said plurality of analytes.	US6471916B1 CLAIM 6. The microarray scanning system of claim 1 wherein said means for detecting comprises at least one member of the group consisting of a photomultiplier tube, an avalanche photodiode, and a solid state optical detection device (test device, detection method) .

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US6352854B1 Filed: 1995-06-07 Issued: 2002-03-05 Remotely programmable matrices with memories (Original Assignee) Discovery Partners International Inc (Current Assignee) IRORI TECHNOLOGIES Inc Michael P. Nova, Andrew E. Senyei
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US6352854B1 CLAIM 1. A combination of a matrix with memory, comprising: (a) a memory device, comprising a data storage unit, wherein the memory device is remotely programmable and/or remotely readable using transmitted electromagnetic radiation; and (b) a matrix material comprising particles of a size such that at least one dimension is no more than 100 mm, wherein the matrix material is derivatized for linking biological particles or molecules, the biological particles comprising a virus, viral vector, viral capsid with or without packaged nucleic acid (nucleic acid) , phage, phage vector or phage capsid with or without encapsulated nucleic acid, a eukaryotic or prokaryotic cell or fragments of the virus, viral capsid, phage, phage capsid or cell, and the molecules comprising macromolecules or monomeric constituents of macromolecules or organic compounds; wherein the memory device is in contact with the matrix material or in a solution that is in contact with the matrix material.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US6352854B1 CLAIM 1. A combination of a matrix with memory, comprising: (a) a memory device, comprising a data storage unit, wherein the memory device is remotely programmable and/or remotely readable using transmitted electromagnetic radiation; and (b) a matrix material comprising particles of a size such that at least one dimension is no more than 100 mm, wherein the matrix material is derivatized for linking biological particles or molecules, the biological particles comprising a virus, viral vector, viral capsid with or without packaged nucleic acid (nucleic acid) , phage, phage vector or phage capsid with or without encapsulated nucleic acid, a eukaryotic or prokaryotic cell or fragments of the virus, viral capsid, phage, phage capsid or cell, and the molecules comprising macromolecules or monomeric constituents of macromolecules or organic compounds; wherein the memory device is in contact with the matrix material or in a solution that is in contact with the matrix material.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US6352854B1 CLAIM 1. A combination of a matrix with memory, comprising: (a) a memory device, comprising a data storage unit, wherein the memory device is remotely programmable and/or remotely readable using transmitted electromagnetic radiation; and (b) a matrix material comprising particles of a size such that at least one dimension is no more than 100 mm, wherein the matrix material is derivatized for linking biological particles or molecules, the biological particles comprising a virus, viral vector, viral capsid with or without packaged nucleic acid (nucleic acid) , phage, phage vector or phage capsid with or without encapsulated nucleic acid, a eukaryotic or prokaryotic cell or fragments of the virus, viral capsid, phage, phage capsid or cell, and the molecules comprising macromolecules or monomeric constituents of macromolecules or organic compounds; wherein the memory device is in contact with the matrix material or in a solution that is in contact with the matrix material.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US6352854B1 CLAIM 1. A combination of a matrix with memory, comprising: (a) a memory device, comprising a data storage unit, wherein the memory device is remotely programmable and/or remotely readable using transmitted electromagnetic radiation; and (b) a matrix material comprising particles of a size such that at least one dimension is no more than 100 mm, wherein the matrix material is derivatized for linking biological particles or molecules, the biological particles comprising a virus, viral vector, viral capsid with or without packaged nucleic acid (nucleic acid) , phage, phage vector or phage capsid with or without encapsulated nucleic acid, a eukaryotic or prokaryotic cell or fragments of the virus, viral capsid, phage, phage capsid or cell, and the molecules comprising macromolecules or monomeric constituents of macromolecules or organic compounds; wherein the memory device is in contact with the matrix material or in a solution that is in contact with the matrix material.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US6482593B2 Filed: 1998-11-05 Issued: 2002-11-19 Fiber optic biosensor for selectively detecting oligonucleotide species in a mixed fluid sample (Original Assignee) Tufts University (Current Assignee) Tufts University David R. Walt, Brian G. Healey
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit (second end face, first end face) configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	US6482593B2 CLAIM 6. A sensor according to claim 1 wherein said nucleic acid is attached to said portion by introducing light energy to at least said first end face (sample collection unit) in the presence of a photoactivatable compound. US6482593B2 CLAIM 11. A method according to claim 10 further comprising: d) contacting at least a second nucleic acid and a photoactivatable compound with at least a second proximal first optic fiber strand end face; and e) attaching said second nucleic acid to said second end face (sample collection unit) by introducing light energy to said second optic fiber strand.
US8283155B2 CLAIM 9. The system of claim 1 wherein the sample collection unit (second end face, first end face) collects a sample of bodily fluid which is less than about 500 uL.	US6482593B2 CLAIM 6. A sensor according to claim 1 wherein said nucleic acid is attached to said portion by introducing light energy to at least said first end face (sample collection unit) in the presence of a photoactivatable compound. US6482593B2 CLAIM 11. A method according to claim 10 further comprising: d) contacting at least a second nucleic acid and a photoactivatable compound with at least a second proximal first optic fiber strand end face; and e) attaching said second nucleic acid to said second end face (sample collection unit) by introducing light energy to said second optic fiber strand.
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (said nucleic acid) reagents immobilized within the assay assembly.	US6482593B2 CLAIM 2. A sensor according to claim 1 wherein said nucleic acid (nucleic acid, nucleic acid reagents) is selected from the group consisting of DNA, RNA and PNA.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (said nucleic acid) reagents for said plurality of analytes.	US6482593B2 CLAIM 2. A sensor according to claim 1 wherein said nucleic acid (nucleic acid, nucleic acid reagents) is selected from the group consisting of DNA, RNA and PNA.
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit (second end face, first end face) configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	US6482593B2 CLAIM 6. A sensor according to claim 1 wherein said nucleic acid is attached to said portion by introducing light energy to at least said first end face (sample collection unit) in the presence of a photoactivatable compound. US6482593B2 CLAIM 11. A method according to claim 10 further comprising: d) contacting at least a second nucleic acid and a photoactivatable compound with at least a second proximal first optic fiber strand end face; and e) attaching said second nucleic acid to said second end face (sample collection unit) by introducing light energy to said second optic fiber strand.
US8283155B2 CLAIM 38. The system of claim 30 wherein the sample collection unit (second end face, first end face) collects a sample of bodily fluid which is less than about 500 uL.	US6482593B2 CLAIM 6. A sensor according to claim 1 wherein said nucleic acid is attached to said portion by introducing light energy to at least said first end face (sample collection unit) in the presence of a photoactivatable compound. US6482593B2 CLAIM 11. A method according to claim 10 further comprising: d) contacting at least a second nucleic acid and a photoactivatable compound with at least a second proximal first optic fiber strand end face; and e) attaching said second nucleic acid to said second end face (sample collection unit) by introducing light energy to said second optic fiber strand.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (said nucleic acid) reagents immobilized within the assay assembly.	US6482593B2 CLAIM 2. A sensor according to claim 1 wherein said nucleic acid (nucleic acid, nucleic acid reagents) is selected from the group consisting of DNA, RNA and PNA.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (said nucleic acid) reagents for said plurality of analytes.	US6482593B2 CLAIM 2. A sensor according to claim 1 wherein said nucleic acid (nucleic acid, nucleic acid reagents) is selected from the group consisting of DNA, RNA and PNA.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US5687716A Filed: 1995-11-15 Issued: 1997-11-18 Selective differentiating diagnostic process based on broad data bases (Original Assignee) Kaufmann; Peter; Beving; Haakan; Olsson; Nils U. Peter Kaufmann, Håkan Beving, Nils U. Olsson
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid (bodily fluid) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	US5687716A CLAIM 3. The process of claim 2 wherein the laboratory data includes the diagnostic analysis of bodily fluid (bodily fluid) s, cells, soft and hard tissues, and organs.
US8283155B2 CLAIM 9. The system of claim 1 wherein the sample collection unit collects a sample of bodily fluid (bodily fluid) which is less than about 500 uL.	US5687716A CLAIM 3. The process of claim 2 wherein the laboratory data includes the diagnostic analysis of bodily fluid (bodily fluid) s, cells, soft and hard tissues, and organs.
US8283155B2 CLAIM 22. A method for detecting an analyte in a bodily fluid (bodily fluid) of a subject, comprising: a) providing a system of claim 1 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	US5687716A CLAIM 3. The process of claim 2 wherein the laboratory data includes the diagnostic analysis of bodily fluid (bodily fluid) s, cells, soft and hard tissues, and organs.
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid (bodily fluid) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	US5687716A CLAIM 3. The process of claim 2 wherein the laboratory data includes the diagnostic analysis of bodily fluid (bodily fluid) s, cells, soft and hard tissues, and organs.
US8283155B2 CLAIM 38. The system of claim 30 wherein the sample collection unit collects a sample of bodily fluid (bodily fluid) which is less than about 500 uL.	US5687716A CLAIM 3. The process of claim 2 wherein the laboratory data includes the diagnostic analysis of bodily fluid (bodily fluid) s, cells, soft and hard tissues, and organs.
US8283155B2 CLAIM 45. The system of claim 30 further comprising a dilution chamber containing a diluents for diluting the sample of bodily fluid (bodily fluid) according to said protocol transmitted by the external device and received by the reader assembly.	US5687716A CLAIM 3. The process of claim 2 wherein the laboratory data includes the diagnostic analysis of bodily fluid (bodily fluid) s, cells, soft and hard tissues, and organs.
US8283155B2 CLAIM 48. A method for detecting an analyte in a bodily fluid (bodily fluid) of a subject, comprising: a) providing a system of claim 30 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	US5687716A CLAIM 3. The process of claim 2 wherein the laboratory data includes the diagnostic analysis of bodily fluid (bodily fluid) s, cells, soft and hard tissues, and organs.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US20030104590A1 Filed: 2002-12-19 Issued: 2003-06-05 Microfabricated devices for the storage and selective exposure of chemicals and devices (Original Assignee) Santini, John T.; Sheppard, Norman F.; Young Chung Chang; Langer Robert S. (Current Assignee) MICROCHIPS BIOTECH Inc John Santini, Norman Sheppard, Chung Young, Robert Langer
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US20030104590A1 CLAIM 9 . The microchip device of claim 8 , wherein the reacting component is selected from the group consisting of cells, proteins, nucleic acid (nucleic acid) s, and polysaccharides.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US20030104590A1 CLAIM 9 . The microchip device of claim 8 , wherein the reacting component is selected from the group consisting of cells, proteins, nucleic acid (nucleic acid) s, and polysaccharides.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	US20030104590A1 CLAIM 9 . The microchip device of claim 8 , wherein the reacting component is selected from the group consisting of cells, proteins, nucleic acid (nucleic acid) s, and polysaccharides.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	US20030104590A1 CLAIM 9 . The microchip device of claim 8 , wherein the reacting component is selected from the group consisting of cells, proteins, nucleic acid (nucleic acid) s, and polysaccharides.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	US6372428B1 Filed: 1998-06-16 Issued: 2002-04-16 Remotely programmable matrices with memories (Original Assignee) Discovery Partners International Inc (Current Assignee) IRORI TECHNOLOGIES Inc Michael P. Nova, Andrew E. Senyei, Gary S. David
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method (optical storage medium) for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	US6372428B1 CLAIM 32. The combination of claim 1 , wherein the memory device comprises an optical storage medium (detection method, controller having computer) for retaining the encoded information in the form of a plurality of optically readable holes or pits formed in the optical storage medium.
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (stranded nucleic acid) reagents immobilized within the assay assembly.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (stranded nucleic acid) reagents for said plurality of analytes.
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method (optical storage medium) further comprises detecting an optical signal from the sample.	US6372428B1 CLAIM 32. The combination of claim 1 , wherein the memory device comprises an optical storage medium (detection method, controller having computer) for retaining the encoded information in the form of a plurality of optically readable holes or pits formed in the optical storage medium.
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method (optical storage medium) includes collecting signals from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	US6372428B1 CLAIM 32. The combination of claim 1 , wherein the memory device comprises an optical storage medium (detection method, controller having computer) for retaining the encoded information in the form of a plurality of optically readable holes or pits formed in the optical storage medium.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (stranded nucleic acid) reagents immobilized within the assay assembly.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (stranded nucleic acid) reagents for said plurality of analytes.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JP2003166910A Filed: 2001-11-30 Issued: 2003-06-13 送液機構及び該送液機構を備える分析装置 (Original Assignee) Asahi Kasei Corp; 旭化成株式会社 Keisuke Kamisaka, Koichiro Uchida, 圭介上阪, 孝一郎内田
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method further comprises detecting an optical signal (の内部) from the sample.	JP2003166910A CLAIM 1 【特許請求の範囲】【請求項１】壁体に囲まれて形成された液体槽の容積を変化させることによって、前記液体槽に満たされた液体を前記液体槽に連結された流路に送る、又は、前記流路若しくは前記流路に連結された別の液体槽に収納された液体を前記液体槽に送る送液機構であって、前記壁体の少なくとも一部が、前記液体槽の内部 (optical signal) 又は外部に向かって突出するように変形可能な弾性を有する隔壁で構成されていることを特徴とする送液機構。【請求項２】前記隔壁を押圧して又は引いて変形させる隔壁変形手段を備えることを特徴とする請求項１に記載の送液機構。【請求項３】前記隔壁変形手段は、直線運動しつつ前記隔壁を押圧する又は引くプランジャーを備えることを特徴とする請求項２に記載の送液機構。【請求項４】前記隔壁変形手段は、前記プランジャーを収納し前記プランジャーの直線運動を案内するシリンダと、前記プランジャーを直線運動させる駆動手段と、前記シリンダの端部に配され前記隔壁を前記液体槽の外側から囲って密閉するカプラーと、前記カプラーに囲まれた部分の気体の出入りを制御するバルブと、を備えることを特徴とする請求項３に記載の送液機構。【請求項５】前記隔壁変形手段は、前記隔壁を押圧するローラを備えることを特徴とする請求項２に記載の送液機構。【請求項６】前記隔壁の外面に突起を設けたことを特徴とする請求項２〜５のいずれかに記載の送液機構。【請求項７】前記隔壁を、気体は透過し液体は透過しない素材で構成したことを特徴とする請求項１〜６のいずれかに記載の送液機構。【請求項８】前記素材は、疎水性を有する多孔質膜であることを特徴とする請求項７に記載の送液機構。【請求項９】前記多孔質膜が有機ポリマーで形成されていることを特徴とする請求項８に記載の送液機構。【請求項１０】液体状の試料、又は、液体状の試料及び液体状の試薬の混合液を流路内に流して、前記試料又は前記混合液中の所定成分を分析する分析装置であって、前記試料又は前記混合液が充填される液体槽と、前記液体槽に連結された前記流路と、を有するチップと、請求項１〜９のいずれかに記載の送液機構と、を備えることを特徴とする分析装置。【請求項１１】前記チップは一対の平板状部材が張り合わされて構成されており、この一対の平板状部材のうち少なくとも一方は板面に溝を備え、前記溝を備えた板面を内側にして張り合わせることにより前記流路が形成されていることを特徴とする請求項１０に記載の分析装置。【請求項１２】前記チップは乾燥した試薬が収納されている液体槽を備えていて、この液体槽に溶解液を装入して前記試薬を前記溶解液で溶解することにより、前記液体状の試薬を前記チップ内で調製することが可能となっていることを特徴とする請求項１０又は１１に記載の分析装置。【請求項１３】複数の液体槽又は複数の流路内の液体を液押し用液体で押し流すことにより同時に移動させる機構を備える分析装置であって、請求項１〜９のいずれかに記載の送液機構により送液される前記液押し用液体が流れる液押し用流路を、前記複数の液体槽又は前記複数の流路にそれぞれ連結したことを特徴とする請求項１０〜１２のいずれかに記載の分析装置。
US8283155B2 CLAIM 18. The system of claim 17 wherein the optical signal (の内部) is a chemiluminscent signal.	JP2003166910A CLAIM 1 【特許請求の範囲】【請求項１】壁体に囲まれて形成された液体槽の容積を変化させることによって、前記液体槽に満たされた液体を前記液体槽に連結された流路に送る、又は、前記流路若しくは前記流路に連結された別の液体槽に収納された液体を前記液体槽に送る送液機構であって、前記壁体の少なくとも一部が、前記液体槽の内部 (optical signal) 又は外部に向かって突出するように変形可能な弾性を有する隔壁で構成されていることを特徴とする送液機構。【請求項２】前記隔壁を押圧して又は引いて変形させる隔壁変形手段を備えることを特徴とする請求項１に記載の送液機構。【請求項３】前記隔壁変形手段は、直線運動しつつ前記隔壁を押圧する又は引くプランジャーを備えることを特徴とする請求項２に記載の送液機構。【請求項４】前記隔壁変形手段は、前記プランジャーを収納し前記プランジャーの直線運動を案内するシリンダと、前記プランジャーを直線運動させる駆動手段と、前記シリンダの端部に配され前記隔壁を前記液体槽の外側から囲って密閉するカプラーと、前記カプラーに囲まれた部分の気体の出入りを制御するバルブと、を備えることを特徴とする請求項３に記載の送液機構。【請求項５】前記隔壁変形手段は、前記隔壁を押圧するローラを備えることを特徴とする請求項２に記載の送液機構。【請求項６】前記隔壁の外面に突起を設けたことを特徴とする請求項２〜５のいずれかに記載の送液機構。【請求項７】前記隔壁を、気体は透過し液体は透過しない素材で構成したことを特徴とする請求項１〜６のいずれかに記載の送液機構。【請求項８】前記素材は、疎水性を有する多孔質膜であることを特徴とする請求項７に記載の送液機構。【請求項９】前記多孔質膜が有機ポリマーで形成されていることを特徴とする請求項８に記載の送液機構。【請求項１０】液体状の試料、又は、液体状の試料及び液体状の試薬の混合液を流路内に流して、前記試料又は前記混合液中の所定成分を分析する分析装置であって、前記試料又は前記混合液が充填される液体槽と、前記液体槽に連結された前記流路と、を有するチップと、請求項１〜９のいずれかに記載の送液機構と、を備えることを特徴とする分析装置。【請求項１１】前記チップは一対の平板状部材が張り合わされて構成されており、この一対の平板状部材のうち少なくとも一方は板面に溝を備え、前記溝を備えた板面を内側にして張り合わせることにより前記流路が形成されていることを特徴とする請求項１０に記載の分析装置。【請求項１２】前記チップは乾燥した試薬が収納されている液体槽を備えていて、この液体槽に溶解液を装入して前記試薬を前記溶解液で溶解することにより、前記液体状の試薬を前記チップ内で調製することが可能となっていることを特徴とする請求項１０又は１１に記載の分析装置。【請求項１３】複数の液体槽又は複数の流路内の液体を液押し用液体で押し流すことにより同時に移動させる機構を備える分析装置であって、請求項１〜９のいずれかに記載の送液機構により送液される前記液押し用液体が流れる液押し用流路を、前記複数の液体槽又は前記複数の流路にそれぞれ連結したことを特徴とする請求項１０〜１２のいずれかに記載の分析装置。

JP2003166910A

Filed: 2001-11-30 Issued: 2003-06-13

送液機構及び該送液機構を備える分析装置

(Original Assignee) Asahi Kasei Corp; 旭化成株式会社

Keisuke Kamisaka, Koichiro Uchida, 圭介上阪, 孝一郎内田

US8283155B2
CLAIM 17. The system of claim 1 wherein the detection method further comprises detecting an optical signal (の内部) from the sample.

JP2003166910A
CLAIM 1 【特許請求の範囲】【請求項１】壁体に囲まれて形成された液体槽の容積を変化させることによって、前記液体槽に満たされた液体を前記液体槽に連結された流路に送る、又は、前記流路若しくは前記流路に連結された別の液体槽に収納された液体を前記液体槽に送る送液機構であって、前記壁体の少なくとも一部が、前記液体槽の内部 (optical signal) 又は外部に向かって突出するように変形可能な弾性を有する隔壁で構成されていることを特徴とする送液機構。【請求項２】前記隔壁を押圧して又は引いて変形させる隔壁変形手段を備えることを特徴とする請求項１に記載の送液機構。【請求項３】前記隔壁変形手段は、直線運動しつつ前記隔壁を押圧する又は引くプランジャーを備えることを特徴とする請求項２に記載の送液機構。【請求項４】前記隔壁変形手段は、前記プランジャーを収納し前記プランジャーの直線運動を案内するシリンダと、前記プランジャーを直線運動させる駆動手段と、前記シリンダの端部に配され前記隔壁を前記液体槽の外側から囲って密閉するカプラーと、前記カプラーに囲まれた部分の気体の出入りを制御するバルブと、を備えることを特徴とする請求項３に記載の送液機構。【請求項５】前記隔壁変形手段は、前記隔壁を押圧するローラを備えることを特徴とする請求項２に記載の送液機構。【請求項６】前記隔壁の外面に突起を設けたことを特徴とする請求項２〜５のいずれかに記載の送液機構。【請求項７】前記隔壁を、気体は透過し液体は透過しない素材で構成したことを特徴とする請求項１〜６のいずれかに記載の送液機構。【請求項８】前記素材は、疎水性を有する多孔質膜であることを特徴とする請求項７に記載の送液機構。【請求項９】前記多孔質膜が有機ポリマーで形成されていることを特徴とする請求項８に記載の送液機構。【請求項１０】液体状の試料、又は、液体状の試料及び液体状の試薬の混合液を流路内に流して、前記試料又は前記混合液中の所定成分を分析する分析装置であって、前記試料又は前記混合液が充填される液体槽と、前記液体槽に連結された前記流路と、を有するチップと、請求項１〜９のいずれかに記載の送液機構と、を備えることを特徴とする分析装置。【請求項１１】前記チップは一対の平板状部材が張り合わされて構成されており、この一対の平板状部材のうち少なくとも一方は板面に溝を備え、前記溝を備えた板面を内側にして張り合わせることにより前記流路が形成されていることを特徴とする請求項１０に記載の分析装置。【請求項１２】前記チップは乾燥した試薬が収納されている液体槽を備えていて、この液体槽に溶解液を装入して前記試薬を前記溶解液で溶解することにより、前記液体状の試薬を前記チップ内で調製することが可能となっていることを特徴とする請求項１０又は１１に記載の分析装置。【請求項１３】複数の液体槽又は複数の流路内の液体を液押し用液体で押し流すことにより同時に移動させる機構を備える分析装置であって、請求項１〜９のいずれかに記載の送液機構により送液される前記液押し用液体が流れる液押し用流路を、前記複数の液体槽又は前記複数の流路にそれぞれ連結したことを特徴とする請求項１０〜１２のいずれかに記載の分析装置。

US8283155B2
CLAIM 18. The system of claim 17 wherein the optical signal (の内部) is a chemiluminscent signal.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	CN2559986Y Filed: 2002-08-23 Issued: 2003-07-09 集成微流体和微阵列探针的微芯片 (Original Assignee) 上海博昇微晶科技有限公司温龙平, 唐飞, 连崑
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid (微流体) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	CN2559986Y CLAIM 1.一种集成微流体 (bodily fluid) 和微阵列探针的微芯片，其特征是：在所述的微芯片上具有试剂池和微流体管道，各试剂池通过各微流体管道相连；在所述各试剂池中，一个或几个试剂池的底部上具有阵列探针。
US8283155B2 CLAIM 9. The system of claim 1 wherein the sample collection unit collects a sample of bodily fluid (微流体) which is less than about 500 uL.	CN2559986Y CLAIM 1.一种集成微流体 (bodily fluid) 和微阵列探针的微芯片，其特征是：在所述的微芯片上具有试剂池和微流体管道，各试剂池通过各微流体管道相连；在所述各试剂池中，一个或几个试剂池的底部上具有阵列探针。
US8283155B2 CLAIM 22. A method for detecting an analyte in a bodily fluid (微流体) of a subject, comprising: a) providing a system of claim 1 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	CN2559986Y CLAIM 1.一种集成微流体 (bodily fluid) 和微阵列探针的微芯片，其特征是：在所述的微芯片上具有试剂池和微流体管道，各试剂池通过各微流体管道相连；在所述各试剂池中，一个或几个试剂池的底部上具有阵列探针。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid (微流体) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	CN2559986Y CLAIM 1.一种集成微流体 (bodily fluid) 和微阵列探针的微芯片，其特征是：在所述的微芯片上具有试剂池和微流体管道，各试剂池通过各微流体管道相连；在所述各试剂池中，一个或几个试剂池的底部上具有阵列探针。
US8283155B2 CLAIM 38. The system of claim 30 wherein the sample collection unit collects a sample of bodily fluid (微流体) which is less than about 500 uL.	CN2559986Y CLAIM 1.一种集成微流体 (bodily fluid) 和微阵列探针的微芯片，其特征是：在所述的微芯片上具有试剂池和微流体管道，各试剂池通过各微流体管道相连；在所述各试剂池中，一个或几个试剂池的底部上具有阵列探针。
US8283155B2 CLAIM 45. The system of claim 30 further comprising a dilution chamber containing a diluents for diluting the sample of bodily fluid (微流体) according to said protocol transmitted by the external device and received by the reader assembly.	CN2559986Y CLAIM 1.一种集成微流体 (bodily fluid) 和微阵列探针的微芯片，其特征是：在所述的微芯片上具有试剂池和微流体管道，各试剂池通过各微流体管道相连；在所述各试剂池中，一个或几个试剂池的底部上具有阵列探针。
US8283155B2 CLAIM 48. A method for detecting an analyte in a bodily fluid (微流体) of a subject, comprising: a) providing a system of claim 30 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	CN2559986Y CLAIM 1.一种集成微流体 (bodily fluid) 和微阵列探针的微芯片，其特征是：在所述的微芯片上具有试剂池和微流体管道，各试剂池通过各微流体管道相连；在所述各试剂池中，一个或几个试剂池的底部上具有阵列探针。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JP2005010179A Filed: 2004-09-27 Issued: 2005-01-13 容器 (Original Assignee) Precision System Science Co Ltd; プレシジョン・システム・サイエンス株式会社 Hideji Tajima, 秀二田島
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly (受光部) for detecting said signal which is transmitted via said communication assembly (少なくとも１) to said external device.	JP2005010179A CLAIM 11 前記カートリッジ容器は、基部と、当該基部に列状に設けられた複数個の収容部とを有し、当該複数個の収容部には、処理用の収容部、光学測定用の測定器若しくは受光部 (detection assembly) と遮光状態で連結可能な測定用収容部若しくはその保持用穴部、ピペットチップの収容部若しくはその保持用穴部、ＰＣＲ用チューブ若しくはその保持用穴部、又は固相された収容部若しくはその保持用穴部の全部若しくはいずれかが処理に応じた必要数含まれていることを特徴とする請求項６乃至請求項１０のいずれかに記載された容器。 JP2005010179A CLAIM 18 前記収容部の少なくとも１ (communication assembly) つは、恒温手段に対応する構造に形成されたことを特徴とする請求項６乃至請求項１７のいずれかに記載された容器。
US8283155B2 CLAIM 14. The system of claim 13 wherein the system is configured to detect a plurality of analytes that generate distinct signals, wherein the intensities of said distinct signals vary over a range of 3 orders (ＰＣＲ) of magnitude.	JP2005010179A CLAIM 11 前記カートリッジ容器は、基部と、当該基部に列状に設けられた複数個の収容部とを有し、当該複数個の収容部には、処理用の収容部、光学測定用の測定器若しくは受光部と遮光状態で連結可能な測定用収容部若しくはその保持用穴部、ピペットチップの収容部若しくはその保持用穴部、ＰＣＲ (3 orders) 用チューブ若しくはその保持用穴部、又は固相された収容部若しくはその保持用穴部の全部若しくはいずれかが処理に応じた必要数含まれていることを特徴とする請求項６乃至請求項１０のいずれかに記載された容器。
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method further comprises detecting an optical signal (放射状) from the sample.	JP2005010179A CLAIM 3 前記溝は、放射状 (optical signal) に形成された複数条の溝であることを特徴とする請求項２に記載された容器。
US8283155B2 CLAIM 18. The system of claim 17 wherein the optical signal (放射状) is a chemiluminscent signal.	JP2005010179A CLAIM 3 前記溝は、放射状 (optical signal) に形成された複数条の溝であることを特徴とする請求項２に記載された容器。
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method includes collecting signals (収納部) from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	JP2005010179A CLAIM 6 前記容器本体は、複数個の液体等の収容部が列状に配列されたカートリッジまたはマイクロプレートで構成されており、これら各収納部 (detection method includes collecting signals) には、請求項１乃至請求項５のいずれかに記載の手段が施されていることを特徴とする容器。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly (受光部) for detecting said signal which is transmitted via said communication assembly (少なくとも１) to said external device.	JP2005010179A CLAIM 11 前記カートリッジ容器は、基部と、当該基部に列状に設けられた複数個の収容部とを有し、当該複数個の収容部には、処理用の収容部、光学測定用の測定器若しくは受光部 (detection assembly) と遮光状態で連結可能な測定用収容部若しくはその保持用穴部、ピペットチップの収容部若しくはその保持用穴部、ＰＣＲ用チューブ若しくはその保持用穴部、又は固相された収容部若しくはその保持用穴部の全部若しくはいずれかが処理に応じた必要数含まれていることを特徴とする請求項６乃至請求項１０のいずれかに記載された容器。 JP2005010179A CLAIM 18 前記収容部の少なくとも１ (communication assembly) つは、恒温手段に対応する構造に形成されたことを特徴とする請求項６乃至請求項１７のいずれかに記載された容器。
US8283155B2 CLAIM 43. The system of claim 42 wherein the system is configured to detect a plurality of analytes that generate distinct signals, wherein the intensities of said distinct signals vary over a range of 3 orders (ＰＣＲ) of magnitude.	JP2005010179A CLAIM 11 前記カートリッジ容器は、基部と、当該基部に列状に設けられた複数個の収容部とを有し、当該複数個の収容部には、処理用の収容部、光学測定用の測定器若しくは受光部と遮光状態で連結可能な測定用収容部若しくはその保持用穴部、ピペットチップの収容部若しくはその保持用穴部、ＰＣＲ (3 orders) 用チューブ若しくはその保持用穴部、又は固相された収容部若しくはその保持用穴部の全部若しくはいずれかが処理に応じた必要数含まれていることを特徴とする請求項６乃至請求項１０のいずれかに記載された容器。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JPH08211071A Filed: 1995-10-27 Issued: 1996-08-20 自動分析装置及びその方法 (Original Assignee) Precision Syst Sci Kk; プレシジョン・システム・サイエンス株式会社 Hideji Tajima, 秀二田島
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (定位置) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	JPH08211071A CLAIM 1 【請求項１】指令によって分注位置で分注作業を行うピペット装置と、指令によって装填されたカートリッジ容器を所定位置 (test device, detection method includes collecting signals) まで移送するカートリッジ容器移送手段と、指令によってカートリッジ容器内の試料に対して測定を行う測定手段と、カートリッジ容器を分注位置及び測定位置へと移送させて分注及び測定を指令する制御装置と、を有して構成されてなる自動分析装置。
US8283155B2 CLAIM 8. The system of claim 1 wherein the test device (定位置) further comprises a microneedle useful for collecting the sample.	JPH08211071A CLAIM 1 【請求項１】指令によって分注位置で分注作業を行うピペット装置と、指令によって装填されたカートリッジ容器を所定位置 (test device, detection method includes collecting signals) まで移送するカートリッジ容器移送手段と、指令によってカートリッジ容器内の試料に対して測定を行う測定手段と、カートリッジ容器を分注位置及び測定位置へと移送させて分注及び測定を指令する制御装置と、を有して構成されてなる自動分析装置。
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device (定位置) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents for said plurality of analytes.	JPH08211071A CLAIM 1 【請求項１】指令によって分注位置で分注作業を行うピペット装置と、指令によって装填されたカートリッジ容器を所定位置 (test device, detection method includes collecting signals) まで移送するカートリッジ容器移送手段と、指令によってカートリッジ容器内の試料に対して測定を行う測定手段と、カートリッジ容器を分注位置及び測定位置へと移送させて分注及び測定を指令する制御装置と、を有して構成されてなる自動分析装置。
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method further comprises detecting an optical signal (放射状) from the sample.	JPH08211071A CLAIM 12 【請求項１２】指令によって所定の領域内で移動可能で、当該領域内で検体の吸排が可能で、マグネット脱着制御ユニットが設けられ、分注チップを装着して、分注位置で分注作業を行うピペット装置と、指令によって、恒温槽の近傍で、放射状 (optical signal) に装填されたカートリッジ容器を所定位置まで回転移送するカートリッジ容器移送手段と、指令によって測定位置で光子数の計測を行う光学測定手段とを有し、前記制御装置は、同一のカートリッジ容器を用いて一連の処理を行うことができる項目の指定を行う項目指定手段と、該項目指定手段によって指定された項目に対し、各項目に含まれる洗浄工程の数や指定された各項目数、各項目の処理時間又は各項目に含まれる各工程の処理時間又はカートリッジ容器位置に基づいて各工程の処理パターンを設定する処理パターン設定手段と、を有して構成されてなる自動分析装置。
US8283155B2 CLAIM 18. The system of claim 17 wherein the optical signal (放射状) is a chemiluminscent signal.	JPH08211071A CLAIM 12 【請求項１２】指令によって所定の領域内で移動可能で、当該領域内で検体の吸排が可能で、マグネット脱着制御ユニットが設けられ、分注チップを装着して、分注位置で分注作業を行うピペット装置と、指令によって、恒温槽の近傍で、放射状 (optical signal) に装填されたカートリッジ容器を所定位置まで回転移送するカートリッジ容器移送手段と、指令によって測定位置で光子数の計測を行う光学測定手段とを有し、前記制御装置は、同一のカートリッジ容器を用いて一連の処理を行うことができる項目の指定を行う項目指定手段と、該項目指定手段によって指定された項目に対し、各項目に含まれる洗浄工程の数や指定された各項目数、各項目の処理時間又は各項目に含まれる各工程の処理時間又はカートリッジ容器位置に基づいて各工程の処理パターンを設定する処理パターン設定手段と、を有して構成されてなる自動分析装置。
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method includes collecting signals (定位置) from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	JPH08211071A CLAIM 1 【請求項１】指令によって分注位置で分注作業を行うピペット装置と、指令によって装填されたカートリッジ容器を所定位置 (test device, detection method includes collecting signals) まで移送するカートリッジ容器移送手段と、指令によってカートリッジ容器内の試料に対して測定を行う測定手段と、カートリッジ容器を分注位置及び測定位置へと移送させて分注及び測定を指令する制御装置と、を有して構成されてなる自動分析装置。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (定位置) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	JPH08211071A CLAIM 1 【請求項１】指令によって分注位置で分注作業を行うピペット装置と、指令によって装填されたカートリッジ容器を所定位置 (test device, detection method includes collecting signals) まで移送するカートリッジ容器移送手段と、指令によってカートリッジ容器内の試料に対して測定を行う測定手段と、カートリッジ容器を分注位置及び測定位置へと移送させて分注及び測定を指令する制御装置と、を有して構成されてなる自動分析装置。
US8283155B2 CLAIM 37. The system of claim 30 wherein the test device (定位置) further comprises a microneedle useful for collecting the sample.	JPH08211071A CLAIM 1 【請求項１】指令によって分注位置で分注作業を行うピペット装置と、指令によって装填されたカートリッジ容器を所定位置 (test device, detection method includes collecting signals) まで移送するカートリッジ容器移送手段と、指令によってカートリッジ容器内の試料に対して測定を行う測定手段と、カートリッジ容器を分注位置及び測定位置へと移送させて分注及び測定を指令する制御装置と、を有して構成されてなる自動分析装置。
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device (定位置) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents for said plurality of analytes.	JPH08211071A CLAIM 1 【請求項１】指令によって分注位置で分注作業を行うピペット装置と、指令によって装填されたカートリッジ容器を所定位置 (test device, detection method includes collecting signals) まで移送するカートリッジ容器移送手段と、指令によってカートリッジ容器内の試料に対して測定を行う測定手段と、カートリッジ容器を分注位置及び測定位置へと移送させて分注及び測定を指令する制御装置と、を有して構成されてなる自動分析装置。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	EP0684315A1 Filed: 1995-03-13 Issued: 1995-11-29 Strand displacement amplification using thermophilic enzymes (Original Assignee) Becton Dickinson and Co (Current Assignee) Becton Dickinson and Co Melinda S. Fraiser, Catherine A. Spargo, George Terrance Walker, Mark Van Cleve, David James Wright
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid fragment, stranded nucleic acid, about 50 ° C) reagents immobilized within the assay assembly.	EP0684315A1 CLAIM 1. A method for amplifying a target sequence comprising: a) providing a single stranded nucleic acid fragment (nucleic acid, nucleic acid reagents) containing the target sequence, the fragment having a 5' end and a 3' end; b) binding an amplification primer for SDA to the 3' end of the fragment such that the primer forms a 5' single stranded overhang, the amplification primer comprising a recognition/cleavage site for a thermophilic restriction endonuclease which does not cut the target nucleic acid sequence; c) extending the amplification primer on the fragment in the presence of i) a thermophilic DNA polymerase, the polymerase being active between about 50 ° C (nucleic acid, nucleic acid reagents) and 70 ° C, having strand displacing activity and lacking 5'-3' exonuclease activity, ii) deoxynucleoside triphosphates, iii) at least one derivatized deoxynucleoside triphosphate, and iv) a thermophilic restriction endonuclease which nicks the recognition/cleavage site when the site is hemimodified by incorporation of the derivatized deoxynucleoside triphosphate, the endonuclease being active between 50 ° C and 70 ° C, thereby producing a first extension product of the amplification primer comprising a first newly synthesized strand complementary to the target sequence and a double stranded hemimodified restriction endonuclease recognition/cleavage site; d) nicking the double stranded hemimodified restriction endonuclease recognition/cleavage site with the restriction endonuclease; e) extending from the nick using the DNA polymerase, thereby displacing the first newly synthesized strand from the fragment and generating a second extension product comprising a second newly synthesized strand, and; f) repeating the nicking, extending and displacing steps such that the target sequence is amplified.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid fragment, stranded nucleic acid, about 50 ° C) reagents for said plurality of analytes.	EP0684315A1 CLAIM 1. A method for amplifying a target sequence comprising: a) providing a single stranded nucleic acid fragment (nucleic acid, nucleic acid reagents) containing the target sequence, the fragment having a 5' end and a 3' end; b) binding an amplification primer for SDA to the 3' end of the fragment such that the primer forms a 5' single stranded overhang, the amplification primer comprising a recognition/cleavage site for a thermophilic restriction endonuclease which does not cut the target nucleic acid sequence; c) extending the amplification primer on the fragment in the presence of i) a thermophilic DNA polymerase, the polymerase being active between about 50 ° C (nucleic acid, nucleic acid reagents) and 70 ° C, having strand displacing activity and lacking 5'-3' exonuclease activity, ii) deoxynucleoside triphosphates, iii) at least one derivatized deoxynucleoside triphosphate, and iv) a thermophilic restriction endonuclease which nicks the recognition/cleavage site when the site is hemimodified by incorporation of the derivatized deoxynucleoside triphosphate, the endonuclease being active between 50 ° C and 70 ° C, thereby producing a first extension product of the amplification primer comprising a first newly synthesized strand complementary to the target sequence and a double stranded hemimodified restriction endonuclease recognition/cleavage site; d) nicking the double stranded hemimodified restriction endonuclease recognition/cleavage site with the restriction endonuclease; e) extending from the nick using the DNA polymerase, thereby displacing the first newly synthesized strand from the fragment and generating a second extension product comprising a second newly synthesized strand, and; f) repeating the nicking, extending and displacing steps such that the target sequence is amplified.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid fragment, stranded nucleic acid, about 50 ° C) reagents immobilized within the assay assembly.	EP0684315A1 CLAIM 1. A method for amplifying a target sequence comprising: a) providing a single stranded nucleic acid fragment (nucleic acid, nucleic acid reagents) containing the target sequence, the fragment having a 5' end and a 3' end; b) binding an amplification primer for SDA to the 3' end of the fragment such that the primer forms a 5' single stranded overhang, the amplification primer comprising a recognition/cleavage site for a thermophilic restriction endonuclease which does not cut the target nucleic acid sequence; c) extending the amplification primer on the fragment in the presence of i) a thermophilic DNA polymerase, the polymerase being active between about 50 ° C (nucleic acid, nucleic acid reagents) and 70 ° C, having strand displacing activity and lacking 5'-3' exonuclease activity, ii) deoxynucleoside triphosphates, iii) at least one derivatized deoxynucleoside triphosphate, and iv) a thermophilic restriction endonuclease which nicks the recognition/cleavage site when the site is hemimodified by incorporation of the derivatized deoxynucleoside triphosphate, the endonuclease being active between 50 ° C and 70 ° C, thereby producing a first extension product of the amplification primer comprising a first newly synthesized strand complementary to the target sequence and a double stranded hemimodified restriction endonuclease recognition/cleavage site; d) nicking the double stranded hemimodified restriction endonuclease recognition/cleavage site with the restriction endonuclease; e) extending from the nick using the DNA polymerase, thereby displacing the first newly synthesized strand from the fragment and generating a second extension product comprising a second newly synthesized strand, and; f) repeating the nicking, extending and displacing steps such that the target sequence is amplified.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid fragment, stranded nucleic acid, about 50 ° C) reagents for said plurality of analytes.	EP0684315A1 CLAIM 1. A method for amplifying a target sequence comprising: a) providing a single stranded nucleic acid fragment (nucleic acid, nucleic acid reagents) containing the target sequence, the fragment having a 5' end and a 3' end; b) binding an amplification primer for SDA to the 3' end of the fragment such that the primer forms a 5' single stranded overhang, the amplification primer comprising a recognition/cleavage site for a thermophilic restriction endonuclease which does not cut the target nucleic acid sequence; c) extending the amplification primer on the fragment in the presence of i) a thermophilic DNA polymerase, the polymerase being active between about 50 ° C (nucleic acid, nucleic acid reagents) and 70 ° C, having strand displacing activity and lacking 5'-3' exonuclease activity, ii) deoxynucleoside triphosphates, iii) at least one derivatized deoxynucleoside triphosphate, and iv) a thermophilic restriction endonuclease which nicks the recognition/cleavage site when the site is hemimodified by incorporation of the derivatized deoxynucleoside triphosphate, the endonuclease being active between 50 ° C and 70 ° C, thereby producing a first extension product of the amplification primer comprising a first newly synthesized strand complementary to the target sequence and a double stranded hemimodified restriction endonuclease recognition/cleavage site; d) nicking the double stranded hemimodified restriction endonuclease recognition/cleavage site with the restriction endonuclease; e) extending from the nick using the DNA polymerase, thereby displacing the first newly synthesized strand from the fragment and generating a second extension product comprising a second newly synthesized strand, and; f) repeating the nicking, extending and displacing steps such that the target sequence is amplified.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JP2003329696A Filed: 2002-05-15 Issued: 2003-11-19 化学発光酵素免疫測定装置 (Original Assignee) Horiba Ltd; Precision System Science Co Ltd; プレシジョン・システム・サイエンス株式会社; 株式会社堀場製作所 Takeshi Kono, Yasumi Nakajima, Hideji Tajima, 保泉中島, 猛河野, 秀二田島
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly (移動自在) comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly (移動自在) containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	JP2003329696A CLAIM 1 【特許請求の範囲】【請求項１】表面に抗原や抗体を固相した磁性微粒子を用いた化学発光酵素免疫測定装置において、平面視円形のターンテーブルの上面にインキュベート機能を有する複数のステージを形成し、各ステージは、検体、磁性微粒子、免疫反応に必要な試薬および洗浄液等の液体を収容するとともに所定の免疫反応を行わせるための複数のウェルが形成された複数のカートリッジを着脱自在に、かつ各カートリッジの外側の端面が前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶようにして位置させる一方、一つのステージにセットされた複数のカートリッジに対してそれぞれ対応するように設けられ、磁性微粒子吸着保持機能を有するディスペンサを複数備えたディスペンサユニットを、前記ターンテーブルの回転中心側から装置前面側との間を直線的に移動自在 (reader assembly, assay assembly) に設け、さらに、前記複数のディスペンサを、前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶように配列したことを特徴とする化学発光酵素免疫測定装置。【請求項２】カートリッジは、その複数のウェルの底部が尖っているとともに、液を収容したときの液面の高さがどのウェルにおいても等しくなるようにそれらの形状および大きさが設定されている請求項１に記載の化学発光酵素免疫測定装置。【請求項３】ターンテーブルの周辺に設けられカートリッジの測定ウェルに収容された免疫反応後の液体に発光基質を注入する発光基質注入部と、前記測定ウェルにおいて生ずる化学発光を測定する化学発光測定部と、装置各部を制御するとともに前記化学発光測定部からの信号を処理する演算制御部とを備えている請求項１または２に記載の化学発光酵素免疫測定装置。
US8283155B2 CLAIM 2. The system of claim 1 wherein the reader assembly (移動自在) further comprises a controller having computer-executable commands for performing the reaction at a designated point-of-care location.	JP2003329696A CLAIM 1 【特許請求の範囲】【請求項１】表面に抗原や抗体を固相した磁性微粒子を用いた化学発光酵素免疫測定装置において、平面視円形のターンテーブルの上面にインキュベート機能を有する複数のステージを形成し、各ステージは、検体、磁性微粒子、免疫反応に必要な試薬および洗浄液等の液体を収容するとともに所定の免疫反応を行わせるための複数のウェルが形成された複数のカートリッジを着脱自在に、かつ各カートリッジの外側の端面が前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶようにして位置させる一方、一つのステージにセットされた複数のカートリッジに対してそれぞれ対応するように設けられ、磁性微粒子吸着保持機能を有するディスペンサを複数備えたディスペンサユニットを、前記ターンテーブルの回転中心側から装置前面側との間を直線的に移動自在 (reader assembly, assay assembly) に設け、さらに、前記複数のディスペンサを、前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶように配列したことを特徴とする化学発光酵素免疫測定装置。【請求項２】カートリッジは、その複数のウェルの底部が尖っているとともに、液を収容したときの液面の高さがどのウェルにおいても等しくなるようにそれらの形状および大きさが設定されている請求項１に記載の化学発光酵素免疫測定装置。【請求項３】ターンテーブルの周辺に設けられカートリッジの測定ウェルに収容された免疫反応後の液体に発光基質を注入する発光基質注入部と、前記測定ウェルにおいて生ずる化学発光を測定する化学発光測定部と、装置各部を制御するとともに前記化学発光測定部からの信号を処理する演算制御部とを備えている請求項１または２に記載の化学発光酵素免疫測定装置。
US8283155B2 CLAIM 10. The system of claim 1 wherein the reader assembly (移動自在) is configured to receive said protocol wirelessly from said external device.	JP2003329696A CLAIM 1 【特許請求の範囲】【請求項１】表面に抗原や抗体を固相した磁性微粒子を用いた化学発光酵素免疫測定装置において、平面視円形のターンテーブルの上面にインキュベート機能を有する複数のステージを形成し、各ステージは、検体、磁性微粒子、免疫反応に必要な試薬および洗浄液等の液体を収容するとともに所定の免疫反応を行わせるための複数のウェルが形成された複数のカートリッジを着脱自在に、かつ各カートリッジの外側の端面が前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶようにして位置させる一方、一つのステージにセットされた複数のカートリッジに対してそれぞれ対応するように設けられ、磁性微粒子吸着保持機能を有するディスペンサを複数備えたディスペンサユニットを、前記ターンテーブルの回転中心側から装置前面側との間を直線的に移動自在 (reader assembly, assay assembly) に設け、さらに、前記複数のディスペンサを、前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶように配列したことを特徴とする化学発光酵素免疫測定装置。【請求項２】カートリッジは、その複数のウェルの底部が尖っているとともに、液を収容したときの液面の高さがどのウェルにおいても等しくなるようにそれらの形状および大きさが設定されている請求項１に記載の化学発光酵素免疫測定装置。【請求項３】ターンテーブルの周辺に設けられカートリッジの測定ウェルに収容された免疫反応後の液体に発光基質を注入する発光基質注入部と、前記測定ウェルにおいて生ずる化学発光を測定する化学発光測定部と、装置各部を制御するとともに前記化学発光測定部からの信号を処理する演算制御部とを備えている請求項１または２に記載の化学発光酵素免疫測定装置。
US8283155B2 CLAIM 11. The system of claim 1 wherein said reader assembly (移動自在) comprises an identifier detector that detects said identifier.	JP2003329696A CLAIM 1 【特許請求の範囲】【請求項１】表面に抗原や抗体を固相した磁性微粒子を用いた化学発光酵素免疫測定装置において、平面視円形のターンテーブルの上面にインキュベート機能を有する複数のステージを形成し、各ステージは、検体、磁性微粒子、免疫反応に必要な試薬および洗浄液等の液体を収容するとともに所定の免疫反応を行わせるための複数のウェルが形成された複数のカートリッジを着脱自在に、かつ各カートリッジの外側の端面が前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶようにして位置させる一方、一つのステージにセットされた複数のカートリッジに対してそれぞれ対応するように設けられ、磁性微粒子吸着保持機能を有するディスペンサを複数備えたディスペンサユニットを、前記ターンテーブルの回転中心側から装置前面側との間を直線的に移動自在 (reader assembly, assay assembly) に設け、さらに、前記複数のディスペンサを、前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶように配列したことを特徴とする化学発光酵素免疫測定装置。【請求項２】カートリッジは、その複数のウェルの底部が尖っているとともに、液を収容したときの液面の高さがどのウェルにおいても等しくなるようにそれらの形状および大きさが設定されている請求項１に記載の化学発光酵素免疫測定装置。【請求項３】ターンテーブルの周辺に設けられカートリッジの測定ウェルに収容された免疫反応後の液体に発光基質を注入する発光基質注入部と、前記測定ウェルにおいて生ずる化学発光を測定する化学発光測定部と、装置各部を制御するとともに前記化学発光測定部からの信号を処理する演算制御部とを備えている請求項１または２に記載の化学発光酵素免疫測定装置。
US8283155B2 CLAIM 16. The system of claim 1 wherein the assay assembly (移動自在) is configured to run a plurality of types of assays.	JP2003329696A CLAIM 1 【特許請求の範囲】【請求項１】表面に抗原や抗体を固相した磁性微粒子を用いた化学発光酵素免疫測定装置において、平面視円形のターンテーブルの上面にインキュベート機能を有する複数のステージを形成し、各ステージは、検体、磁性微粒子、免疫反応に必要な試薬および洗浄液等の液体を収容するとともに所定の免疫反応を行わせるための複数のウェルが形成された複数のカートリッジを着脱自在に、かつ各カートリッジの外側の端面が前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶようにして位置させる一方、一つのステージにセットされた複数のカートリッジに対してそれぞれ対応するように設けられ、磁性微粒子吸着保持機能を有するディスペンサを複数備えたディスペンサユニットを、前記ターンテーブルの回転中心側から装置前面側との間を直線的に移動自在 (reader assembly, assay assembly) に設け、さらに、前記複数のディスペンサを、前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶように配列したことを特徴とする化学発光酵素免疫測定装置。【請求項２】カートリッジは、その複数のウェルの底部が尖っているとともに、液を収容したときの液面の高さがどのウェルにおいても等しくなるようにそれらの形状および大きさが設定されている請求項１に記載の化学発光酵素免疫測定装置。【請求項３】ターンテーブルの周辺に設けられカートリッジの測定ウェルに収容された免疫反応後の液体に発光基質を注入する発光基質注入部と、前記測定ウェルにおいて生ずる化学発光を測定する化学発光測定部と、装置各部を制御するとともに前記化学発光測定部からの信号を処理する演算制御部とを備えている請求項１または２に記載の化学発光酵素免疫測定装置。
US8283155B2 CLAIM 22. A method for detecting an analyte in a bodily fluid of a subject, comprising: a) providing a system of claim 1 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly (移動自在) to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	JP2003329696A CLAIM 1 【特許請求の範囲】【請求項１】表面に抗原や抗体を固相した磁性微粒子を用いた化学発光酵素免疫測定装置において、平面視円形のターンテーブルの上面にインキュベート機能を有する複数のステージを形成し、各ステージは、検体、磁性微粒子、免疫反応に必要な試薬および洗浄液等の液体を収容するとともに所定の免疫反応を行わせるための複数のウェルが形成された複数のカートリッジを着脱自在に、かつ各カートリッジの外側の端面が前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶようにして位置させる一方、一つのステージにセットされた複数のカートリッジに対してそれぞれ対応するように設けられ、磁性微粒子吸着保持機能を有するディスペンサを複数備えたディスペンサユニットを、前記ターンテーブルの回転中心側から装置前面側との間を直線的に移動自在 (reader assembly, assay assembly) に設け、さらに、前記複数のディスペンサを、前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶように配列したことを特徴とする化学発光酵素免疫測定装置。【請求項２】カートリッジは、その複数のウェルの底部が尖っているとともに、液を収容したときの液面の高さがどのウェルにおいても等しくなるようにそれらの形状および大きさが設定されている請求項１に記載の化学発光酵素免疫測定装置。【請求項３】ターンテーブルの周辺に設けられカートリッジの測定ウェルに収容された免疫反応後の液体に発光基質を注入する発光基質注入部と、前記測定ウェルにおいて生ずる化学発光を測定する化学発光測定部と、装置各部を制御するとともに前記化学発光測定部からの信号を処理する演算制御部とを備えている請求項１または２に記載の化学発光酵素免疫測定装置。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly (移動自在) comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly (移動自在) configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	JP2003329696A CLAIM 1 【特許請求の範囲】【請求項１】表面に抗原や抗体を固相した磁性微粒子を用いた化学発光酵素免疫測定装置において、平面視円形のターンテーブルの上面にインキュベート機能を有する複数のステージを形成し、各ステージは、検体、磁性微粒子、免疫反応に必要な試薬および洗浄液等の液体を収容するとともに所定の免疫反応を行わせるための複数のウェルが形成された複数のカートリッジを着脱自在に、かつ各カートリッジの外側の端面が前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶようにして位置させる一方、一つのステージにセットされた複数のカートリッジに対してそれぞれ対応するように設けられ、磁性微粒子吸着保持機能を有するディスペンサを複数備えたディスペンサユニットを、前記ターンテーブルの回転中心側から装置前面側との間を直線的に移動自在 (reader assembly, assay assembly) に設け、さらに、前記複数のディスペンサを、前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶように配列したことを特徴とする化学発光酵素免疫測定装置。【請求項２】カートリッジは、その複数のウェルの底部が尖っているとともに、液を収容したときの液面の高さがどのウェルにおいても等しくなるようにそれらの形状および大きさが設定されている請求項１に記載の化学発光酵素免疫測定装置。【請求項３】ターンテーブルの周辺に設けられカートリッジの測定ウェルに収容された免疫反応後の液体に発光基質を注入する発光基質注入部と、前記測定ウェルにおいて生ずる化学発光を測定する化学発光測定部と、装置各部を制御するとともに前記化学発光測定部からの信号を処理する演算制御部とを備えている請求項１または２に記載の化学発光酵素免疫測定装置。
US8283155B2 CLAIM 31. The system of claim 30 wherein the reader assembly (移動自在) further comprises a controller having computer-executable commands for performing the reaction at a designated point-of-care location.	JP2003329696A CLAIM 1 【特許請求の範囲】【請求項１】表面に抗原や抗体を固相した磁性微粒子を用いた化学発光酵素免疫測定装置において、平面視円形のターンテーブルの上面にインキュベート機能を有する複数のステージを形成し、各ステージは、検体、磁性微粒子、免疫反応に必要な試薬および洗浄液等の液体を収容するとともに所定の免疫反応を行わせるための複数のウェルが形成された複数のカートリッジを着脱自在に、かつ各カートリッジの外側の端面が前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶようにして位置させる一方、一つのステージにセットされた複数のカートリッジに対してそれぞれ対応するように設けられ、磁性微粒子吸着保持機能を有するディスペンサを複数備えたディスペンサユニットを、前記ターンテーブルの回転中心側から装置前面側との間を直線的に移動自在 (reader assembly, assay assembly) に設け、さらに、前記複数のディスペンサを、前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶように配列したことを特徴とする化学発光酵素免疫測定装置。【請求項２】カートリッジは、その複数のウェルの底部が尖っているとともに、液を収容したときの液面の高さがどのウェルにおいても等しくなるようにそれらの形状および大きさが設定されている請求項１に記載の化学発光酵素免疫測定装置。【請求項３】ターンテーブルの周辺に設けられカートリッジの測定ウェルに収容された免疫反応後の液体に発光基質を注入する発光基質注入部と、前記測定ウェルにおいて生ずる化学発光を測定する化学発光測定部と、装置各部を制御するとともに前記化学発光測定部からの信号を処理する演算制御部とを備えている請求項１または２に記載の化学発光酵素免疫測定装置。
US8283155B2 CLAIM 39. The system of claim 30 wherein the reader assembly (移動自在) is configured to receive said protocol wirelessly from said external device.	JP2003329696A CLAIM 1 【特許請求の範囲】【請求項１】表面に抗原や抗体を固相した磁性微粒子を用いた化学発光酵素免疫測定装置において、平面視円形のターンテーブルの上面にインキュベート機能を有する複数のステージを形成し、各ステージは、検体、磁性微粒子、免疫反応に必要な試薬および洗浄液等の液体を収容するとともに所定の免疫反応を行わせるための複数のウェルが形成された複数のカートリッジを着脱自在に、かつ各カートリッジの外側の端面が前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶようにして位置させる一方、一つのステージにセットされた複数のカートリッジに対してそれぞれ対応するように設けられ、磁性微粒子吸着保持機能を有するディスペンサを複数備えたディスペンサユニットを、前記ターンテーブルの回転中心側から装置前面側との間を直線的に移動自在 (reader assembly, assay assembly) に設け、さらに、前記複数のディスペンサを、前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶように配列したことを特徴とする化学発光酵素免疫測定装置。【請求項２】カートリッジは、その複数のウェルの底部が尖っているとともに、液を収容したときの液面の高さがどのウェルにおいても等しくなるようにそれらの形状および大きさが設定されている請求項１に記載の化学発光酵素免疫測定装置。【請求項３】ターンテーブルの周辺に設けられカートリッジの測定ウェルに収容された免疫反応後の液体に発光基質を注入する発光基質注入部と、前記測定ウェルにおいて生ずる化学発光を測定する化学発光測定部と、装置各部を制御するとともに前記化学発光測定部からの信号を処理する演算制御部とを備えている請求項１または２に記載の化学発光酵素免疫測定装置。
US8283155B2 CLAIM 40. The system of claim 30 wherein said reader assembly (移動自在) comprises an identifier detector that detects said identifier.	JP2003329696A CLAIM 1 【特許請求の範囲】【請求項１】表面に抗原や抗体を固相した磁性微粒子を用いた化学発光酵素免疫測定装置において、平面視円形のターンテーブルの上面にインキュベート機能を有する複数のステージを形成し、各ステージは、検体、磁性微粒子、免疫反応に必要な試薬および洗浄液等の液体を収容するとともに所定の免疫反応を行わせるための複数のウェルが形成された複数のカートリッジを着脱自在に、かつ各カートリッジの外側の端面が前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶようにして位置させる一方、一つのステージにセットされた複数のカートリッジに対してそれぞれ対応するように設けられ、磁性微粒子吸着保持機能を有するディスペンサを複数備えたディスペンサユニットを、前記ターンテーブルの回転中心側から装置前面側との間を直線的に移動自在 (reader assembly, assay assembly) に設け、さらに、前記複数のディスペンサを、前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶように配列したことを特徴とする化学発光酵素免疫測定装置。【請求項２】カートリッジは、その複数のウェルの底部が尖っているとともに、液を収容したときの液面の高さがどのウェルにおいても等しくなるようにそれらの形状および大きさが設定されている請求項１に記載の化学発光酵素免疫測定装置。【請求項３】ターンテーブルの周辺に設けられカートリッジの測定ウェルに収容された免疫反応後の液体に発光基質を注入する発光基質注入部と、前記測定ウェルにおいて生ずる化学発光を測定する化学発光測定部と、装置各部を制御するとともに前記化学発光測定部からの信号を処理する演算制御部とを備えている請求項１または２に記載の化学発光酵素免疫測定装置。
US8283155B2 CLAIM 48. A method for detecting an analyte in a bodily fluid of a subject, comprising: a) providing a system of claim 30 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly (移動自在) to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	JP2003329696A CLAIM 1 【特許請求の範囲】【請求項１】表面に抗原や抗体を固相した磁性微粒子を用いた化学発光酵素免疫測定装置において、平面視円形のターンテーブルの上面にインキュベート機能を有する複数のステージを形成し、各ステージは、検体、磁性微粒子、免疫反応に必要な試薬および洗浄液等の液体を収容するとともに所定の免疫反応を行わせるための複数のウェルが形成された複数のカートリッジを着脱自在に、かつ各カートリッジの外側の端面が前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶようにして位置させる一方、一つのステージにセットされた複数のカートリッジに対してそれぞれ対応するように設けられ、磁性微粒子吸着保持機能を有するディスペンサを複数備えたディスペンサユニットを、前記ターンテーブルの回転中心側から装置前面側との間を直線的に移動自在 (reader assembly, assay assembly) に設け、さらに、前記複数のディスペンサを、前記ターンテーブルの外周の曲率半径と等しい曲率半径を有する円弧上に並ぶように配列したことを特徴とする化学発光酵素免疫測定装置。【請求項２】カートリッジは、その複数のウェルの底部が尖っているとともに、液を収容したときの液面の高さがどのウェルにおいても等しくなるようにそれらの形状および大きさが設定されている請求項１に記載の化学発光酵素免疫測定装置。【請求項３】ターンテーブルの周辺に設けられカートリッジの測定ウェルに収容された免疫反応後の液体に発光基質を注入する発光基質注入部と、前記測定ウェルにおいて生ずる化学発光を測定する化学発光測定部と、装置各部を制御するとともに前記化学発光測定部からの信号を処理する演算制御部とを備えている請求項１または２に記載の化学発光酵素免疫測定装置。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JPH1157560A Filed: 1997-08-27 Issued: 1999-03-02 液体散布車 (Original Assignee) Shin Meiwa Ind Co Ltd; 新明和工業株式会社 Masaru Nitta, Yasushi Okamoto, 靖岡本, 優新田
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method (検出信号) for detecting said signal, and wherein said reader further comprises a detection assembly (検出信号) for detecting said signal which is transmitted via said communication assembly to said external device.	JPH1157560A CLAIM 1 【請求項１】車体上に液体貯留タンクが載置され、液体貯留タンクに連通された散布ノズルが車体の適所に配置された液体散布車において、前記散布ノズルは、適宜なアクチュエータにより少なくとも車輌の幅方向に水平面上を揺動自在に設けられ、車輌の走行状況を検出する検出装置からの検出信号 (detection method, detection assembly) に基づいて散布ノズルの揺動動作が制御されるように構成されたことを特徴とする液体散布車。
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method (検出信号) further comprises detecting an optical signal from the sample.	JPH1157560A CLAIM 1 【請求項１】車体上に液体貯留タンクが載置され、液体貯留タンクに連通された散布ノズルが車体の適所に配置された液体散布車において、前記散布ノズルは、適宜なアクチュエータにより少なくとも車輌の幅方向に水平面上を揺動自在に設けられ、車輌の走行状況を検出する検出装置からの検出信号 (detection method, detection assembly) に基づいて散布ノズルの揺動動作が制御されるように構成されたことを特徴とする液体散布車。
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method (検出信号) includes collecting signals from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	JPH1157560A CLAIM 1 【請求項１】車体上に液体貯留タンクが載置され、液体貯留タンクに連通された散布ノズルが車体の適所に配置された液体散布車において、前記散布ノズルは、適宜なアクチュエータにより少なくとも車輌の幅方向に水平面上を揺動自在に設けられ、車輌の走行状況を検出する検出装置からの検出信号 (detection method, detection assembly) に基づいて散布ノズルの揺動動作が制御されるように構成されたことを特徴とする液体散布車。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly (検出信号) for detecting said signal which is transmitted via said communication assembly to said external device.	JPH1157560A CLAIM 1 【請求項１】車体上に液体貯留タンクが載置され、液体貯留タンクに連通された散布ノズルが車体の適所に配置された液体散布車において、前記散布ノズルは、適宜なアクチュエータにより少なくとも車輌の幅方向に水平面上を揺動自在に設けられ、車輌の走行状況を検出する検出装置からの検出信号 (detection method, detection assembly) に基づいて散布ノズルの揺動動作が制御されるように構成されたことを特徴とする液体散布車。
US8283155B2 CLAIM 45. The system of claim 30 further comprising a dilution chamber (水平面) containing a diluents for diluting the sample of bodily fluid according to said protocol transmitted by the external device and received by the reader assembly.	JPH1157560A CLAIM 1 【請求項１】車体上に液体貯留タンクが載置され、液体貯留タンクに連通された散布ノズルが車体の適所に配置された液体散布車において、前記散布ノズルは、適宜なアクチュエータにより少なくとも車輌の幅方向に水平面 (dilution chamber) 上を揺動自在に設けられ、車輌の走行状況を検出する検出装置からの検出信号に基づいて散布ノズルの揺動動作が制御されるように構成されたことを特徴とする液体散布車。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	CN1526074A Filed: 2002-05-09 Issued: 2004-09-01 检测系统 (Original Assignee) 阿克西斯-希尔德公司乔斯坦・霍尔特伦德, 乔斯坦·霍尔特伦德, ・M・博尔奇, 施蒂格·M·博尔奇, 坦・塞姆, 索尔斯坦·塞姆, 詹森, 托尔·詹森, 托恩, 赫格·托恩, たǘ森, 简·R·卡尔森, L・劳夫斯塔德, 英格·L·劳夫斯塔德
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants (其中一种) that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	CN1526074A CLAIM 43.一种检测方法，其中一种 (assay assembly containing reactants) 液体从一容器中被传送到一吸管里面，其特征在于液体经由其进入的所述吸管的端部由一可允许液体透过的薄膜予以密封。
US8283155B2 CLAIM 11. The system of claim 1 wherein said reader assembly comprises an identifier detector (薄膜的) that detects said identifier.	CN1526074A CLAIM 1.一种检测装置，包括：i)一检测盒(52，53)，包括至少两个插孔(57-62)和一个吸管(55)，后者可置放在至少两个所述插孔之中，所述吸管具有一近端和一远端，所述远端由一可渗透液体的薄膜封闭；ii)一托座，配置用来纳放所述检测盒；iii)一驱动器，用以将所述吸管置放在所述检测盒的选定的插孔之中；iv)一气体加压器，可联接于所述吸管，借以造成穿过所述薄膜的 (identifier detector) 液流；以及v)一辐射探测器，用以探测所述检测盒一插孔或所述吸管的辐射。
US8283155B2 CLAIM 23. The method of claim 22 further comprising quantifying the amount of said analyte present (检测试剂) in said sample.	CN1526074A CLAIM 35.按照权利要求21至24中任何一项所述的一种检测盒，其中至少一个所述插孔装有一种检测试剂 (analyte present) 。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants (其中一种) for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	CN1526074A CLAIM 43.一种检测方法，其中一种 (assay assembly containing reactants) 液体从一容器中被传送到一吸管里面，其特征在于液体经由其进入的所述吸管的端部由一可允许液体透过的薄膜予以密封。
US8283155B2 CLAIM 40. The system of claim 30 wherein said reader assembly comprises an identifier detector (薄膜的) that detects said identifier.	CN1526074A CLAIM 1.一种检测装置，包括：i)一检测盒(52，53)，包括至少两个插孔(57-62)和一个吸管(55)，后者可置放在至少两个所述插孔之中，所述吸管具有一近端和一远端，所述远端由一可渗透液体的薄膜封闭；ii)一托座，配置用来纳放所述检测盒；iii)一驱动器，用以将所述吸管置放在所述检测盒的选定的插孔之中；iv)一气体加压器，可联接于所述吸管，借以造成穿过所述薄膜的 (identifier detector) 液流；以及v)一辐射探测器，用以探测所述检测盒一插孔或所述吸管的辐射。
US8283155B2 CLAIM 49. The method of claim 48 further comprising quantifying the amount of said analyte present (检测试剂) in said sample.	CN1526074A CLAIM 35.按照权利要求21至24中任何一项所述的一种检测盒，其中至少一个所述插孔装有一种检测试剂 (analyte present) 。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	EP1203959A1 Filed: 2000-08-11 Issued: 2002-05-08 Analyzing cartridge and liquid feed control device (Original Assignee) Asahi Kasei Corp; Asahi Chemical Industry Co Ltd (Current Assignee) Asahi Kasei Corp ; Asahi Chemical Industry Co Ltd Akira Kiguchi, Nobuya Kitaguchi
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (hydrophobic porous membrane) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	EP1203959A1 CLAIM 5 The analyzing cartridge according to claim 4, characterized in that said hydrophobic member having pores is a hydrophobic porous membrane (test device, nucleic acid reagents, analyte present) .
US8283155B2 CLAIM 8. The system of claim 1 wherein the test device (hydrophobic porous membrane) further comprises a microneedle useful for collecting the sample.	EP1203959A1 CLAIM 5 The analyzing cartridge according to claim 4, characterized in that said hydrophobic member having pores is a hydrophobic porous membrane (test device, nucleic acid reagents, analyte present) .
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid reagents (hydrophobic porous membrane) immobilized within the assay assembly.	EP1203959A1 CLAIM 5 The analyzing cartridge according to claim 4, characterized in that said hydrophobic member having pores is a hydrophobic porous membrane (test device, nucleic acid reagents, analyte present) .
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device (hydrophobic porous membrane) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents (hydrophobic porous membrane) for said plurality of analytes.	EP1203959A1 CLAIM 5 The analyzing cartridge according to claim 4, characterized in that said hydrophobic member having pores is a hydrophobic porous membrane (test device, nucleic acid reagents, analyte present) .
US8283155B2 CLAIM 23. The method of claim 22 further comprising quantifying the amount of said analyte present (hydrophobic porous membrane) in said sample.	EP1203959A1 CLAIM 5 The analyzing cartridge according to claim 4, characterized in that said hydrophobic member having pores is a hydrophobic porous membrane (test device, nucleic acid reagents, analyte present) .
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (hydrophobic porous membrane) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	EP1203959A1 CLAIM 5 The analyzing cartridge according to claim 4, characterized in that said hydrophobic member having pores is a hydrophobic porous membrane (test device, nucleic acid reagents, analyte present) .
US8283155B2 CLAIM 37. The system of claim 30 wherein the test device (hydrophobic porous membrane) further comprises a microneedle useful for collecting the sample.	EP1203959A1 CLAIM 5 The analyzing cartridge according to claim 4, characterized in that said hydrophobic member having pores is a hydrophobic porous membrane (test device, nucleic acid reagents, analyte present) .
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid reagents (hydrophobic porous membrane) immobilized within the assay assembly.	EP1203959A1 CLAIM 5 The analyzing cartridge according to claim 4, characterized in that said hydrophobic member having pores is a hydrophobic porous membrane (test device, nucleic acid reagents, analyte present) .
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device (hydrophobic porous membrane) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents (hydrophobic porous membrane) for said plurality of analytes.	EP1203959A1 CLAIM 5 The analyzing cartridge according to claim 4, characterized in that said hydrophobic member having pores is a hydrophobic porous membrane (test device, nucleic acid reagents, analyte present) .
US8283155B2 CLAIM 49. The method of claim 48 further comprising quantifying the amount of said analyte present (hydrophobic porous membrane) in said sample.	EP1203959A1 CLAIM 5 The analyzing cartridge according to claim 4, characterized in that said hydrophobic member having pores is a hydrophobic porous membrane (test device, nucleic acid reagents, analyte present) .

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	EP0723146A1 Filed: 1993-09-14 Issued: 1996-07-24 Up-converting reporters for biological and other assays using laser excitation techniques (Original Assignee) SRI International (Current Assignee) SRI International designation of the inventor has not yet been filed The
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants (second electrical signal) that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	EP0723146A1 CLAIM 5 Apparatus for analysing a sample possible containing first and second up-converting luminescent reporters, wherein the first reporter is characterised by an excitation band in a first range of wavelengths and an emission band in a second range of wavelengths that are shorter than the wavelengths in the first range, wherein the second reporter is characterised by an excitation band in a third range of wavelengths and an emission band in a fourth range of wavelengths, and wherein the first and third ranges do not overlap and the second and fourth ranges overlap, the apparatus comprising: a first source capable of emitting light in a range of wavelengths that overlaps with at least a portion of the excitation band of the first reporter; a second source capable of emitting light in a range of wavelengths that overlaps with a least a portion of the excitation band of the second reporter; means for energizing said first and second sources including means for imposing different intensity patterns on said first-mentioned and second sources; means for directing at least a portion of the light emitted by said first and second sources to a location at the sample, including light in the first and third ranges of wavelengths and excluding light in the second and fourth ranges of wavelengths; and means, coupled to said detector, for generating first and second electrical signal (assay assembly containing reactants) s representative of the respective intensities of light incident on said detector at wavelengths in the second and fourth ranges and outside the first and third ranges, including means for distinguishing said different intensity patterns.
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants (second electrical signal) for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	EP0723146A1 CLAIM 5 Apparatus for analysing a sample possible containing first and second up-converting luminescent reporters, wherein the first reporter is characterised by an excitation band in a first range of wavelengths and an emission band in a second range of wavelengths that are shorter than the wavelengths in the first range, wherein the second reporter is characterised by an excitation band in a third range of wavelengths and an emission band in a fourth range of wavelengths, and wherein the first and third ranges do not overlap and the second and fourth ranges overlap, the apparatus comprising: a first source capable of emitting light in a range of wavelengths that overlaps with at least a portion of the excitation band of the first reporter; a second source capable of emitting light in a range of wavelengths that overlaps with a least a portion of the excitation band of the second reporter; means for energizing said first and second sources including means for imposing different intensity patterns on said first-mentioned and second sources; means for directing at least a portion of the light emitted by said first and second sources to a location at the sample, including light in the first and third ranges of wavelengths and excluding light in the second and fourth ranges of wavelengths; and means, coupled to said detector, for generating first and second electrical signal (assay assembly containing reactants) s representative of the respective intensities of light incident on said detector at wavelengths in the second and fourth ranges and outside the first and third ranges, including means for distinguishing said different intensity patterns.

EP0723146A1

Filed: 1993-09-14 Issued: 1996-07-24

Up-converting reporters for biological and other assays using laser excitation techniques

(Original Assignee) SRI International (Current Assignee) SRI International

designation of the inventor has not yet been filed The

US8283155B2
CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly containing reactants (second electrical signal) that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.

EP0723146A1
CLAIM 5 Apparatus for analysing a sample possible containing first and second up-converting luminescent reporters, wherein the first reporter is characterised by an excitation band in a first range of wavelengths and an emission band in a second range of wavelengths that are shorter than the wavelengths in the first range, wherein the second reporter is characterised by an excitation band in a third range of wavelengths and an emission band in a fourth range of wavelengths, and wherein the first and third ranges do not overlap and the second and fourth ranges overlap, the apparatus comprising: a first source capable of emitting light in a range of wavelengths that overlaps with at least a portion of the excitation band of the first reporter; a second source capable of emitting light in a range of wavelengths that overlaps with a least a portion of the excitation band of the second reporter; means for energizing said first and second sources including means for imposing different intensity patterns on said first-mentioned and second sources; means for directing at least a portion of the light emitted by said first and second sources to a location at the sample, including light in the first and third ranges of wavelengths and excluding light in the second and fourth ranges of wavelengths; and means, coupled to said detector, for generating first and second electrical signal (assay assembly containing reactants) s representative of the respective intensities of light incident on said detector at wavelengths in the second and fourth ranges and outside the first and third ranges, including means for distinguishing said different intensity patterns.

US8283155B2
CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants (second electrical signal) for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JPH0727700A Filed: 1993-07-14 Issued: 1995-01-31 光学式成分濃度測定装置および方法 (Original Assignee) Kyoto Daiichi Kagaku:Kk; 株式会社京都第一科学 Kakin Jiyo, Takeshi Sakura, Seizo Uenoyama, Yutaka Yamazaki, 晴三上野山, 武司佐倉, 豊山崎, 可欣徐
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (照射部) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method (検出手段, 受光部) for detecting said signal, and wherein said reader further comprises a detection assembly (検出手段, 受光部) for detecting said signal which is transmitted via said communication assembly to said external device.	JPH0727700A CLAIM 1 【請求項１】試料を収容し、内部の光路長を異ならせることが可能なセルと、このセルに対して選択された波長の光を照射するとともに、この照射する光の波長を変え得る光照射部 (test device) と、上記セルを透過した光を受け、この透過光量を検出する受光部 (detection method, detection assembly) と、この受光部で検出した透過光量に対する光量測定感度のピーク値が生じるときの光路長を波長毎に算出、記憶し、この波長毎に記憶したピーク位置での透過光量値、光路長の値に基づいて上記試料中の成分の濃度を算出し、算出結果を出力する演算部とからなる光学式成分濃度測定装置。 JPH0727700A CLAIM 9 【請求項９】上記受光部が選択された光を受けて光量を検出する光量検出手段 (detection method, detection assembly) を備えたことを特徴とする請求項１から８のいずれかに記載の光学式成分濃度測定装置。
US8283155B2 CLAIM 8. The system of claim 1 wherein the test device (照射部) further comprises a microneedle useful for collecting the sample.	JPH0727700A CLAIM 1 【請求項１】試料を収容し、内部の光路長を異ならせることが可能なセルと、このセルに対して選択された波長の光を照射するとともに、この照射する光の波長を変え得る光照射部 (test device) と、上記セルを透過した光を受け、この透過光量を検出する受光部と、この受光部で検出した透過光量に対する光量測定感度のピーク値が生じるときの光路長を波長毎に算出、記憶し、この波長毎に記憶したピーク位置での透過光量値、光路長の値に基づいて上記試料中の成分の濃度を算出し、算出結果を出力する演算部とからなる光学式成分濃度測定装置。
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device (照射部) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents for said plurality of analytes.	JPH0727700A CLAIM 1 【請求項１】試料を収容し、内部の光路長を異ならせることが可能なセルと、このセルに対して選択された波長の光を照射するとともに、この照射する光の波長を変え得る光照射部 (test device) と、上記セルを透過した光を受け、この透過光量を検出する受光部と、この受光部で検出した透過光量に対する光量測定感度のピーク値が生じるときの光路長を波長毎に算出、記憶し、この波長毎に記憶したピーク位置での透過光量値、光路長の値に基づいて上記試料中の成分の濃度を算出し、算出結果を出力する演算部とからなる光学式成分濃度測定装置。
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method (検出手段, 受光部) further comprises detecting an optical signal from the sample.	JPH0727700A CLAIM 1 【請求項１】試料を収容し、内部の光路長を異ならせることが可能なセルと、このセルに対して選択された波長の光を照射するとともに、この照射する光の波長を変え得る光照射部と、上記セルを透過した光を受け、この透過光量を検出する受光部 (detection method, detection assembly) と、この受光部で検出した透過光量に対する光量測定感度のピーク値が生じるときの光路長を波長毎に算出、記憶し、この波長毎に記憶したピーク位置での透過光量値、光路長の値に基づいて上記試料中の成分の濃度を算出し、算出結果を出力する演算部とからなる光学式成分濃度測定装置。 JPH0727700A CLAIM 9 【請求項９】上記受光部が選択された光を受けて光量を検出する光量検出手段 (detection method, detection assembly) を備えたことを特徴とする請求項１から８のいずれかに記載の光学式成分濃度測定装置。
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method (検出手段, 受光部) includes collecting signals from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	JPH0727700A CLAIM 1 【請求項１】試料を収容し、内部の光路長を異ならせることが可能なセルと、このセルに対して選択された波長の光を照射するとともに、この照射する光の波長を変え得る光照射部と、上記セルを透過した光を受け、この透過光量を検出する受光部 (detection method, detection assembly) と、この受光部で検出した透過光量に対する光量測定感度のピーク値が生じるときの光路長を波長毎に算出、記憶し、この波長毎に記憶したピーク位置での透過光量値、光路長の値に基づいて上記試料中の成分の濃度を算出し、算出結果を出力する演算部とからなる光学式成分濃度測定装置。 JPH0727700A CLAIM 9 【請求項９】上記受光部が選択された光を受けて光量を検出する光量検出手段 (detection method, detection assembly) を備えたことを特徴とする請求項１から８のいずれかに記載の光学式成分濃度測定装置。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (照射部) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly (検出手段, 受光部) for detecting said signal which is transmitted via said communication assembly to said external device.	JPH0727700A CLAIM 1 【請求項１】試料を収容し、内部の光路長を異ならせることが可能なセルと、このセルに対して選択された波長の光を照射するとともに、この照射する光の波長を変え得る光照射部 (test device) と、上記セルを透過した光を受け、この透過光量を検出する受光部 (detection method, detection assembly) と、この受光部で検出した透過光量に対する光量測定感度のピーク値が生じるときの光路長を波長毎に算出、記憶し、この波長毎に記憶したピーク位置での透過光量値、光路長の値に基づいて上記試料中の成分の濃度を算出し、算出結果を出力する演算部とからなる光学式成分濃度測定装置。 JPH0727700A CLAIM 9 【請求項９】上記受光部が選択された光を受けて光量を検出する光量検出手段 (detection method, detection assembly) を備えたことを特徴とする請求項１から８のいずれかに記載の光学式成分濃度測定装置。
US8283155B2 CLAIM 37. The system of claim 30 wherein the test device (照射部) further comprises a microneedle useful for collecting the sample.	JPH0727700A CLAIM 1 【請求項１】試料を収容し、内部の光路長を異ならせることが可能なセルと、このセルに対して選択された波長の光を照射するとともに、この照射する光の波長を変え得る光照射部 (test device) と、上記セルを透過した光を受け、この透過光量を検出する受光部と、この受光部で検出した透過光量に対する光量測定感度のピーク値が生じるときの光路長を波長毎に算出、記憶し、この波長毎に記憶したピーク位置での透過光量値、光路長の値に基づいて上記試料中の成分の濃度を算出し、算出結果を出力する演算部とからなる光学式成分濃度測定装置。
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device (照射部) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents for said plurality of analytes.	JPH0727700A CLAIM 1 【請求項１】試料を収容し、内部の光路長を異ならせることが可能なセルと、このセルに対して選択された波長の光を照射するとともに、この照射する光の波長を変え得る光照射部 (test device) と、上記セルを透過した光を受け、この透過光量を検出する受光部と、この受光部で検出した透過光量に対する光量測定感度のピーク値が生じるときの光路長を波長毎に算出、記憶し、この波長毎に記憶したピーク位置での透過光量値、光路長の値に基づいて上記試料中の成分の濃度を算出し、算出結果を出力する演算部とからなる光学式成分濃度測定装置。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JP2004358261A Filed: 2004-06-04 Issued: 2004-12-24 体液の抽出及びその抽出物中の分析物の監視のための装置、システム、及び方法 (Original Assignee) Lifescan Inc; ライフスキャン・インコーポレイテッドＬｉｆｅｓｃａｎ，Ｉｎｃ． Cass A Hanson, Michael Hilgers, Joel Mechelke, Joel Racchini, Thomas Rademacher, Phil Stout, カス・エイ・ハンソン, ジョエル・メケルケ, ジョエル・ラクチーニー, トーマス・レードメーカー, フィル・スタウト, マイケル・ヒルガース
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid (使い捨てカートリッジ) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly (少なくとも１) to said external device.	JP2004358261A CLAIM 1 体液試料を抽出してその抽出物中の分析物を監視するためのシステムであって、使い捨てカートリッジ (bodily fluid) 及びローカル制御モジュールを含み、前記使い捨てカートリッジが、体から体液試料を抽出できるように適合されたサンプリングモジュールと、前記体液試料の分析物を測定できるように適合された分析モジュールとを含み、前記ローカル制御モジュールが、前記使い捨てカートリッジと電気的に接続されており、前記分析モジュールから測定データを受け取ってその測定データを保存できるように適合されていることを特徴とするシステム。 JP2004358261A CLAIM 2 間質液（ＩＳＦ）抽出装置であって、刺入部材及び少なくとも１ (communication assembly) つの圧力リングを含み、前記刺入部材が、使用者の皮膚層に刺入でき、刺入後に前記使用者の皮膚層に留まってその皮膚層からＩＳＦ試料を抽出できるように構成されており、前記少なくとも１つの圧力リングが、前記刺入部材が前記使用者の皮膚層に留まっている状態で、前記標的部位の近傍の前記使用者の皮膚層に圧力を加えることができるように適合されており、前記圧力リングが往復動方式で圧力を加えて、前記刺入部材によって抽出される前記ＩＳＦ試料のＩＳＦグルコース遅延を緩和できるように、前記ＩＳＦ抽出装置が構成されていることを特徴とするＩＳＦ抽出装置。
US8283155B2 CLAIM 9. The system of claim 1 wherein the sample collection unit collects a sample of bodily fluid (使い捨てカートリッジ) which is less than about 500 uL.	JP2004358261A CLAIM 1 体液試料を抽出してその抽出物中の分析物を監視するためのシステムであって、使い捨てカートリッジ (bodily fluid) 及びローカル制御モジュールを含み、前記使い捨てカートリッジが、体から体液試料を抽出できるように適合されたサンプリングモジュールと、前記体液試料の分析物を測定できるように適合された分析モジュールとを含み、前記ローカル制御モジュールが、前記使い捨てカートリッジと電気的に接続されており、前記分析モジュールから測定データを受け取ってその測定データを保存できるように適合されていることを特徴とするシステム。
US8283155B2 CLAIM 22. A method for detecting an analyte in a bodily fluid (使い捨てカートリッジ) of a subject, comprising: a) providing a system of claim 1 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	JP2004358261A CLAIM 1 体液試料を抽出してその抽出物中の分析物を監視するためのシステムであって、使い捨てカートリッジ (bodily fluid) 及びローカル制御モジュールを含み、前記使い捨てカートリッジが、体から体液試料を抽出できるように適合されたサンプリングモジュールと、前記体液試料の分析物を測定できるように適合された分析モジュールとを含み、前記ローカル制御モジュールが、前記使い捨てカートリッジと電気的に接続されており、前記分析モジュールから測定データを受け取ってその測定データを保存できるように適合されていることを特徴とするシステム。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid (使い捨てカートリッジ) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly (少なくとも１) to said external device.	JP2004358261A CLAIM 1 体液試料を抽出してその抽出物中の分析物を監視するためのシステムであって、使い捨てカートリッジ (bodily fluid) 及びローカル制御モジュールを含み、前記使い捨てカートリッジが、体から体液試料を抽出できるように適合されたサンプリングモジュールと、前記体液試料の分析物を測定できるように適合された分析モジュールとを含み、前記ローカル制御モジュールが、前記使い捨てカートリッジと電気的に接続されており、前記分析モジュールから測定データを受け取ってその測定データを保存できるように適合されていることを特徴とするシステム。 JP2004358261A CLAIM 2 間質液（ＩＳＦ）抽出装置であって、刺入部材及び少なくとも１ (communication assembly) つの圧力リングを含み、前記刺入部材が、使用者の皮膚層に刺入でき、刺入後に前記使用者の皮膚層に留まってその皮膚層からＩＳＦ試料を抽出できるように構成されており、前記少なくとも１つの圧力リングが、前記刺入部材が前記使用者の皮膚層に留まっている状態で、前記標的部位の近傍の前記使用者の皮膚層に圧力を加えることができるように適合されており、前記圧力リングが往復動方式で圧力を加えて、前記刺入部材によって抽出される前記ＩＳＦ試料のＩＳＦグルコース遅延を緩和できるように、前記ＩＳＦ抽出装置が構成されていることを特徴とするＩＳＦ抽出装置。
US8283155B2 CLAIM 38. The system of claim 30 wherein the sample collection unit collects a sample of bodily fluid (使い捨てカートリッジ) which is less than about 500 uL.	JP2004358261A CLAIM 1 体液試料を抽出してその抽出物中の分析物を監視するためのシステムであって、使い捨てカートリッジ (bodily fluid) 及びローカル制御モジュールを含み、前記使い捨てカートリッジが、体から体液試料を抽出できるように適合されたサンプリングモジュールと、前記体液試料の分析物を測定できるように適合された分析モジュールとを含み、前記ローカル制御モジュールが、前記使い捨てカートリッジと電気的に接続されており、前記分析モジュールから測定データを受け取ってその測定データを保存できるように適合されていることを特徴とするシステム。
US8283155B2 CLAIM 45. The system of claim 30 further comprising a dilution chamber containing a diluents for diluting the sample of bodily fluid (使い捨てカートリッジ) according to said protocol transmitted by the external device and received by the reader assembly.	JP2004358261A CLAIM 1 体液試料を抽出してその抽出物中の分析物を監視するためのシステムであって、使い捨てカートリッジ (bodily fluid) 及びローカル制御モジュールを含み、前記使い捨てカートリッジが、体から体液試料を抽出できるように適合されたサンプリングモジュールと、前記体液試料の分析物を測定できるように適合された分析モジュールとを含み、前記ローカル制御モジュールが、前記使い捨てカートリッジと電気的に接続されており、前記分析モジュールから測定データを受け取ってその測定データを保存できるように適合されていることを特徴とするシステム。
US8283155B2 CLAIM 48. A method for detecting an analyte in a bodily fluid (使い捨てカートリッジ) of a subject, comprising: a) providing a system of claim 30 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	JP2004358261A CLAIM 1 体液試料を抽出してその抽出物中の分析物を監視するためのシステムであって、使い捨てカートリッジ (bodily fluid) 及びローカル制御モジュールを含み、前記使い捨てカートリッジが、体から体液試料を抽出できるように適合されたサンプリングモジュールと、前記体液試料の分析物を測定できるように適合された分析モジュールとを含み、前記ローカル制御モジュールが、前記使い捨てカートリッジと電気的に接続されており、前記分析モジュールから測定データを受け取ってその測定データを保存できるように適合されていることを特徴とするシステム。

JP2003322653A

Filed: 2002-05-07 Issued: 2003-11-14

プローブ固定支持体及びプローブ固定担体

(Original Assignee) Toshiba Corp; 株式会社東芝

Seiji Imai, Makoto Mizukami, 聖支今井, 誠水上

US8283155B2
CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly (前記基) to said external device.

JP2003322653A
CLAIM 1 【特許請求の範囲】【請求項１】支持体と、この支持体の１面に少なくともその１端を介して延出する無機物の長細担体と、前記長細担体に固定され、標的物質に特異的に結合するプローブとを具備することを特徴とするプローブ固定支持体。【請求項２】前記長細担体が結晶であることを特徴とする請求項１に記載のプローブ固定支持体。【請求項３】前記長細担体がウィスカーであることを特徴とする請求項１に記載のプローブ固定支持体。【請求項４】前記長細担体がカーボンナノチューブであることを特徴とする請求項１に記載のプローブ固定支持体。【請求項５】前記支持体がα−Ａｌ２Ｏ３単結晶基板であり、前記長細担体が前記α−Ａｌ２Ｏ３単結晶基板からのエピタキシャル成長によって形成されたＺｎＯウィスカーであることを特徴とする請求項１に記載のプローブ固定支持体。【請求項６】前記支持体が耐熱性の基板であり、前記長細担体が前記基 (communication assembly) 板上で金属微粒子を核として合成され、当該基板の表面に延出するカーボンナノチューブであることを特徴とする請求項１に記載のプローブ固定支持体。【請求項７】前記支持体がＳｉ表面及びＣ表面を有する基板であり、前記基板を真空加熱することによって合成され、前記基板の表面に複数延出するカーボンナノチューブと、前記カーボンナノチューブの夫々に１ずつ固定され、標的物質に特異的に結合するプローブとを具備するプローブ固定支持体。【請求項８】前記カーボンナノチューブの先端が開口していることを特徴とする請求項７に記載のプローブ固定支持体。【請求項９】前記標的物質が核酸、ポリペプチド、蛋白、抗体及び酵素からなる群より選択されることを特徴とする請求項１乃至７の何れか１項に記載のプローブ固定支持体。【請求項１０】前記標的物質が核酸であり、前記プローブが前記核酸の塩基配列に相補的な配列を含み、更に前記長細単体が電気伝導性を有し、それによって当該プローブと標的物質との間に生じた結合の検出が電気化学的に行われることを特徴とする請求項１乃至９の何れか１項に記載のプローブ固定支持体。【請求項１１】無機物の長細担体と、前記長細担体に複数固定され、標的物質に特異的に結合するプローブとを具備するプローブ固定担体。

US8283155B2
CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly (前記基) to said external device.

JP2003315348A

Filed: 2002-04-22 Issued: 2003-11-06

検体処理システム及びそれを用いた検体検査自動化システム

(Original Assignee) Hitachi High-Technologies Corp; 株式会社日立ハイテクノロジーズ

Tatsutoshi Imaoka, Nobuo Suzuki, Hitoshi Tokieda, 龍勇今岡, 仁時枝, 信雄鈴木

US8283155B2
CLAIM 14. The system of claim 13 wherein the system is configured to detect a plurality of analytes that generate distinct signals, wherein the intensities of said distinct signals vary over a range of 3 orders (遠心分離) of magnitude.

JP2003315348A
CLAIM 1 【特許請求の範囲】【請求項１】採取された生体サンプルを収容する生体サンプル収容容器と、前記生体サンプル収容容器に収容された生体サンプルを処理して、分析装置での分析が可能な被検査サンプルを生成する、少なくとも遠心分離 (3 orders) 処理を含む前処理手段と、前記前処理手段で生成された被検査サンプルの量を測定する被検査サンプル量測定手段と、被検査サンプルの検査項目及び該検査項目の分析に必要な被検査サンプルの量を記憶する検査項目記憶手段と、該検査項目の検査優先度を記憶する優先度記憶手段と、前記被検査サンプル量測定手段により測定された被検査サンプル量と、前記検査項目記憶手段に記憶された検査項目及び該検査項目の分析に必要な被検査サンプルの量から算出された被検査サンプルの分析に必要な被検査サンプル量とを比較する比較手段と、前記比較手段での比較の結果、被検査サンプル量が必要な被検査サンプル量に比べ少ない場合は、該被検査サンプルに対して記憶された検査項目の優先度に従い前記被検査サンプル量で測定が可能な検査項目を選択する検査項目選択手段と、前記検査項目選択手段で選択された検査項目の分析に必要な被検査サンプルの量を、被検査サンプルを収容する被検査サンプル収容容器に分注する分注手段と、を備えたことを特徴とする検体処理システム。【請求項２】請求項１記載の検体処理システムにおいて、同一の前記生体サンプル収容容器に収容されている生体サンプルから、複数の被検査サンプル収容容器にサンプルが分注される機能を備えたことを特徴とする検体処理システム。【請求項３】請求項２記載の検体処理システムにおいて、前記被検査サンプルの分析を行う複数の分析装置がある場合、該複数の分析装置ごとに、異なる被検査サンプル収容容器に分注する機能を備えたことを特徴とする検体処理システム。【請求項４】請求項１〜３のいずれかに記載の検体処理システムに、搬送ラインを介して自動分析装置が接続され、前記分注された被検査サンプルが前記搬送ラインを介して前記分析装置へと搬送され、分析が行われる機構を備えたことを特徴とする検体検査自動化システム。【請求項５】請求項４記載の検体検査自動化システムにおいて、前記搬送ラインは前記検体処理システムの中央制御部にて制御されるものであって、前記被検査サンプル量測定手段での測定結果に基づき優先的に分注された被検査サンプルの分注結果に基づき、該被検査サンプルが架設されているラックの搬送先を制御する機構を備えたことを特徴とする検体検査自動化システム。

US8283155B2
CLAIM 43. The system of claim 42 wherein the system is configured to detect a plurality of analytes that generate distinct signals, wherein the intensities of said distinct signals vary over a range of 3 orders (遠心分離) of magnitude.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JPH10267888A Filed: 1997-03-24 Issued: 1998-10-09 バイオセンサ (Original Assignee) Kokuritsu Shintai Shogaisha Rehabilitation Center Souchiyou; 国立身体障害者リハビリテーションセンター総長 Yoshito Ikariyama, Shigeru Toyama, 滋外山, 義人碇山
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid (過酸化水素) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (のパルス) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	JPH10267888A CLAIM 7 【請求項７】最終産物が過酸化水素 (bodily fluid) やＮＡＤ（Ｐ）Ｈであるときは、適当なメディエータを用いる請求項１〜５のいずれかの易酸化（あるいは易還元）型電極及びその作製法。 JPH10267888A CLAIM 8 【請求項８】上記請求項に関して、検出感度を高めるためのパルス (test device) 電位検出法などの電気化学的測定法、そのデバイス及び作製法
US8283155B2 CLAIM 8. The system of claim 1 wherein the test device (のパルス) further comprises a microneedle useful for collecting the sample.	JPH10267888A CLAIM 8 【請求項８】上記請求項に関して、検出感度を高めるためのパルス (test device) 電位検出法などの電気化学的測定法、そのデバイス及び作製法
US8283155B2 CLAIM 9. The system of claim 1 wherein the sample collection unit collects a sample of bodily fluid (過酸化水素) which is less than about 500 uL.	JPH10267888A CLAIM 7 【請求項７】最終産物が過酸化水素 (bodily fluid) やＮＡＤ（Ｐ）Ｈであるときは、適当なメディエータを用いる請求項１〜５のいずれかの易酸化（あるいは易還元）型電極及びその作製法。
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device (のパルス) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents for said plurality of analytes.	JPH10267888A CLAIM 8 【請求項８】上記請求項に関して、検出感度を高めるためのパルス (test device) 電位検出法などの電気化学的測定法、そのデバイス及び作製法
US8283155B2 CLAIM 22. A method for detecting an analyte in a bodily fluid (過酸化水素) of a subject, comprising: a) providing a system of claim 1 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	JPH10267888A CLAIM 7 【請求項７】最終産物が過酸化水素 (bodily fluid) やＮＡＤ（Ｐ）Ｈであるときは、適当なメディエータを用いる請求項１〜５のいずれかの易酸化（あるいは易還元）型電極及びその作製法。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid (過酸化水素) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (のパルス) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	JPH10267888A CLAIM 7 【請求項７】最終産物が過酸化水素 (bodily fluid) やＮＡＤ（Ｐ）Ｈであるときは、適当なメディエータを用いる請求項１〜５のいずれかの易酸化（あるいは易還元）型電極及びその作製法。 JPH10267888A CLAIM 8 【請求項８】上記請求項に関して、検出感度を高めるためのパルス (test device) 電位検出法などの電気化学的測定法、そのデバイス及び作製法
US8283155B2 CLAIM 37. The system of claim 30 wherein the test device (のパルス) further comprises a microneedle useful for collecting the sample.	JPH10267888A CLAIM 8 【請求項８】上記請求項に関して、検出感度を高めるためのパルス (test device) 電位検出法などの電気化学的測定法、そのデバイス及び作製法
US8283155B2 CLAIM 38. The system of claim 30 wherein the sample collection unit collects a sample of bodily fluid (過酸化水素) which is less than about 500 uL.	JPH10267888A CLAIM 7 【請求項７】最終産物が過酸化水素 (bodily fluid) やＮＡＤ（Ｐ）Ｈであるときは、適当なメディエータを用いる請求項１〜５のいずれかの易酸化（あるいは易還元）型電極及びその作製法。
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device (のパルス) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents for said plurality of analytes.	JPH10267888A CLAIM 8 【請求項８】上記請求項に関して、検出感度を高めるためのパルス (test device) 電位検出法などの電気化学的測定法、そのデバイス及び作製法
US8283155B2 CLAIM 45. The system of claim 30 further comprising a dilution chamber containing a diluents for diluting the sample of bodily fluid (過酸化水素) according to said protocol transmitted by the external device and received by the reader assembly.	JPH10267888A CLAIM 7 【請求項７】最終産物が過酸化水素 (bodily fluid) やＮＡＤ（Ｐ）Ｈであるときは、適当なメディエータを用いる請求項１〜５のいずれかの易酸化（あるいは易還元）型電極及びその作製法。
US8283155B2 CLAIM 48. A method for detecting an analyte in a bodily fluid (過酸化水素) of a subject, comprising: a) providing a system of claim 30 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	JPH10267888A CLAIM 7 【請求項７】最終産物が過酸化水素 (bodily fluid) やＮＡＤ（Ｐ）Ｈであるときは、適当なメディエータを用いる請求項１〜５のいずれかの易酸化（あるいは易還元）型電極及びその作製法。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	EP0564254A1 Filed: 1993-03-30 Issued: 1993-10-06 Polycyclic aromatic ring cleavage (parc) process (Original Assignee) SUN COMPANY Inc (R& M); Sunoco Inc (R&M) (Current Assignee) SUN COMPANY Inc (R& M) ; Sunoco Inc (R&M) Vincent A. Durante
US8283155B2 CLAIM 45. The system of claim 30 further comprising a dilution chamber (Group VIII metals) containing a diluents for diluting the sample of bodily fluid according to said protocol transmitted by the external device and received by the reader assembly.	EP0564254A1 CLAIM 10 The process as claimed in Claim 9, wherein at least one of said Group VIII metals (dilution chamber) comprises osmium.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	EP0478319A1 Filed: 1991-09-26 Issued: 1992-04-01 Gene detection method (Original Assignee) Toshiba Corp (Current Assignee) Toshiba Corp Koji c/o Intellectual Property Div. Hashimoto, Keiko c/o Intellectual Property Div. Miwa, Yoshio C/O Intellectual Property Div. Ishimori
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method (detection method) for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	EP0478319A1 CLAIM 1 A gene detection method (detection method) wherein a single stranded nucleic acid probe having a base sequence complementary to the gene to be detected is reacted with a gene sample denatured into a single stranded form and then said nucleic acid probe hybridized with the gene is detected to confirm the presence of the gene, characterized in that: said nucleic acid probe is immobilized onto a carrier sensitive to a physical change; a double stranded nucleic acid recognizing substance capable of binding specifically to a double stranded nucleic acid and being active physicochemically is added to the reaction system of said nucleic acid probe and the gene sample; and, the double stranded nucleic acid recognizing substance bound to the double stranded nucleic acid formed by conjugation of said nucleic acid probe and the gene to be detected is detected by means of physical determination using said carrier, whereby detecting the presence of said nucleic acid probe hybridized with the gene to be detected.
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (said nucleic acid) reagents immobilized within the assay assembly.	EP0478319A1 CLAIM 1 A gene detection method wherein a single stranded nucleic acid probe having a base sequence complementary to the gene to be detected is reacted with a gene sample denatured into a single stranded form and then said nucleic acid (nucleic acid, nucleic acid reagents) probe hybridized with the gene is detected to confirm the presence of the gene, characterized in that: said nucleic acid probe is immobilized onto a carrier sensitive to a physical change; a double stranded nucleic acid recognizing substance capable of binding specifically to a double stranded nucleic acid and being active physicochemically is added to the reaction system of said nucleic acid probe and the gene sample; and, the double stranded nucleic acid recognizing substance bound to the double stranded nucleic acid formed by conjugation of said nucleic acid probe and the gene to be detected is detected by means of physical determination using said carrier, whereby detecting the presence of said nucleic acid probe hybridized with the gene to be detected.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (said nucleic acid) reagents for said plurality of analytes.	EP0478319A1 CLAIM 1 A gene detection method wherein a single stranded nucleic acid probe having a base sequence complementary to the gene to be detected is reacted with a gene sample denatured into a single stranded form and then said nucleic acid (nucleic acid, nucleic acid reagents) probe hybridized with the gene is detected to confirm the presence of the gene, characterized in that: said nucleic acid probe is immobilized onto a carrier sensitive to a physical change; a double stranded nucleic acid recognizing substance capable of binding specifically to a double stranded nucleic acid and being active physicochemically is added to the reaction system of said nucleic acid probe and the gene sample; and, the double stranded nucleic acid recognizing substance bound to the double stranded nucleic acid formed by conjugation of said nucleic acid probe and the gene to be detected is detected by means of physical determination using said carrier, whereby detecting the presence of said nucleic acid probe hybridized with the gene to be detected.
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method (detection method) further comprises detecting an optical signal (optical signal) from the sample.	EP0478319A1 CLAIM 1 A gene detection method (detection method) wherein a single stranded nucleic acid probe having a base sequence complementary to the gene to be detected is reacted with a gene sample denatured into a single stranded form and then said nucleic acid probe hybridized with the gene is detected to confirm the presence of the gene, characterized in that: said nucleic acid probe is immobilized onto a carrier sensitive to a physical change; a double stranded nucleic acid recognizing substance capable of binding specifically to a double stranded nucleic acid and being active physicochemically is added to the reaction system of said nucleic acid probe and the gene sample; and, the double stranded nucleic acid recognizing substance bound to the double stranded nucleic acid formed by conjugation of said nucleic acid probe and the gene to be detected is detected by means of physical determination using said carrier, whereby detecting the presence of said nucleic acid probe hybridized with the gene to be detected. EP0478319A1 CLAIM 15 A method according to claim 11, wherein said double stranded nucleic acid recognizing substance is an intercalating agent to which one or more substances generating optical signal (optical signal) s which can be detected by said optical fiber directly or indirectly are bound.
US8283155B2 CLAIM 18. The system of claim 17 wherein the optical signal (optical signal) is a chemiluminscent signal.	EP0478319A1 CLAIM 15 A method according to claim 11, wherein said double stranded nucleic acid recognizing substance is an intercalating agent to which one or more substances generating optical signal (optical signal) s which can be detected by said optical fiber directly or indirectly are bound.
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method (detection method) includes collecting signals from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	EP0478319A1 CLAIM 1 A gene detection method (detection method) wherein a single stranded nucleic acid probe having a base sequence complementary to the gene to be detected is reacted with a gene sample denatured into a single stranded form and then said nucleic acid probe hybridized with the gene is detected to confirm the presence of the gene, characterized in that: said nucleic acid probe is immobilized onto a carrier sensitive to a physical change; a double stranded nucleic acid recognizing substance capable of binding specifically to a double stranded nucleic acid and being active physicochemically is added to the reaction system of said nucleic acid probe and the gene sample; and, the double stranded nucleic acid recognizing substance bound to the double stranded nucleic acid formed by conjugation of said nucleic acid probe and the gene to be detected is detected by means of physical determination using said carrier, whereby detecting the presence of said nucleic acid probe hybridized with the gene to be detected.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (said nucleic acid) reagents immobilized within the assay assembly.	EP0478319A1 CLAIM 1 A gene detection method wherein a single stranded nucleic acid probe having a base sequence complementary to the gene to be detected is reacted with a gene sample denatured into a single stranded form and then said nucleic acid (nucleic acid, nucleic acid reagents) probe hybridized with the gene is detected to confirm the presence of the gene, characterized in that: said nucleic acid probe is immobilized onto a carrier sensitive to a physical change; a double stranded nucleic acid recognizing substance capable of binding specifically to a double stranded nucleic acid and being active physicochemically is added to the reaction system of said nucleic acid probe and the gene sample; and, the double stranded nucleic acid recognizing substance bound to the double stranded nucleic acid formed by conjugation of said nucleic acid probe and the gene to be detected is detected by means of physical determination using said carrier, whereby detecting the presence of said nucleic acid probe hybridized with the gene to be detected.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (said nucleic acid) reagents for said plurality of analytes.	EP0478319A1 CLAIM 1 A gene detection method wherein a single stranded nucleic acid probe having a base sequence complementary to the gene to be detected is reacted with a gene sample denatured into a single stranded form and then said nucleic acid (nucleic acid, nucleic acid reagents) probe hybridized with the gene is detected to confirm the presence of the gene, characterized in that: said nucleic acid probe is immobilized onto a carrier sensitive to a physical change; a double stranded nucleic acid recognizing substance capable of binding specifically to a double stranded nucleic acid and being active physicochemically is added to the reaction system of said nucleic acid probe and the gene sample; and, the double stranded nucleic acid recognizing substance bound to the double stranded nucleic acid formed by conjugation of said nucleic acid probe and the gene to be detected is detected by means of physical determination using said carrier, whereby detecting the presence of said nucleic acid probe hybridized with the gene to be detected.

CN1192567C

Filed: 1999-09-09 Issued: 2005-03-09

基于功率频谱密度估计的数据速率确定

(Original Assignee) 诺基亚公司

卡里·霍尼曼, 杰尔基·凯萨拉

US8283155B2
CLAIM 45. The system of claim 30 further comprising a dilution chamber (包括下述) containing a diluents for diluting the sample of bodily fluid according to said protocol transmitted by the external device and received by the reader assembly.

CN1192567C
CLAIM 1.一种在通信系统中估计数据帧的数据传输速率的方法，所述通信系统具有包括遍布在一系列数据帧中的多个数据符号的传输信号，其中所述序列中的至少一些数据帧具有不同的数据传输速率，以便所述数据帧中的数据符号的数量是可变的，所述方法包括下述 (dilution chamber) 步骤：按照所述数据传输速率的预定分类，对所接收的传输信号的数据帧分类；根据所述分类，估计所接收数据帧的数据传输速率。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JP2005030983A Filed: 2003-07-09 Issued: 2005-02-03 測定装置 (Original Assignee) Matsushita Electric Ind Co Ltd; 松下電器産業株式会社 Yoshihiro Kataoka, 義博片岡
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor (メモリ) that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (試験片) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	JP2005030983A CLAIM 1 試験片 (test device) が着脱自在に装着され、前記試験片における検査対象物の反応を計測するために、一連の計測を制御のためのファームウェアと、前記計測に関連する各種情報を使用者に対し表示するための表示手段と、使用者が計測の操作を行うための操作手段とを備えた測定装置において、前記測定装置は、前記試験片の製造ロット毎に異なる特性を較正するための較正データを記憶した第１のメモリ (programmable processor) カードと、前記ファームウェアを更新すべきプログラムを記憶した第２のメモリカードとが、測定装置本体に共通して設けたコネクタに択一的に接続される構成としたことを特徴とする測定装置。
US8283155B2 CLAIM 8. The system of claim 1 wherein the test device (試験片) further comprises a microneedle useful for collecting the sample.	JP2005030983A CLAIM 1 試験片 (test device) が着脱自在に装着され、前記試験片における検査対象物の反応を計測するために、一連の計測を制御のためのファームウェアと、前記計測に関連する各種情報を使用者に対し表示するための表示手段と、使用者が計測の操作を行うための操作手段とを備えた測定装置において、前記測定装置は、前記試験片の製造ロット毎に異なる特性を較正するための較正データを記憶した第１のメモリカードと、前記ファームウェアを更新すべきプログラムを記憶した第２のメモリカードとが、測定装置本体に共通して設けたコネクタに択一的に接続される構成としたことを特徴とする測定装置。
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device (試験片) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents for said plurality of analytes.	JP2005030983A CLAIM 1 試験片 (test device) が着脱自在に装着され、前記試験片における検査対象物の反応を計測するために、一連の計測を制御のためのファームウェアと、前記計測に関連する各種情報を使用者に対し表示するための表示手段と、使用者が計測の操作を行うための操作手段とを備えた測定装置において、前記測定装置は、前記試験片の製造ロット毎に異なる特性を較正するための較正データを記憶した第１のメモリカードと、前記ファームウェアを更新すべきプログラムを記憶した第２のメモリカードとが、測定装置本体に共通して設けたコネクタに択一的に接続される構成としたことを特徴とする測定装置。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor (メモリ) that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (試験片) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	JP2005030983A CLAIM 1 試験片 (test device) が着脱自在に装着され、前記試験片における検査対象物の反応を計測するために、一連の計測を制御のためのファームウェアと、前記計測に関連する各種情報を使用者に対し表示するための表示手段と、使用者が計測の操作を行うための操作手段とを備えた測定装置において、前記測定装置は、前記試験片の製造ロット毎に異なる特性を較正するための較正データを記憶した第１のメモリ (programmable processor) カードと、前記ファームウェアを更新すべきプログラムを記憶した第２のメモリカードとが、測定装置本体に共通して設けたコネクタに択一的に接続される構成としたことを特徴とする測定装置。
US8283155B2 CLAIM 37. The system of claim 30 wherein the test device (試験片) further comprises a microneedle useful for collecting the sample.	JP2005030983A CLAIM 1 試験片 (test device) が着脱自在に装着され、前記試験片における検査対象物の反応を計測するために、一連の計測を制御のためのファームウェアと、前記計測に関連する各種情報を使用者に対し表示するための表示手段と、使用者が計測の操作を行うための操作手段とを備えた測定装置において、前記測定装置は、前記試験片の製造ロット毎に異なる特性を較正するための較正データを記憶した第１のメモリカードと、前記ファームウェアを更新すべきプログラムを記憶した第２のメモリカードとが、測定装置本体に共通して設けたコネクタに択一的に接続される構成としたことを特徴とする測定装置。
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device (試験片) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents for said plurality of analytes.	JP2005030983A CLAIM 1 試験片 (test device) が着脱自在に装着され、前記試験片における検査対象物の反応を計測するために、一連の計測を制御のためのファームウェアと、前記計測に関連する各種情報を使用者に対し表示するための表示手段と、使用者が計測の操作を行うための操作手段とを備えた測定装置において、前記測定装置は、前記試験片の製造ロット毎に異なる特性を較正するための較正データを記憶した第１のメモリカードと、前記ファームウェアを更新すべきプログラムを記憶した第２のメモリカードとが、測定装置本体に共通して設けたコネクタに択一的に接続される構成としたことを特徴とする測定装置。

CN1572320A

Filed: 2000-05-10 Issued: 2005-02-02

利用药代动力学和药效模型进行红细胞生成素给药的方法

(Original Assignee) 奥索－麦克尼尔药物公司

W·程, D·吉布森, C·戈特, E·韦科曼

US8283155B2
CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly (或多个) for detecting said signal which is transmitted via said communication assembly to said external device.

CN1572320A
CLAIM 1.一种方法，其包括以下步骤：(a)选择一个或多个 (detection assembly) EPO剂量方案；(b)用药代动力学/药效学模型来确定所述一个或多个EPO剂量方案的药效学曲线；和(c)根据所述的药效学曲线选择在患者中产生需要的药效学反应的所述一个或多个EPO剂量方案。

US8283155B2
CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly (或多个) for detecting said signal which is transmitted via said communication assembly to said external device.

JP2004333452A

Filed: 2003-05-12 Issued: 2004-11-25

糖化タンパク質測定用試験片

(Original Assignee) Asahi Kasei Pharma Kk; 旭化成ファーマ株式会社

Takashi Eto, Takuji Takatsuma, 高志江藤, 卓司高妻

US8283155B2
CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly containing reactants (酵素反応, １２〜) that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.

JP2004333452A
CLAIM 15 試験片の酵素反応 (assay assembly containing reactants) を試料中の水分によって行うことを特徴とする請求項１２〜 (assay assembly containing reactants) １４のいずれかに記載の測定方法。

US8283155B2
CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants (酵素反応, １２〜) for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.

JP2004317498A

Filed: 2004-03-18 Issued: 2004-11-11

生化学反応カートリッジ及びその使用方法

(Original Assignee) Canon Inc; キヤノン株式会社

Yasuyuki Numajiri, 泰幸沼尻

US8283155B2
CLAIM 45. The system of claim 30 further comprising a dilution chamber (チャンバ内) containing a diluents for diluting the sample of bodily fluid according to said protocol transmitted by the external device and received by the reader assembly.

JP2004317498A
CLAIM 1 液体が蓄積された蓄積チャンバと、前記液体を移動して利用する第１、第２の機能チャンバと、前記蓄積チャンバと前記第１の機能チャンバを接続し前記液体を前記蓄積チャンバから前記第１の機能チャンバに移動する第１の流路と、前記第１の機能チャンバの底部と前記第２の機能チャンバの底部を接続し前記第１の機能チャンバ内 (dilution chamber) の液体を前記第２の機能チャンバに移動する第２の流路とを有し、前記第１の流路と前記第１の機能チャンバとを接続する第１の接続部の高さを、前記第１の機能チャンバと前記第２の流路を接続する第２の接続部の高さよりも高くしたことを特徴とする生化学反応カートリッジ。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	CN1499949A Filed: 2001-12-19 Issued: 2004-05-26 分析物测量 (Original Assignee) 因弗内斯医疗有限公司 M・斯蒂尼, M·斯蒂尼, L, T·里希特, 税⒗扯, J·阿伦, J·麦克阿莱尔
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid (流体连通, 装置流体) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (执行一, 时间间) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly (或多个) for detecting said signal which is transmitted via said communication assembly (一次性) to said external device.	CN1499949A CLAIM 3.如权利要求1或2中所述的装置，其特征在于，其包括至少一个用于将间质流体传送到一个或多个 (detection assembly) 传感装置的微通道。 CN1499949A CLAIM 6.一种用于测量流体中分析物浓度的装置，所述装置包括：一支撑元件、设在其上的用于测量所述浓度的分析物传感装置、以及与所述分析物传感装置流体连通 (way communication system, bodily fluid) 的用于将所述流体传送到所述传感装置的微通道。 CN1499949A CLAIM 28.如前述任何一项权利要求所述的装置，所述装置被布置成在指定时间间 (test device) 隔时形成测量。 CN1499949A CLAIM 43.如权利要求42中所述的装置，所述装置包括多个独立的传感装置以便于执行一 (test device) 系列的周期性校准测量。 CN1499949A CLAIM 78.一种一次性 (communication assembly) 皮肤贴片，所述皮肤贴片包括在使用中试样流体沿其吸入的延长导管部分和所述导管部分上面的模压塑料透镜。
US8283155B2 CLAIM 8. The system of claim 1 wherein the test device (执行一, 时间间) further comprises a microneedle useful for collecting the sample.	CN1499949A CLAIM 28.如前述任何一项权利要求所述的装置，所述装置被布置成在指定时间间 (test device) 隔时形成测量。 CN1499949A CLAIM 43.如权利要求42中所述的装置，所述装置包括多个独立的传感装置以便于执行一 (test device) 系列的周期性校准测量。
US8283155B2 CLAIM 9. The system of claim 1 wherein the sample collection unit collects a sample of bodily fluid (流体连通, 装置流体) which is less than about 500 uL.	CN1499949A CLAIM 6.一种用于测量流体中分析物浓度的装置，所述装置包括：一支撑元件、设在其上的用于测量所述浓度的分析物传感装置、以及与所述分析物传感装置流体连通 (way communication system, bodily fluid) 的用于将所述流体传送到所述传感装置的微通道。
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid reagents (多种试剂, 定壁上) immobilized within the assay assembly.	CN1499949A CLAIM 7.如权利要求6中所述的装置，其特征在于，所述分析物传感装置包括一种或多种试剂 (nucleic acid reagents) ，其用于与所述分析物起反应，从而给出可测量的输出结果。 CN1499949A CLAIM 142.依照权利要求131所述的设备，其特征在于：所述通道是多个通道中的一个，每个所述通道都通过在支撑元件上形成限定壁而被形成于所述支撑元件上，并且每个通道都具有用于接收所述体液的入口；每个所述通道都在所述通道的限定壁上 (nucleic acid reagents) 设有相应的试剂。
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device (执行一, 时间间) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents (多种试剂, 定壁上) for said plurality of analytes.	CN1499949A CLAIM 7.如权利要求6中所述的装置，其特征在于，所述分析物传感装置包括一种或多种试剂 (nucleic acid reagents) ，其用于与所述分析物起反应，从而给出可测量的输出结果。 CN1499949A CLAIM 28.如前述任何一项权利要求所述的装置，所述装置被布置成在指定时间间 (test device) 隔时形成测量。 CN1499949A CLAIM 43.如权利要求42中所述的装置，所述装置包括多个独立的传感装置以便于执行一 (test device) 系列的周期性校准测量。 CN1499949A CLAIM 142.依照权利要求131所述的设备，其特征在于：所述通道是多个通道中的一个，每个所述通道都通过在支撑元件上形成限定壁而被形成于所述支撑元件上，并且每个通道都具有用于接收所述体液的入口；每个所述通道都在所述通道的限定壁上 (nucleic acid reagents) 设有相应的试剂。
US8283155B2 CLAIM 14. The system of claim 13 wherein the system is configured to detect a plurality of analytes that generate distinct signals, wherein the intensities of said distinct signals vary over a range of 3 orders (传感器中) of magnitude.	CN1499949A CLAIM 100.依照权利要求84所述的设备，其特征在于：所述通道是多个通道中的一个，每个所述通道都通过在支撑元件上形成限定壁而被形成于所述支撑元件上，并且每个通道都具有用于接收所述体液的入口；所述分析物传感器是多个分析物传感器中 (3 orders) 的一个，所述每个分析物传感器都与所述多个通道中对应的一个相连。
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method includes collecting signals (控制装置) from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	CN1499949A CLAIM 29.如权利要求28中所述的装置，所述装置包括流动控制装置 (detection method includes collecting signals) ，所述流动控制装置用于形成到传感装置的流体流动。
US8283155B2 CLAIM 22. A method for detecting an analyte in a bodily fluid (流体连通, 装置流体) of a subject, comprising: a) providing a system of claim 1 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	CN1499949A CLAIM 6.一种用于测量流体中分析物浓度的装置，所述装置包括：一支撑元件、设在其上的用于测量所述浓度的分析物传感装置、以及与所述分析物传感装置流体连通 (way communication system, bodily fluid) 的用于将所述流体传送到所述传感装置的微通道。
US8283155B2 CLAIM 23. The method of claim 22 further comprising quantifying the amount of said analyte present (电化学传感器, 分析物的浓度) in said sample.	CN1499949A CLAIM 5.如权利要求4中所述的装置，所述装置被如此布置，即，在使用中，多个传感装置在不同的时间进行流体测量，以便于能够在一段时期内监测该流体中的分析物的浓度 (analyte present) 。 CN1499949A CLAIM 125.依照权利要求106所述的设备，其特征在于，所述分析物传感器包括电化学传感器 (analyte present) 。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid (流体连通, 装置流体) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (执行一, 时间间) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly (或多个) for detecting said signal which is transmitted via said communication assembly (一次性) to said external device.	CN1499949A CLAIM 3.如权利要求1或2中所述的装置，其特征在于，其包括至少一个用于将间质流体传送到一个或多个 (detection assembly) 传感装置的微通道。 CN1499949A CLAIM 6.一种用于测量流体中分析物浓度的装置，所述装置包括：一支撑元件、设在其上的用于测量所述浓度的分析物传感装置、以及与所述分析物传感装置流体连通 (way communication system, bodily fluid) 的用于将所述流体传送到所述传感装置的微通道。 CN1499949A CLAIM 28.如前述任何一项权利要求所述的装置，所述装置被布置成在指定时间间 (test device) 隔时形成测量。 CN1499949A CLAIM 43.如权利要求42中所述的装置，所述装置包括多个独立的传感装置以便于执行一 (test device) 系列的周期性校准测量。 CN1499949A CLAIM 78.一种一次性 (communication assembly) 皮肤贴片，所述皮肤贴片包括在使用中试样流体沿其吸入的延长导管部分和所述导管部分上面的模压塑料透镜。
US8283155B2 CLAIM 37. The system of claim 30 wherein the test device (执行一, 时间间) further comprises a microneedle useful for collecting the sample.	CN1499949A CLAIM 28.如前述任何一项权利要求所述的装置，所述装置被布置成在指定时间间 (test device) 隔时形成测量。 CN1499949A CLAIM 43.如权利要求42中所述的装置，所述装置包括多个独立的传感装置以便于执行一 (test device) 系列的周期性校准测量。
US8283155B2 CLAIM 38. The system of claim 30 wherein the sample collection unit collects a sample of bodily fluid (流体连通, 装置流体) which is less than about 500 uL.	CN1499949A CLAIM 6.一种用于测量流体中分析物浓度的装置，所述装置包括：一支撑元件、设在其上的用于测量所述浓度的分析物传感装置、以及与所述分析物传感装置流体连通 (way communication system, bodily fluid) 的用于将所述流体传送到所述传感装置的微通道。
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid reagents (多种试剂, 定壁上) immobilized within the assay assembly.	CN1499949A CLAIM 7.如权利要求6中所述的装置，其特征在于，所述分析物传感装置包括一种或多种试剂 (nucleic acid reagents) ，其用于与所述分析物起反应，从而给出可测量的输出结果。 CN1499949A CLAIM 142.依照权利要求131所述的设备，其特征在于：所述通道是多个通道中的一个，每个所述通道都通过在支撑元件上形成限定壁而被形成于所述支撑元件上，并且每个通道都具有用于接收所述体液的入口；每个所述通道都在所述通道的限定壁上 (nucleic acid reagents) 设有相应的试剂。
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device (执行一, 时间间) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents (多种试剂, 定壁上) for said plurality of analytes.	CN1499949A CLAIM 7.如权利要求6中所述的装置，其特征在于，所述分析物传感装置包括一种或多种试剂 (nucleic acid reagents) ，其用于与所述分析物起反应，从而给出可测量的输出结果。 CN1499949A CLAIM 28.如前述任何一项权利要求所述的装置，所述装置被布置成在指定时间间 (test device) 隔时形成测量。 CN1499949A CLAIM 43.如权利要求42中所述的装置，所述装置包括多个独立的传感装置以便于执行一 (test device) 系列的周期性校准测量。 CN1499949A CLAIM 142.依照权利要求131所述的设备，其特征在于：所述通道是多个通道中的一个，每个所述通道都通过在支撑元件上形成限定壁而被形成于所述支撑元件上，并且每个通道都具有用于接收所述体液的入口；每个所述通道都在所述通道的限定壁上 (nucleic acid reagents) 设有相应的试剂。
US8283155B2 CLAIM 43. The system of claim 42 wherein the system is configured to detect a plurality of analytes that generate distinct signals, wherein the intensities of said distinct signals vary over a range of 3 orders (传感器中) of magnitude.	CN1499949A CLAIM 100.依照权利要求84所述的设备，其特征在于：所述通道是多个通道中的一个，每个所述通道都通过在支撑元件上形成限定壁而被形成于所述支撑元件上，并且每个通道都具有用于接收所述体液的入口；所述分析物传感器是多个分析物传感器中 (3 orders) 的一个，所述每个分析物传感器都与所述多个通道中对应的一个相连。
US8283155B2 CLAIM 45. The system of claim 30 further comprising a dilution chamber (的测量) containing a diluents for diluting the sample of bodily fluid (流体连通, 装置流体) according to said protocol transmitted by the external device and received by the reader assembly.	CN1499949A CLAIM 6.一种用于测量流体中分析物浓度的装置，所述装置包括：一支撑元件、设在其上的用于测量所述浓度的分析物传感装置、以及与所述分析物传感装置流体连通 (way communication system, bodily fluid) 的用于将所述流体传送到所述传感装置的微通道。 CN1499949A CLAIM 27.一种用于测量体液中给定分析物浓度的装置，所述装置包括：用于将所述装置附于受检者的皮肤上的装置以及多个传感装置，所述传感装置用于在一段时期期间形成多个所述浓度的测量 (dilution chamber) 结果。

JP2004028589A

Filed: 2002-06-21 Issued: 2004-01-29

分析チップ及び分析装置

(Original Assignee) Hitachi Ltd; 株式会社日立製作所

Hisao Inami, Akira Miyake, Yasuhiko Sasaki, 三宅　亮, 佐々木　康彦, 稲波　久雄

US8283155B2
CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly (前記基) to said external device.

JP2004028589A
CLAIM 1 基板と、前記基 (communication assembly) 板に形成され、生体から採取される被検体が導入される反応セルと、前記反応セルに供給される試薬が貯蔵される試薬貯蔵部と、前記反応セルと前記試薬貯蔵部とを連絡し、前記試薬貯蔵部に貯蔵される前記試薬が前記反応セルに流れる流路を構成する試薬ノズル部と、を有することを特徴とする分析チップ。

US8283155B2
CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly (前記基) to said external device.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JP2003222611A Filed: 2002-11-20 Issued: 2003-08-08 分離装置、分離方法および分離装置の製造方法 (Original Assignee) Nec Corp; 日本電気株式会社 Masakazu Baba, Noriyuki Iguchi, Kazuhiro Iida, Hisao Kawaura, Toshimori Sakamoto, Toru Sano, Hiroko Someya, 憲幸井口, 亨佐野, 久雄川浦, 浩子染谷, 利司阪本, 一浩飯田, 雅和馬場
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method (有する基板) for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	JP2003222611A CLAIM 1 【特許請求の範囲】【請求項１】基板と、該基板の表面に形成された試料の通る流路と、前記流路に設けられた試料導入部および試料分離部とを備える分離装置であって、前記試料分離部の表面は、親水性領域と疎水性領域とを有することを特徴とする分離装置。【請求項２】基板と、該基板の表面に形成された試料の通る流路と、前記流路に設けられた試料導入部および試料排出部と、試料導入部から試料排出部に至るまでの間の流路中に設けられた試料分離部とを備える分離装置であって、前記試料分離部の表面は、離間して配置された複数の第一の領域と、該第一の領域を除く試料分離部表面を占める第二の領域と、を有し、第一の領域および第二の領域のうち、一方が疎水性領域であり、他方が親水性領域であることを特徴とする分離装置。【請求項３】請求項２に記載の分離装置において、前記第一の領域が２次元的に略等間隔で配置されていることを特徴とする分離装置。【請求項４】請求項２または３に記載の分離装置において、前記試料分離部を複数備えたことを特徴とする分離装置。【請求項５】請求項４に記載の分離装置において、隣接する試料分離部の間隔が、各試料分離部を構成する第一の領域の間隔よりも広いことを特徴とする分離装置。【請求項６】請求項４または５に記載の分離装置において、各試料分離部における第一の領域の間隔が互いに異なることを特徴とする分離装置。【請求項７】請求項１乃至６いずれかに記載の分離装置において、外力付与手段をさらに備え、外力により前記試料を試料導入部から前記試料分離部の方向へ移動せしめるようにしたことを特徴とする分離装置。【請求項８】請求項１乃至７いずれかに記載の分離装置において、前記試料分離部の下流側に検出部を備えたことを特徴とする分離装置。【請求項９】請求項１乃至８いずれかに記載の分離装置において、前記疎水性領域は、疎水基を有する化合物を含む膜により構成されたことを特徴とする分離装置。【請求項１０】請求項９に記載の分離装置において、前記疎水基を有する化合物は、疎水基を有するシランカップリング剤であることを特徴とする分離装置。【請求項１１】請求項９または１０に記載の分離装置において、前記疎水基はチオール基であることを特徴とする分離装置。【請求項１２】請求項１乃至８いずれかに記載の分離装置において、前記疎水性領域は、シリコーン化合物を含むことを特徴とする分離装置。【請求項１３】請求項１乃至１２いずれかに記載の分離装置において、前記親水性領域は、親水基を有する化合物を含む膜により構成されたことを特徴とする分離装置。【請求項１４】請求項１３に記載の分離装置において、前記親水基を有する化合物は、親水基を有するシランカップリング剤であることを特徴とする分離装置。【請求項１５】請求項１４に記載の分離装置において、前記シランカップリング剤はアミノ基を有する化合物であることを特徴とする分離装置。【請求項１６】請求項１乃至１５いずれかに記載の分離装置を用い、前記試料導入部から試料を導入し、試料中の所定成分を分離することを特徴とする試料分離方法。【請求項１７】基板と、該基板の表面に形成された試料の通る流路と、前記流路中に設けられた試料分離部とを備える分離装置の製造方法であって、親水性表面を有する前記流路を形成する工程と、前記流路の表面の少なくとも一部に、開口部を有するマスクを設けた後、該開口部から前記流路表面に疎水基を有する化合物を堆積し、次いで該マスクを除去することにより、疎水性領域が配置された前記試料分離部を形成する工程と、を含むことを特徴とする分離装置の製造方法。【請求項１８】請求項１７に記載の分離装置の製造方法において、前記化合物は、疎水基を有するシランカップリング剤であることを特徴とする分離装置の製造方法。【請求項１９】請求項１８に記載の分離装置の製造方法において、前記疎水基はチオール基であることを特徴とする分離装置の製造方法。【請求項２０】基板と、該基板の表面に形成された試料の通る流路と、前記流路中に設けられた試料分離部とを備える分離装置の製造方法であって、疎水性表面を有する基板 (detection method) に前記流路を形成する工程と、前記流路の表面の少なくとも一部に開口部を有するマスクを設けた後、該開口部から前記流路表面に親水基を有する化合物を堆積し、次いで該マスクを除去することにより、親水性領域が配置された前記試料分離部を形成する工程と、を含むことを特徴とする分離装置の製造方法。【請求項２１】請求項２０に記載の分離装置の製造方法において、前記化合物は、親水基を有するシランカップリング剤であることを特徴とする分離装置の製造方法。【請求項２２】請求項２１に記載の分離装置の製造方法において、前記親水基はアミノ基であることを特徴とする分離装置の製造方法。【請求項２３】基板と、該基板の表面に形成された試料の通る流路と、前記流路中に設けられた試料分離部とを備える分離装置の製造方法であって、親水性表面を有する前記流路を形成する工程と、前記流路の表面に対して液状シリコーン化合物を付着し、疎水性領域が配置された前記試料分離部を形成する工程と、を含むことを特徴とする分離装置の製造方法。【請求項２４】請求項２３に記載の分離装置の製造方法において、前記試料分離部を形成する前記工程は、前記液状シリコーン化合物を含有するシリコーン樹脂の表面を前記前記流路表面に接触させる工程を含むことを特徴とする分離装置の製造方法。
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method (有する基板) further comprises detecting an optical signal from the sample.	JP2003222611A CLAIM 1 【特許請求の範囲】【請求項１】基板と、該基板の表面に形成された試料の通る流路と、前記流路に設けられた試料導入部および試料分離部とを備える分離装置であって、前記試料分離部の表面は、親水性領域と疎水性領域とを有することを特徴とする分離装置。【請求項２】基板と、該基板の表面に形成された試料の通る流路と、前記流路に設けられた試料導入部および試料排出部と、試料導入部から試料排出部に至るまでの間の流路中に設けられた試料分離部とを備える分離装置であって、前記試料分離部の表面は、離間して配置された複数の第一の領域と、該第一の領域を除く試料分離部表面を占める第二の領域と、を有し、第一の領域および第二の領域のうち、一方が疎水性領域であり、他方が親水性領域であることを特徴とする分離装置。【請求項３】請求項２に記載の分離装置において、前記第一の領域が２次元的に略等間隔で配置されていることを特徴とする分離装置。【請求項４】請求項２または３に記載の分離装置において、前記試料分離部を複数備えたことを特徴とする分離装置。【請求項５】請求項４に記載の分離装置において、隣接する試料分離部の間隔が、各試料分離部を構成する第一の領域の間隔よりも広いことを特徴とする分離装置。【請求項６】請求項４または５に記載の分離装置において、各試料分離部における第一の領域の間隔が互いに異なることを特徴とする分離装置。【請求項７】請求項１乃至６いずれかに記載の分離装置において、外力付与手段をさらに備え、外力により前記試料を試料導入部から前記試料分離部の方向へ移動せしめるようにしたことを特徴とする分離装置。【請求項８】請求項１乃至７いずれかに記載の分離装置において、前記試料分離部の下流側に検出部を備えたことを特徴とする分離装置。【請求項９】請求項１乃至８いずれかに記載の分離装置において、前記疎水性領域は、疎水基を有する化合物を含む膜により構成されたことを特徴とする分離装置。【請求項１０】請求項９に記載の分離装置において、前記疎水基を有する化合物は、疎水基を有するシランカップリング剤であることを特徴とする分離装置。【請求項１１】請求項９または１０に記載の分離装置において、前記疎水基はチオール基であることを特徴とする分離装置。【請求項１２】請求項１乃至８いずれかに記載の分離装置において、前記疎水性領域は、シリコーン化合物を含むことを特徴とする分離装置。【請求項１３】請求項１乃至１２いずれかに記載の分離装置において、前記親水性領域は、親水基を有する化合物を含む膜により構成されたことを特徴とする分離装置。【請求項１４】請求項１３に記載の分離装置において、前記親水基を有する化合物は、親水基を有するシランカップリング剤であることを特徴とする分離装置。【請求項１５】請求項１４に記載の分離装置において、前記シランカップリング剤はアミノ基を有する化合物であることを特徴とする分離装置。【請求項１６】請求項１乃至１５いずれかに記載の分離装置を用い、前記試料導入部から試料を導入し、試料中の所定成分を分離することを特徴とする試料分離方法。【請求項１７】基板と、該基板の表面に形成された試料の通る流路と、前記流路中に設けられた試料分離部とを備える分離装置の製造方法であって、親水性表面を有する前記流路を形成する工程と、前記流路の表面の少なくとも一部に、開口部を有するマスクを設けた後、該開口部から前記流路表面に疎水基を有する化合物を堆積し、次いで該マスクを除去することにより、疎水性領域が配置された前記試料分離部を形成する工程と、を含むことを特徴とする分離装置の製造方法。【請求項１８】請求項１７に記載の分離装置の製造方法において、前記化合物は、疎水基を有するシランカップリング剤であることを特徴とする分離装置の製造方法。【請求項１９】請求項１８に記載の分離装置の製造方法において、前記疎水基はチオール基であることを特徴とする分離装置の製造方法。【請求項２０】基板と、該基板の表面に形成された試料の通る流路と、前記流路中に設けられた試料分離部とを備える分離装置の製造方法であって、疎水性表面を有する基板 (detection method) に前記流路を形成する工程と、前記流路の表面の少なくとも一部に開口部を有するマスクを設けた後、該開口部から前記流路表面に親水基を有する化合物を堆積し、次いで該マスクを除去することにより、親水性領域が配置された前記試料分離部を形成する工程と、を含むことを特徴とする分離装置の製造方法。【請求項２１】請求項２０に記載の分離装置の製造方法において、前記化合物は、親水基を有するシランカップリング剤であることを特徴とする分離装置の製造方法。【請求項２２】請求項２１に記載の分離装置の製造方法において、前記親水基はアミノ基であることを特徴とする分離装置の製造方法。【請求項２３】基板と、該基板の表面に形成された試料の通る流路と、前記流路中に設けられた試料分離部とを備える分離装置の製造方法であって、親水性表面を有する前記流路を形成する工程と、前記流路の表面に対して液状シリコーン化合物を付着し、疎水性領域が配置された前記試料分離部を形成する工程と、を含むことを特徴とする分離装置の製造方法。【請求項２４】請求項２３に記載の分離装置の製造方法において、前記試料分離部を形成する前記工程は、前記液状シリコーン化合物を含有するシリコーン樹脂の表面を前記前記流路表面に接触させる工程を含むことを特徴とする分離装置の製造方法。
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method (有する基板) includes collecting signals from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	JP2003222611A CLAIM 1 【特許請求の範囲】【請求項１】基板と、該基板の表面に形成された試料の通る流路と、前記流路に設けられた試料導入部および試料分離部とを備える分離装置であって、前記試料分離部の表面は、親水性領域と疎水性領域とを有することを特徴とする分離装置。【請求項２】基板と、該基板の表面に形成された試料の通る流路と、前記流路に設けられた試料導入部および試料排出部と、試料導入部から試料排出部に至るまでの間の流路中に設けられた試料分離部とを備える分離装置であって、前記試料分離部の表面は、離間して配置された複数の第一の領域と、該第一の領域を除く試料分離部表面を占める第二の領域と、を有し、第一の領域および第二の領域のうち、一方が疎水性領域であり、他方が親水性領域であることを特徴とする分離装置。【請求項３】請求項２に記載の分離装置において、前記第一の領域が２次元的に略等間隔で配置されていることを特徴とする分離装置。【請求項４】請求項２または３に記載の分離装置において、前記試料分離部を複数備えたことを特徴とする分離装置。【請求項５】請求項４に記載の分離装置において、隣接する試料分離部の間隔が、各試料分離部を構成する第一の領域の間隔よりも広いことを特徴とする分離装置。【請求項６】請求項４または５に記載の分離装置において、各試料分離部における第一の領域の間隔が互いに異なることを特徴とする分離装置。【請求項７】請求項１乃至６いずれかに記載の分離装置において、外力付与手段をさらに備え、外力により前記試料を試料導入部から前記試料分離部の方向へ移動せしめるようにしたことを特徴とする分離装置。【請求項８】請求項１乃至７いずれかに記載の分離装置において、前記試料分離部の下流側に検出部を備えたことを特徴とする分離装置。【請求項９】請求項１乃至８いずれかに記載の分離装置において、前記疎水性領域は、疎水基を有する化合物を含む膜により構成されたことを特徴とする分離装置。【請求項１０】請求項９に記載の分離装置において、前記疎水基を有する化合物は、疎水基を有するシランカップリング剤であることを特徴とする分離装置。【請求項１１】請求項９または１０に記載の分離装置において、前記疎水基はチオール基であることを特徴とする分離装置。【請求項１２】請求項１乃至８いずれかに記載の分離装置において、前記疎水性領域は、シリコーン化合物を含むことを特徴とする分離装置。【請求項１３】請求項１乃至１２いずれかに記載の分離装置において、前記親水性領域は、親水基を有する化合物を含む膜により構成されたことを特徴とする分離装置。【請求項１４】請求項１３に記載の分離装置において、前記親水基を有する化合物は、親水基を有するシランカップリング剤であることを特徴とする分離装置。【請求項１５】請求項１４に記載の分離装置において、前記シランカップリング剤はアミノ基を有する化合物であることを特徴とする分離装置。【請求項１６】請求項１乃至１５いずれかに記載の分離装置を用い、前記試料導入部から試料を導入し、試料中の所定成分を分離することを特徴とする試料分離方法。【請求項１７】基板と、該基板の表面に形成された試料の通る流路と、前記流路中に設けられた試料分離部とを備える分離装置の製造方法であって、親水性表面を有する前記流路を形成する工程と、前記流路の表面の少なくとも一部に、開口部を有するマスクを設けた後、該開口部から前記流路表面に疎水基を有する化合物を堆積し、次いで該マスクを除去することにより、疎水性領域が配置された前記試料分離部を形成する工程と、を含むことを特徴とする分離装置の製造方法。【請求項１８】請求項１７に記載の分離装置の製造方法において、前記化合物は、疎水基を有するシランカップリング剤であることを特徴とする分離装置の製造方法。【請求項１９】請求項１８に記載の分離装置の製造方法において、前記疎水基はチオール基であることを特徴とする分離装置の製造方法。【請求項２０】基板と、該基板の表面に形成された試料の通る流路と、前記流路中に設けられた試料分離部とを備える分離装置の製造方法であって、疎水性表面を有する基板 (detection method) に前記流路を形成する工程と、前記流路の表面の少なくとも一部に開口部を有するマスクを設けた後、該開口部から前記流路表面に親水基を有する化合物を堆積し、次いで該マスクを除去することにより、親水性領域が配置された前記試料分離部を形成する工程と、を含むことを特徴とする分離装置の製造方法。【請求項２１】請求項２０に記載の分離装置の製造方法において、前記化合物は、親水基を有するシランカップリング剤であることを特徴とする分離装置の製造方法。【請求項２２】請求項２１に記載の分離装置の製造方法において、前記親水基はアミノ基であることを特徴とする分離装置の製造方法。【請求項２３】基板と、該基板の表面に形成された試料の通る流路と、前記流路中に設けられた試料分離部とを備える分離装置の製造方法であって、親水性表面を有する前記流路を形成する工程と、前記流路の表面に対して液状シリコーン化合物を付着し、疎水性領域が配置された前記試料分離部を形成する工程と、を含むことを特徴とする分離装置の製造方法。【請求項２４】請求項２３に記載の分離装置の製造方法において、前記試料分離部を形成する前記工程は、前記液状シリコーン化合物を含有するシリコーン樹脂の表面を前記前記流路表面に接触させる工程を含むことを特徴とする分離装置の製造方法。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JP2003207454A Filed: 2002-01-15 Issued: 2003-07-25 透過光検出装置 (Original Assignee) Minolta Co Ltd; ミノルタ株式会社 Shunichi Hayamizu, Yasuhiro Santo, 康博山東, 俊一速水
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (照射部) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly (光検出装置, 受光部) for detecting said signal which is transmitted via said communication assembly to said external device.	JP2003207454A CLAIM 1 【特許請求の範囲】【請求項１】マイクロ流路に光を照射して、マイクロ流路を透過した透過光の変化を検出する透過光検出装置 (detection assembly) において、複数対の第１及び第２の開口を有する絞り部材であって、上記第１の開口がそれぞれマイクロ流路に対向して配置され、マイクロ流路を透過した透過光が上記第１の開口にそれぞれ入射し、対応する上記第２の開口からそれぞれ出射する、絞り部材と、上記絞り部材の上記第２の開口からそれぞれ出射した透過光を受光する一つの受光部 (detection assembly) とを備えたことを特徴とする、透過光検出装置。【請求項２】平行光を上記マイクロ流路に照射する平行光照射部 (test device) 材を備え、上記絞り部材は、対応する上記第１の開口と上記第２の開口とを結ぶ方向が、上記平行光と平行であることを特徴とする、請求項１記載の透過光検出装置。【請求項３】上記絞り部材の対応する上記第１の開口と上記第２の開口とのそれぞれの周縁上の点を結んだ直線がなす角度の最大値である光の進行角度が、１０度以下であることを特徴とする、請求項１記載の透過光検出装置。【請求項４】上記光の進行角度が、３度以下であることを特徴とする、請求項１記載の透過光検出装置。【請求項５】上記絞り部材の上記第１の開口は、上記マイクロ流路の流路方向に複数配置されたことを特徴とする、透過光検出装置。
US8283155B2 CLAIM 8. The system of claim 1 wherein the test device (照射部) further comprises a microneedle useful for collecting the sample.	JP2003207454A CLAIM 1 【特許請求の範囲】【請求項１】マイクロ流路に光を照射して、マイクロ流路を透過した透過光の変化を検出する透過光検出装置において、複数対の第１及び第２の開口を有する絞り部材であって、上記第１の開口がそれぞれマイクロ流路に対向して配置され、マイクロ流路を透過した透過光が上記第１の開口にそれぞれ入射し、対応する上記第２の開口からそれぞれ出射する、絞り部材と、上記絞り部材の上記第２の開口からそれぞれ出射した透過光を受光する一つの受光部とを備えたことを特徴とする、透過光検出装置。【請求項２】平行光を上記マイクロ流路に照射する平行光照射部 (test device) 材を備え、上記絞り部材は、対応する上記第１の開口と上記第２の開口とを結ぶ方向が、上記平行光と平行であることを特徴とする、請求項１記載の透過光検出装置。【請求項３】上記絞り部材の対応する上記第１の開口と上記第２の開口とのそれぞれの周縁上の点を結んだ直線がなす角度の最大値である光の進行角度が、１０度以下であることを特徴とする、請求項１記載の透過光検出装置。【請求項４】上記光の進行角度が、３度以下であることを特徴とする、請求項１記載の透過光検出装置。【請求項５】上記絞り部材の上記第１の開口は、上記マイクロ流路の流路方向に複数配置されたことを特徴とする、透過光検出装置。
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device (照射部) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents for said plurality of analytes.	JP2003207454A CLAIM 1 【特許請求の範囲】【請求項１】マイクロ流路に光を照射して、マイクロ流路を透過した透過光の変化を検出する透過光検出装置において、複数対の第１及び第２の開口を有する絞り部材であって、上記第１の開口がそれぞれマイクロ流路に対向して配置され、マイクロ流路を透過した透過光が上記第１の開口にそれぞれ入射し、対応する上記第２の開口からそれぞれ出射する、絞り部材と、上記絞り部材の上記第２の開口からそれぞれ出射した透過光を受光する一つの受光部とを備えたことを特徴とする、透過光検出装置。【請求項２】平行光を上記マイクロ流路に照射する平行光照射部 (test device) 材を備え、上記絞り部材は、対応する上記第１の開口と上記第２の開口とを結ぶ方向が、上記平行光と平行であることを特徴とする、請求項１記載の透過光検出装置。【請求項３】上記絞り部材の対応する上記第１の開口と上記第２の開口とのそれぞれの周縁上の点を結んだ直線がなす角度の最大値である光の進行角度が、１０度以下であることを特徴とする、請求項１記載の透過光検出装置。【請求項４】上記光の進行角度が、３度以下であることを特徴とする、請求項１記載の透過光検出装置。【請求項５】上記絞り部材の上記第１の開口は、上記マイクロ流路の流路方向に複数配置されたことを特徴とする、透過光検出装置。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (照射部) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly (光検出装置, 受光部) for detecting said signal which is transmitted via said communication assembly to said external device.	JP2003207454A CLAIM 1 【特許請求の範囲】【請求項１】マイクロ流路に光を照射して、マイクロ流路を透過した透過光の変化を検出する透過光検出装置 (detection assembly) において、複数対の第１及び第２の開口を有する絞り部材であって、上記第１の開口がそれぞれマイクロ流路に対向して配置され、マイクロ流路を透過した透過光が上記第１の開口にそれぞれ入射し、対応する上記第２の開口からそれぞれ出射する、絞り部材と、上記絞り部材の上記第２の開口からそれぞれ出射した透過光を受光する一つの受光部 (detection assembly) とを備えたことを特徴とする、透過光検出装置。【請求項２】平行光を上記マイクロ流路に照射する平行光照射部 (test device) 材を備え、上記絞り部材は、対応する上記第１の開口と上記第２の開口とを結ぶ方向が、上記平行光と平行であることを特徴とする、請求項１記載の透過光検出装置。【請求項３】上記絞り部材の対応する上記第１の開口と上記第２の開口とのそれぞれの周縁上の点を結んだ直線がなす角度の最大値である光の進行角度が、１０度以下であることを特徴とする、請求項１記載の透過光検出装置。【請求項４】上記光の進行角度が、３度以下であることを特徴とする、請求項１記載の透過光検出装置。【請求項５】上記絞り部材の上記第１の開口は、上記マイクロ流路の流路方向に複数配置されたことを特徴とする、透過光検出装置。
US8283155B2 CLAIM 37. The system of claim 30 wherein the test device (照射部) further comprises a microneedle useful for collecting the sample.	JP2003207454A CLAIM 1 【特許請求の範囲】【請求項１】マイクロ流路に光を照射して、マイクロ流路を透過した透過光の変化を検出する透過光検出装置において、複数対の第１及び第２の開口を有する絞り部材であって、上記第１の開口がそれぞれマイクロ流路に対向して配置され、マイクロ流路を透過した透過光が上記第１の開口にそれぞれ入射し、対応する上記第２の開口からそれぞれ出射する、絞り部材と、上記絞り部材の上記第２の開口からそれぞれ出射した透過光を受光する一つの受光部とを備えたことを特徴とする、透過光検出装置。【請求項２】平行光を上記マイクロ流路に照射する平行光照射部 (test device) 材を備え、上記絞り部材は、対応する上記第１の開口と上記第２の開口とを結ぶ方向が、上記平行光と平行であることを特徴とする、請求項１記載の透過光検出装置。【請求項３】上記絞り部材の対応する上記第１の開口と上記第２の開口とのそれぞれの周縁上の点を結んだ直線がなす角度の最大値である光の進行角度が、１０度以下であることを特徴とする、請求項１記載の透過光検出装置。【請求項４】上記光の進行角度が、３度以下であることを特徴とする、請求項１記載の透過光検出装置。【請求項５】上記絞り部材の上記第１の開口は、上記マイクロ流路の流路方向に複数配置されたことを特徴とする、透過光検出装置。
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device (照射部) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents for said plurality of analytes.	JP2003207454A CLAIM 1 【特許請求の範囲】【請求項１】マイクロ流路に光を照射して、マイクロ流路を透過した透過光の変化を検出する透過光検出装置において、複数対の第１及び第２の開口を有する絞り部材であって、上記第１の開口がそれぞれマイクロ流路に対向して配置され、マイクロ流路を透過した透過光が上記第１の開口にそれぞれ入射し、対応する上記第２の開口からそれぞれ出射する、絞り部材と、上記絞り部材の上記第２の開口からそれぞれ出射した透過光を受光する一つの受光部とを備えたことを特徴とする、透過光検出装置。【請求項２】平行光を上記マイクロ流路に照射する平行光照射部 (test device) 材を備え、上記絞り部材は、対応する上記第１の開口と上記第２の開口とを結ぶ方向が、上記平行光と平行であることを特徴とする、請求項１記載の透過光検出装置。【請求項３】上記絞り部材の対応する上記第１の開口と上記第２の開口とのそれぞれの周縁上の点を結んだ直線がなす角度の最大値である光の進行角度が、１０度以下であることを特徴とする、請求項１記載の透過光検出装置。【請求項４】上記光の進行角度が、３度以下であることを特徴とする、請求項１記載の透過光検出装置。【請求項５】上記絞り部材の上記第１の開口は、上記マイクロ流路の流路方向に複数配置されたことを特徴とする、透過光検出装置。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	CN1416528A Filed: 2001-03-05 Issued: 2003-05-07 医疗诊断系统 (Original Assignee) 医疗分析公司查德·斯蒂芬·格普哈特, H·威廉·勒施, 查尔斯·弗朗西斯·麦克布雷尔蒂, 爱德华·詹姆斯·麦克布雷尔蒂, 迈克尔·J·雷略, 托马斯·凯特·沙普尔斯, 唐纳德·韦恩·夏夫
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly (网络接) comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit (处理器, 个数字) configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly (输出端) for detecting said signal which is transmitted via said communication assembly (一次性) to said external device.	CN1416528A CLAIM 1.一种用于实施多种不同的医疗诊断检验的系统，该系统包括：一个手提便携式自动电子装置，其用于与一个容纳有待检流体的一次性 (communication assembly) 试槽，所述装置用于根据试槽内流体的不同而由所述多种检验中选出一种诊断检验并实施这种诊断检验，所述将要进行的诊断检验是由装置根据试槽上的识别信息选出的；一个一次性试槽，其用于容纳将受到诊断检验的流体，所述试槽包括有识别信息，这些信息表示出根据试槽内所容纳的流体的不同将要进行一种特定的诊断检验，所述试槽的尺寸和形状适合与装置10相接合。 CN1416528A CLAIM 5.根据权利要求1所述的系统，其特征在于：所述装置包括一个处理器 (sample collection unit) 和一个存储器，所述存储器内存储着用于执行每种诊断检验所需的数据和指令，所述处理器能够进入所述存储器，以根据从处于接合状态的试槽获得的信息获取所选检验的数据和指令。 CN1416528A CLAIM 27.根据权利要求26所述的系统，其特征在于：所述输入装置是一个数字 (sample collection unit) 字母键盘。 CN1416528A CLAIM 30.根据权利要求1所述的系统，其特征在于：所述装置包括一个用于与其它设备通讯的输入/输出端 (detection assembly) 口。 CN1416528A CLAIM 31.根据权利要求30所述的系统，其特征在于：所述输入/输出端口包括RS232接口和网络接 (reader assembly) 口中的至少一个。
US8283155B2 CLAIM 2. The system of claim 1 wherein the reader assembly (网络接) further comprises a controller having computer-executable commands for performing the reaction at a designated point-of-care location.	CN1416528A CLAIM 31.根据权利要求30所述的系统，其特征在于：所述输入/输出端口包括RS232接口和网络接 (reader assembly) 口中的至少一个。
US8283155B2 CLAIM 9. The system of claim 1 wherein the sample collection unit (处理器, 个数字) collects a sample of bodily fluid which is less than about 500 uL.	CN1416528A CLAIM 5.根据权利要求1所述的系统，其特征在于：所述装置包括一个处理器 (sample collection unit) 和一个存储器，所述存储器内存储着用于执行每种诊断检验所需的数据和指令，所述处理器能够进入所述存储器，以根据从处于接合状态的试槽获得的信息获取所选检验的数据和指令。 CN1416528A CLAIM 27.根据权利要求26所述的系统，其特征在于：所述输入装置是一个数字 (sample collection unit) 字母键盘。
US8283155B2 CLAIM 10. The system of claim 1 wherein the reader assembly (网络接) is configured to receive said protocol wirelessly from said external device.	CN1416528A CLAIM 31.根据权利要求30所述的系统，其特征在于：所述输入/输出端口包括RS232接口和网络接 (reader assembly) 口中的至少一个。
US8283155B2 CLAIM 11. The system of claim 1 wherein said reader assembly (网络接) comprises an identifier detector that detects said identifier.	CN1416528A CLAIM 31.根据权利要求30所述的系统，其特征在于：所述输入/输出端口包括RS232接口和网络接 (reader assembly) 口中的至少一个。
US8283155B2 CLAIM 14. The system of claim 13 wherein the system is configured to detect a plurality of analytes that generate distinct signals, wherein the intensities of said distinct signals vary over a range of 3 orders (的位置) of magnitude.	CN1416528A CLAIM 54.根据权利要求39所述的试槽，其特征在于：所述壳体包括一个腔室，而且所述电极在相互隔开的位置 (3 orders) 上设置在一个腔室内。
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method further comprises detecting an optical signal (电极之间) from the sample.	CN1416528A CLAIM 37.根据权利要求6所述的系统，其特征在于：所述装置对在两个保持在一个受控制的电压下的电极之间 (optical signal) 流动的电流进行测定。
US8283155B2 CLAIM 18. The system of claim 17 wherein the optical signal (电极之间) is a chemiluminscent signal.	CN1416528A CLAIM 37.根据权利要求6所述的系统，其特征在于：所述装置对在两个保持在一个受控制的电压下的电极之间 (optical signal) 流动的电流进行测定。
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method includes collecting signals (电解质) from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	CN1416528A CLAIM 13.根据权利要求6所述的系统，其特征在于：至少一个电极被一电解质 (detection method includes collecting signals) 所覆盖，电解质的成分决定于采用试槽所要进行的特定检验。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly (网络接) comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit (处理器, 个数字) configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly (输出端) for detecting said signal which is transmitted via said communication assembly (一次性) to said external device.	CN1416528A CLAIM 1.一种用于实施多种不同的医疗诊断检验的系统，该系统包括：一个手提便携式自动电子装置，其用于与一个容纳有待检流体的一次性 (communication assembly) 试槽，所述装置用于根据试槽内流体的不同而由所述多种检验中选出一种诊断检验并实施这种诊断检验，所述将要进行的诊断检验是由装置根据试槽上的识别信息选出的；一个一次性试槽，其用于容纳将受到诊断检验的流体，所述试槽包括有识别信息，这些信息表示出根据试槽内所容纳的流体的不同将要进行一种特定的诊断检验，所述试槽的尺寸和形状适合与装置10相接合。 CN1416528A CLAIM 5.根据权利要求1所述的系统，其特征在于：所述装置包括一个处理器 (sample collection unit) 和一个存储器，所述存储器内存储着用于执行每种诊断检验所需的数据和指令，所述处理器能够进入所述存储器，以根据从处于接合状态的试槽获得的信息获取所选检验的数据和指令。 CN1416528A CLAIM 27.根据权利要求26所述的系统，其特征在于：所述输入装置是一个数字 (sample collection unit) 字母键盘。 CN1416528A CLAIM 30.根据权利要求1所述的系统，其特征在于：所述装置包括一个用于与其它设备通讯的输入/输出端 (detection assembly) 口。 CN1416528A CLAIM 31.根据权利要求30所述的系统，其特征在于：所述输入/输出端口包括RS232接口和网络接 (reader assembly) 口中的至少一个。
US8283155B2 CLAIM 31. The system of claim 30 wherein the reader assembly (网络接) further comprises a controller having computer-executable commands for performing the reaction at a designated point-of-care location.	CN1416528A CLAIM 31.根据权利要求30所述的系统，其特征在于：所述输入/输出端口包括RS232接口和网络接 (reader assembly) 口中的至少一个。
US8283155B2 CLAIM 38. The system of claim 30 wherein the sample collection unit (处理器, 个数字) collects a sample of bodily fluid which is less than about 500 uL.	CN1416528A CLAIM 5.根据权利要求1所述的系统，其特征在于：所述装置包括一个处理器 (sample collection unit) 和一个存储器，所述存储器内存储着用于执行每种诊断检验所需的数据和指令，所述处理器能够进入所述存储器，以根据从处于接合状态的试槽获得的信息获取所选检验的数据和指令。 CN1416528A CLAIM 27.根据权利要求26所述的系统，其特征在于：所述输入装置是一个数字 (sample collection unit) 字母键盘。
US8283155B2 CLAIM 39. The system of claim 30 wherein the reader assembly (网络接) is configured to receive said protocol wirelessly from said external device.	CN1416528A CLAIM 31.根据权利要求30所述的系统，其特征在于：所述输入/输出端口包括RS232接口和网络接 (reader assembly) 口中的至少一个。
US8283155B2 CLAIM 40. The system of claim 30 wherein said reader assembly (网络接) comprises an identifier detector that detects said identifier.	CN1416528A CLAIM 31.根据权利要求30所述的系统，其特征在于：所述输入/输出端口包括RS232接口和网络接 (reader assembly) 口中的至少一个。
US8283155B2 CLAIM 43. The system of claim 42 wherein the system is configured to detect a plurality of analytes that generate distinct signals, wherein the intensities of said distinct signals vary over a range of 3 orders (的位置) of magnitude.	CN1416528A CLAIM 54.根据权利要求39所述的试槽，其特征在于：所述壳体包括一个腔室，而且所述电极在相互隔开的位置 (3 orders) 上设置在一个腔室内。
US8283155B2 CLAIM 45. The system of claim 30 further comprising a dilution chamber (的测量, 两个腔) containing a diluents for diluting the sample of bodily fluid according to said protocol transmitted by the external device and received by the reader assembly.	CN1416528A CLAIM 52.根据权利要求39所述的试槽，其特征在于：所述壳体包括两个腔 (dilution chamber) 室、与两个腔室流体联通的第一和第二孔，电极对中的一个电极设置在一个腔室内，电极对中的另一电极设置在另一腔室内。 CN1416528A CLAIM 60.根据权利要求56所述的试槽，其特征在于：所述诊断检验以下述方式进行：利用第一对电极测定一个腔室内的流体电导率，利用第二对电极测定另一腔室内的流体电导率，然后对比电导率的测量 (dilution chamber) 结果。

JP2003057244A

Filed: 2001-08-10 Issued: 2003-02-26

記録媒体およびこの記録媒体を用いた血糖測定システム

(Original Assignee) Nipro Corp; ニプロ株式会社

Takehito Ito, Hideyuki Tomita, 武仁伊藤, 英幸富田

US8283155B2
CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (電源部と) (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.

JP2003057244A
CLAIM 1 【特許請求の範囲】【請求項１】電源の供給が可能な携帯端末装置に装着されて動作する記録媒体であって、前記携帯端末装置とデータをやり取りする通信制御部と、採取された血液中の血糖値に応じた電流を発生するセンサー回路部と、前記発生した電流をデジタル変換して出力する信号処理部と、前記信号処理部から出力されたデータに基づいて変換された血糖値データを記憶する電気的に消去および書換えが可能な不揮発性の記憶部と、前記信号処理部から出力されたデータを前記血糖値データに変換して前記記憶部に書込み、前記記憶部から前記血糖値データを読出して前記通信制御部を介して前記携帯端末装置へ送信する制御部と、前記携帯端末装置から電源を受電し、前記センサー回路部と、前記信号処理部と、前記記憶部と、前記通信制御部と、前記制御部とに電源を供給する電源制御部とを備える記録媒体。【請求項２】前記携帯端末装置は、顧客の血糖値を管理するサーバへ前記測定された血糖値データを通信網を介して送信する、請求項１に記載の記録媒体。【請求項３】前記携帯端末装置は、前記測定された血糖値データを表示する、請求項１または請求項２に記載の記録媒体。【請求項４】前記携帯端末装置は、携帯電話機、携帯情報端末装置および携帯型パソコンのいずれかである、請求項１から３のいずれか１項に記載の記録媒体。【請求項５】携帯端末装置と、前記携帯端末装置に装着されて動作する記録媒体とを備える血糖測定システムであって、前記携帯端末装置は、前記記録媒体とデータをやり取りする第１の通信制御部と、前記記録媒体に電源を供給する電源部と (turn effects) 、第１の制御部とを含み、前記記録媒体は、前記携帯端末装置とデータをやり取りする第２の通信制御部と、採取された血液中の血糖値に応じた電流を発生するセンサー回路部と、前記発生した電流をデジタル変換して出力する信号処理部と、前記信号処理部から出力されたデータに基づいて変換された血糖値データを記憶する電気的に消去および書換えが可能な不揮発性の記憶部と、前記信号処理部から出力されたデータを前記血糖値データに変換して前記記憶部に書込み、前記記憶部から前記血糖値データを読出して前記第２の通信制御部を介して前記携帯端末装置へ送信する第２の制御部と、前記携帯端末装置から電源を受電し、前記センサー回路部と、前記信号処理部と、前記記憶部と、前記第２の通信制御部と、前記第２の制御部とに電源を供給する電源制御部とを含み、前記第１の制御部は、前記記録媒体から血糖値データを受信するに際して前記第１の通信制御部を制御する、血糖測定システム。【請求項６】前記携帯端末装置は、顧客の血糖値を管理するサーバと通信網を介してデータをやり取りする第３の通信制御部をさらに含み、前記第１の制御部は、前記サーバへ前記血糖値データを送信するに際して前記記録媒体から受信した血糖値データを前記第３の通信制御部にさらに与える、請求項５に記載の血糖測定システム。【請求項７】前記携帯端末装置は、前記血糖値データを表示する表示部をさらに含み、前記第１の制御部は、前記表示部に前記血糖値データを表示するに際して前記記録媒体から受信した血糖値データを前記表示部にさらに与える、請求項５または請求項６に記載の血糖測定システム。【請求項８】前記携帯端末装置は、携帯電話機、携帯情報端末装置および携帯型パソコンのいずれかである、請求項５から７のいずれか１項に記載の血糖測定システム。

US8283155B2
CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (電源部と) a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.

JP2002282217A

Filed: 2001-03-27 Issued: 2002-10-02

測定装置及びそれを含む測定結果管理システム

(Original Assignee) Sysmex Corp; シスメックス株式会社

Kazutoshi Tokunaga, 一敏徳永

US8283155B2
CLAIM 19. The system of claim 1 wherein the detection method includes collecting signals (バーコードリーダ) from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.

JP2002282217A
CLAIM 4 【請求項４】請求項１乃至３記載の測定装置と、前記測定部で得られた測定結果を受信、処理、記憶するホストコンピュータと、前記バーコード表示部によって表示されたバーコードおよび／または前記バーコード印刷部によって印刷されたバーコードを読み取るためのバーコードリーダ、及び、前記バーコードリーダ (detection method includes collecting signals) で読み取った前記測定結果を前記ホストコンピュータに送信するための送信部とから成る携帯データ端末とから成る測定結果管理システム。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	EP1202057A2 Filed: 2001-10-25 Issued: 2002-05-02 Solid state microcuvette using dry films (Original Assignee) Micronix Inc Hans G. Kloepfer, Mary A. Kloepfer, Charles W. Roach
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit (red blood cells) configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	EP1202057A2 CLAIM 21 A test strip device (10) for testing blood glucose levels, comprising a first translucent plate (16) coupled to a second translucent plate (18) that collectively define: a collection component (20) comprising an entry capillary (24) comprising an inlet (30) and an entry vessel (32) that are structured to exert capillary forces on whole blood applied to said inlet (30) in order to draw said whole blood into said entry vessel (32), a collection capillary (26) comprising a collection inlet (34) coupled to said entry vessel (32) and a collection vessel (36) that are structured to draw blood from said entry capillary (24) into said collection vessel (36) by exerting capillary forces on said whole blood in said entry vessel (32), and a translucent reagent film (29) on at least one wall of said collection capillary, said translucent reagent film comprising a glucose oxidase reagent that reacts with glucose in said whole blood as said glucose diffuses into said translucent reagent film; and a wicking capillary (61) comprising a wicking inlet (60) coupled to said collection vessel and a wicking vessel (62) that are structured to effectively sweep said translucent reagent film free of red blood cells (sample collection unit, analyte present) as said whole blood is drawn over said film and into said wicking vessel.
US8283155B2 CLAIM 9. The system of claim 1 wherein the sample collection unit (red blood cells) collects a sample of bodily fluid which is less than about 500 uL.	EP1202057A2 CLAIM 21 A test strip device (10) for testing blood glucose levels, comprising a first translucent plate (16) coupled to a second translucent plate (18) that collectively define: a collection component (20) comprising an entry capillary (24) comprising an inlet (30) and an entry vessel (32) that are structured to exert capillary forces on whole blood applied to said inlet (30) in order to draw said whole blood into said entry vessel (32), a collection capillary (26) comprising a collection inlet (34) coupled to said entry vessel (32) and a collection vessel (36) that are structured to draw blood from said entry capillary (24) into said collection vessel (36) by exerting capillary forces on said whole blood in said entry vessel (32), and a translucent reagent film (29) on at least one wall of said collection capillary, said translucent reagent film comprising a glucose oxidase reagent that reacts with glucose in said whole blood as said glucose diffuses into said translucent reagent film; and a wicking capillary (61) comprising a wicking inlet (60) coupled to said collection vessel and a wicking vessel (62) that are structured to effectively sweep said translucent reagent film free of red blood cells (sample collection unit, analyte present) as said whole blood is drawn over said film and into said wicking vessel.
US8283155B2 CLAIM 23. The method of claim 22 further comprising quantifying the amount of said analyte present (red blood cells) in said sample.	EP1202057A2 CLAIM 21 A test strip device (10) for testing blood glucose levels, comprising a first translucent plate (16) coupled to a second translucent plate (18) that collectively define: a collection component (20) comprising an entry capillary (24) comprising an inlet (30) and an entry vessel (32) that are structured to exert capillary forces on whole blood applied to said inlet (30) in order to draw said whole blood into said entry vessel (32), a collection capillary (26) comprising a collection inlet (34) coupled to said entry vessel (32) and a collection vessel (36) that are structured to draw blood from said entry capillary (24) into said collection vessel (36) by exerting capillary forces on said whole blood in said entry vessel (32), and a translucent reagent film (29) on at least one wall of said collection capillary, said translucent reagent film comprising a glucose oxidase reagent that reacts with glucose in said whole blood as said glucose diffuses into said translucent reagent film; and a wicking capillary (61) comprising a wicking inlet (60) coupled to said collection vessel and a wicking vessel (62) that are structured to effectively sweep said translucent reagent film free of red blood cells (sample collection unit, analyte present) as said whole blood is drawn over said film and into said wicking vessel.
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit (red blood cells) configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	EP1202057A2 CLAIM 21 A test strip device (10) for testing blood glucose levels, comprising a first translucent plate (16) coupled to a second translucent plate (18) that collectively define: a collection component (20) comprising an entry capillary (24) comprising an inlet (30) and an entry vessel (32) that are structured to exert capillary forces on whole blood applied to said inlet (30) in order to draw said whole blood into said entry vessel (32), a collection capillary (26) comprising a collection inlet (34) coupled to said entry vessel (32) and a collection vessel (36) that are structured to draw blood from said entry capillary (24) into said collection vessel (36) by exerting capillary forces on said whole blood in said entry vessel (32), and a translucent reagent film (29) on at least one wall of said collection capillary, said translucent reagent film comprising a glucose oxidase reagent that reacts with glucose in said whole blood as said glucose diffuses into said translucent reagent film; and a wicking capillary (61) comprising a wicking inlet (60) coupled to said collection vessel and a wicking vessel (62) that are structured to effectively sweep said translucent reagent film free of red blood cells (sample collection unit, analyte present) as said whole blood is drawn over said film and into said wicking vessel.
US8283155B2 CLAIM 38. The system of claim 30 wherein the sample collection unit (red blood cells) collects a sample of bodily fluid which is less than about 500 uL.	EP1202057A2 CLAIM 21 A test strip device (10) for testing blood glucose levels, comprising a first translucent plate (16) coupled to a second translucent plate (18) that collectively define: a collection component (20) comprising an entry capillary (24) comprising an inlet (30) and an entry vessel (32) that are structured to exert capillary forces on whole blood applied to said inlet (30) in order to draw said whole blood into said entry vessel (32), a collection capillary (26) comprising a collection inlet (34) coupled to said entry vessel (32) and a collection vessel (36) that are structured to draw blood from said entry capillary (24) into said collection vessel (36) by exerting capillary forces on said whole blood in said entry vessel (32), and a translucent reagent film (29) on at least one wall of said collection capillary, said translucent reagent film comprising a glucose oxidase reagent that reacts with glucose in said whole blood as said glucose diffuses into said translucent reagent film; and a wicking capillary (61) comprising a wicking inlet (60) coupled to said collection vessel and a wicking vessel (62) that are structured to effectively sweep said translucent reagent film free of red blood cells (sample collection unit, analyte present) as said whole blood is drawn over said film and into said wicking vessel.
US8283155B2 CLAIM 49. The method of claim 48 further comprising quantifying the amount of said analyte present (red blood cells) in said sample.	EP1202057A2 CLAIM 21 A test strip device (10) for testing blood glucose levels, comprising a first translucent plate (16) coupled to a second translucent plate (18) that collectively define: a collection component (20) comprising an entry capillary (24) comprising an inlet (30) and an entry vessel (32) that are structured to exert capillary forces on whole blood applied to said inlet (30) in order to draw said whole blood into said entry vessel (32), a collection capillary (26) comprising a collection inlet (34) coupled to said entry vessel (32) and a collection vessel (36) that are structured to draw blood from said entry capillary (24) into said collection vessel (36) by exerting capillary forces on said whole blood in said entry vessel (32), and a translucent reagent film (29) on at least one wall of said collection capillary, said translucent reagent film comprising a glucose oxidase reagent that reacts with glucose in said whole blood as said glucose diffuses into said translucent reagent film; and a wicking capillary (61) comprising a wicking inlet (60) coupled to said collection vessel and a wicking vessel (62) that are structured to effectively sweep said translucent reagent film free of red blood cells (sample collection unit, analyte present) as said whole blood is drawn over said film and into said wicking vessel.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JP2002044007A Filed: 2000-07-26 Issued: 2002-02-08 携帯電話機 (Original Assignee) Ricoh Elemex Corp; リコーエレメックス株式会社 Nobuhiro Takeda, 修宏武田
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method (検出信号) for detecting said signal, and wherein said reader further comprises a detection assembly (検出信号) for detecting said signal which is transmitted via said communication assembly to said external device.	JP2002044007A CLAIM 2 【請求項２】前記センサで呼気中の所定のガスを検出し、その検出信号 (detection method, detection assembly) から計算して前記目的物質測定回路で口臭度を測定する、請求項１に記載の携帯電話機。
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method (検出信号) further comprises detecting an optical signal from the sample.	JP2002044007A CLAIM 2 【請求項２】前記センサで呼気中の所定のガスを検出し、その検出信号 (detection method, detection assembly) から計算して前記目的物質測定回路で口臭度を測定する、請求項１に記載の携帯電話機。
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method (検出信号) includes collecting signals from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	JP2002044007A CLAIM 2 【請求項２】前記センサで呼気中の所定のガスを検出し、その検出信号 (detection method, detection assembly) から計算して前記目的物質測定回路で口臭度を測定する、請求項１に記載の携帯電話機。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly (検出信号) for detecting said signal which is transmitted via said communication assembly to said external device.	JP2002044007A CLAIM 2 【請求項２】前記センサで呼気中の所定のガスを検出し、その検出信号 (detection method, detection assembly) から計算して前記目的物質測定回路で口臭度を測定する、請求項１に記載の携帯電話機。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JP2002010990A Filed: 2001-05-29 Issued: 2002-01-15 組織の電気的特性の計測 (Original Assignee) Given Imaging Ltd; ギブン・イメージング・リミテツド Arkady Glukhovsky, アルカデイ・グルクホフスキイ
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (インピーダン) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants (カップ状) that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	JP2002010990A CLAIM 6 【請求項６】前記電気的特性は、インピーダン (test device) ス値を含む請求項１に記載の装置。 JP2002010990A CLAIM 13 【請求項１３】前記電極はカップ状 (assay assembly containing reactants) であり、且つ前記開口は円形である請求項１に記載の装置。
US8283155B2 CLAIM 8. The system of claim 1 wherein the test device (インピーダン) further comprises a microneedle useful for collecting the sample.	JP2002010990A CLAIM 6 【請求項６】前記電気的特性は、インピーダン (test device) ス値を含む請求項１に記載の装置。
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device (インピーダン) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents for said plurality of analytes.	JP2002010990A CLAIM 6 【請求項６】前記電気的特性は、インピーダン (test device) ス値を含む請求項１に記載の装置。
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method further comprises detecting an optical signal (の内部) from the sample.	JP2002010990A CLAIM 9 【請求項９】前記生物学的組織は、消化管のいずれかの部分の内部 (optical signal) である請求項１に記載の装置。
US8283155B2 CLAIM 18. The system of claim 17 wherein the optical signal (の内部) is a chemiluminscent signal.	JP2002010990A CLAIM 9 【請求項９】前記生物学的組織は、消化管のいずれかの部分の内部 (optical signal) である請求項１に記載の装置。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (インピーダン) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants (カップ状) for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	JP2002010990A CLAIM 6 【請求項６】前記電気的特性は、インピーダン (test device) ス値を含む請求項１に記載の装置。 JP2002010990A CLAIM 13 【請求項１３】前記電極はカップ状 (assay assembly containing reactants) であり、且つ前記開口は円形である請求項１に記載の装置。
US8283155B2 CLAIM 37. The system of claim 30 wherein the test device (インピーダン) further comprises a microneedle useful for collecting the sample.	JP2002010990A CLAIM 6 【請求項６】前記電気的特性は、インピーダン (test device) ス値を含む請求項１に記載の装置。
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device (インピーダン) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents for said plurality of analytes.	JP2002010990A CLAIM 6 【請求項６】前記電気的特性は、インピーダン (test device) ス値を含む請求項１に記載の装置。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JP2001165752A Filed: 1999-12-06 Issued: 2001-06-22 血清量測定装置および測定方法 (Original Assignee) Hitachi Ltd; 株式会社日立製作所 Toshiyuki Ikeda, Tatsutoshi Imaoka, Toshiyuki Tanaka, 龍勇今岡, 俊幸池田, 利幸田中
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method (検出手段) for detecting said signal, and wherein said reader further comprises a detection assembly (検出手段) for detecting said signal which is transmitted via said communication assembly to said external device.	JP2001165752A CLAIM 1 【請求項１】血液検体の画像を取り込んで血清成分の画像を取り出す血清量測定装置において、試験管中の血液の画像の３原色信号を取り込む画像入力手段と、前記画像から特徴部位の色度境界を抽出する抽出手段と、色度境界の連続性を検出して血清成分の上下境界位置を特定する境界特定手段と、特定された少なくとも上下境界位置に基づいて決定された血清領域内の血清成分の画像を取り込む画像入力手段と、取り込んだ画像から色度不均一領域を検出する色度不均一領域検出手段 (detection method, detection assembly) とを含んで構成されることを特徴とする血清量測定装置。
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method (検出手段) further comprises detecting an optical signal from the sample.	JP2001165752A CLAIM 1 【請求項１】血液検体の画像を取り込んで血清成分の画像を取り出す血清量測定装置において、試験管中の血液の画像の３原色信号を取り込む画像入力手段と、前記画像から特徴部位の色度境界を抽出する抽出手段と、色度境界の連続性を検出して血清成分の上下境界位置を特定する境界特定手段と、特定された少なくとも上下境界位置に基づいて決定された血清領域内の血清成分の画像を取り込む画像入力手段と、取り込んだ画像から色度不均一領域を検出する色度不均一領域検出手段 (detection method, detection assembly) とを含んで構成されることを特徴とする血清量測定装置。
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method (検出手段) includes collecting signals from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	JP2001165752A CLAIM 1 【請求項１】血液検体の画像を取り込んで血清成分の画像を取り出す血清量測定装置において、試験管中の血液の画像の３原色信号を取り込む画像入力手段と、前記画像から特徴部位の色度境界を抽出する抽出手段と、色度境界の連続性を検出して血清成分の上下境界位置を特定する境界特定手段と、特定された少なくとも上下境界位置に基づいて決定された血清領域内の血清成分の画像を取り込む画像入力手段と、取り込んだ画像から色度不均一領域を検出する色度不均一領域検出手段 (detection method, detection assembly) とを含んで構成されることを特徴とする血清量測定装置。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly (検出手段) for detecting said signal which is transmitted via said communication assembly to said external device.	JP2001165752A CLAIM 1 【請求項１】血液検体の画像を取り込んで血清成分の画像を取り出す血清量測定装置において、試験管中の血液の画像の３原色信号を取り込む画像入力手段と、前記画像から特徴部位の色度境界を抽出する抽出手段と、色度境界の連続性を検出して血清成分の上下境界位置を特定する境界特定手段と、特定された少なくとも上下境界位置に基づいて決定された血清領域内の血清成分の画像を取り込む画像入力手段と、取り込んだ画像から色度不均一領域を検出する色度不均一領域検出手段 (detection method, detection assembly) とを含んで構成されることを特徴とする血清量測定装置。

JP2000314719A

Filed: 1999-04-30 Issued: 2000-11-14

電気泳動チップ

(Original Assignee) Shimadzu Corp; 株式会社島津製作所

Akihiro Arai, 昭博荒井

US8283155B2
CLAIM 17. The system of claim 1 wherein the detection method further comprises detecting an optical signal (の内部) from the sample.

JP2000314719A
CLAIM 1 【請求項１】透明板状部材の内部 (optical signal) に流路が形成され、その透明板状部材の一表面の流路に対応する位置に流路に達する穴が形成された電気泳動チップにおいて、前記流路及び前記穴に所定の泳動バッファが充填されており、前記透明板状部材の前記一表面の、少なくとも前記穴をフィルム部材で被覆してあることを特徴とする電気泳動チップ。

US8283155B2
CLAIM 18. The system of claim 17 wherein the optical signal (の内部) is a chemiluminscent signal.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	CN1262606A Filed: 1997-12-04 Issued: 2000-08-09 采集诊断测试用血的方法和设备 (Original Assignee) 艾博特公司 D·D·坎宁安, T·P·亨宁, E·B·沙因, D·F·杨, M·G·罗维赖, T·G·沙皮拉, H·W·格拉哈姆, A·J·米特尔蒂斯, G·R·查姆伯斯, G·J·胡赫斯, J·L·瓦特金, G·F·普罗科普, J·P·戈尔德法布
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid (流体连通) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	CN1262606A CLAIM 108.一种适用于采集在诊断测试中供分析用的血样的设备，具有：(a)一壳体，其内具有一可密封室和一与所述可密封室作流体连通 (way communication system, bodily fluid) 的可密封开口；(b)一动力源；(c)一真空泵，与所述动力源作可操作连接，所述真空泵与所述可密封室连通；(d)一刺破组件，位于所述壳体内，所述刺破组件可使一柳叶刀向所述可密封开口移动；(e)一流体收集器，位于所述可密封室内，所述流体收集器与所述可密封开口流体连通。
US8283155B2 CLAIM 9. The system of claim 1 wherein the sample collection unit collects a sample of bodily fluid (流体连通) which is less than about 500 uL.	CN1262606A CLAIM 108.一种适用于采集在诊断测试中供分析用的血样的设备，具有：(a)一壳体，其内具有一可密封室和一与所述可密封室作流体连通 (way communication system, bodily fluid) 的可密封开口；(b)一动力源；(c)一真空泵，与所述动力源作可操作连接，所述真空泵与所述可密封室连通；(d)一刺破组件，位于所述壳体内，所述刺破组件可使一柳叶刀向所述可密封开口移动；(e)一流体收集器，位于所述可密封室内，所述流体收集器与所述可密封开口流体连通。
US8283155B2 CLAIM 14. The system of claim 13 wherein the system is configured to detect a plurality of analytes that generate distinct signals, wherein the intensities of said distinct signals vary over a range of 3 orders (的位置) of magnitude.	CN1262606A CLAIM 31.一种可用柳叶刀在病人皮肤上形成一开口的组件，具有：(a)一夹持器，用以夹持柳叶刀组件；(b)一装置，用以提供足够的力以便使所述夹持器保持在位而使在所述夹持器内的柳叶刀位于离开所述病人皮肤的位置 (3 orders) ；(c)一装置，可使气体提供足够的力而克服由所述夹持器保持装置所提供的力，从而使所述气体将所述夹持器移到某一位置而使在所述夹持器内的柳叶刀可刺破所述病人的皮肤。
US8283155B2 CLAIM 22. A method for detecting an analyte in a bodily fluid (流体连通) of a subject, comprising: a) providing a system of claim 1 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	CN1262606A CLAIM 108.一种适用于采集在诊断测试中供分析用的血样的设备，具有：(a)一壳体，其内具有一可密封室和一与所述可密封室作流体连通 (way communication system, bodily fluid) 的可密封开口；(b)一动力源；(c)一真空泵，与所述动力源作可操作连接，所述真空泵与所述可密封室连通；(d)一刺破组件，位于所述壳体内，所述刺破组件可使一柳叶刀向所述可密封开口移动；(e)一流体收集器，位于所述可密封室内，所述流体收集器与所述可密封开口流体连通。
US8283155B2 CLAIM 23. The method of claim 22 further comprising quantifying the amount of said analyte present (分析物数) in said sample.	CN1262606A CLAIM 53.多层元件，具有：(a)一个可接收和传送通过化学辅助吸收作用接收的血液的层；(b)一个可检测血液内分析物的存在或测定血液中分析物数 (analyte present) 量的层；(c)一个可置于与一计量器接触的层，可接触计量器的该层叠放在传送血液层上，所述层(a)可将血液传送给所述层(b)。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid (流体连通) from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	CN1262606A CLAIM 108.一种适用于采集在诊断测试中供分析用的血样的设备，具有：(a)一壳体，其内具有一可密封室和一与所述可密封室作流体连通 (way communication system, bodily fluid) 的可密封开口；(b)一动力源；(c)一真空泵，与所述动力源作可操作连接，所述真空泵与所述可密封室连通；(d)一刺破组件，位于所述壳体内，所述刺破组件可使一柳叶刀向所述可密封开口移动；(e)一流体收集器，位于所述可密封室内，所述流体收集器与所述可密封开口流体连通。
US8283155B2 CLAIM 38. The system of claim 30 wherein the sample collection unit collects a sample of bodily fluid (流体连通) which is less than about 500 uL.	CN1262606A CLAIM 108.一种适用于采集在诊断测试中供分析用的血样的设备，具有：(a)一壳体，其内具有一可密封室和一与所述可密封室作流体连通 (way communication system, bodily fluid) 的可密封开口；(b)一动力源；(c)一真空泵，与所述动力源作可操作连接，所述真空泵与所述可密封室连通；(d)一刺破组件，位于所述壳体内，所述刺破组件可使一柳叶刀向所述可密封开口移动；(e)一流体收集器，位于所述可密封室内，所述流体收集器与所述可密封开口流体连通。
US8283155B2 CLAIM 43. The system of claim 42 wherein the system is configured to detect a plurality of analytes that generate distinct signals, wherein the intensities of said distinct signals vary over a range of 3 orders (的位置) of magnitude.	CN1262606A CLAIM 31.一种可用柳叶刀在病人皮肤上形成一开口的组件，具有：(a)一夹持器，用以夹持柳叶刀组件；(b)一装置，用以提供足够的力以便使所述夹持器保持在位而使在所述夹持器内的柳叶刀位于离开所述病人皮肤的位置 (3 orders) ；(c)一装置，可使气体提供足够的力而克服由所述夹持器保持装置所提供的力，从而使所述气体将所述夹持器移到某一位置而使在所述夹持器内的柳叶刀可刺破所述病人的皮肤。
US8283155B2 CLAIM 45. The system of claim 30 further comprising a dilution chamber containing a diluents for diluting the sample of bodily fluid (流体连通) according to said protocol transmitted by the external device and received by the reader assembly.	CN1262606A CLAIM 108.一种适用于采集在诊断测试中供分析用的血样的设备，具有：(a)一壳体，其内具有一可密封室和一与所述可密封室作流体连通 (way communication system, bodily fluid) 的可密封开口；(b)一动力源；(c)一真空泵，与所述动力源作可操作连接，所述真空泵与所述可密封室连通；(d)一刺破组件，位于所述壳体内，所述刺破组件可使一柳叶刀向所述可密封开口移动；(e)一流体收集器，位于所述可密封室内，所述流体收集器与所述可密封开口流体连通。
US8283155B2 CLAIM 48. A method for detecting an analyte in a bodily fluid (流体连通) of a subject, comprising: a) providing a system of claim 30 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	CN1262606A CLAIM 108.一种适用于采集在诊断测试中供分析用的血样的设备，具有：(a)一壳体，其内具有一可密封室和一与所述可密封室作流体连通 (way communication system, bodily fluid) 的可密封开口；(b)一动力源；(c)一真空泵，与所述动力源作可操作连接，所述真空泵与所述可密封室连通；(d)一刺破组件，位于所述壳体内，所述刺破组件可使一柳叶刀向所述可密封开口移动；(e)一流体收集器，位于所述可密封室内，所述流体收集器与所述可密封开口流体连通。
US8283155B2 CLAIM 49. The method of claim 48 further comprising quantifying the amount of said analyte present (分析物数) in said sample.	CN1262606A CLAIM 53.多层元件，具有：(a)一个可接收和传送通过化学辅助吸收作用接收的血液的层；(b)一个可检测血液内分析物的存在或测定血液中分析物数 (analyte present) 量的层；(c)一个可置于与一计量器接触的层，可接触计量器的该层叠放在传送血液层上，所述层(a)可将血液传送给所述层(b)。

EP1002229A1

Filed: 1997-05-27 Issued: 2000-05-24

Electrochemical and photochemical electrodes and their use

(Original Assignee) Yissum Research Development Company of Hebrew University of Jerusalem (Current Assignee) Yissum Research Development Company of Hebrew University of Jerusalem

Ron Blonder, Vered Heleg-Shabtai, Eugeny Katz, Itamar Willner

US8283155B2
CLAIM 17. The system of claim 1 wherein the detection method further comprises detecting an optical signal (optical signal) from the sample.

EP1002229A1
CLAIM 12. An electro chemical system for the recordal of optical signal (optical signal) s having a first wavelength and the electrical transduction of the recorded signals, the system having an electrochemical cell comprising: (a) an electrode carrying immobilized FAD-dependent redox enzymes, the enzyme: (aa) having a functionalized FAD comprising a photoisomerizable group which changes its isomerization state from a first to a second state upon photostimulation of light of the first wavelength, a change in the isomerization state giving rise to a change in the rate of catalytic activity of the redox enzyme, (ab) being immobilized onto the surface of the electrode through a linking group which either (aba) forms part of or being covalently bound to the functionalized FAD, or (abb) is covalently bound to an external moiety on the surface of the enzyme; (b) an electron mediator group which can transfer electrons between the electrode and the FAD, the electron mediator group being either (ba) freely tumbling in the medium surrounding the electrode, (bb) independently immobilized onto the surface of the electrode, (be) covalently bound to the enzyme, or (bd) covalently bound to or forming part of the modified FAD; (c) a substrate for the catalytic activity of the enzyme; and (d) an electric circuitry for charging the electrode and measuring the electrical response.

US8283155B2
CLAIM 18. The system of claim 17 wherein the optical signal (optical signal) is a chemiluminscent signal.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	CN1253625A Filed: 1998-04-13 Issued: 2000-05-17 改进了通道几何结构的微型流体装置 (Original Assignee) 卡钳技术有限公司 R·S·杜布罗, C·B·肯尼迪, L·布塞
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid (第一横) from a subject, comprising: a) a reader assembly comprising a programmable processor (将第一) that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit (的样品, 第一样) configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	CN1253625A CLAIM 5.根据权利要求1所述的微型流体装置，它还包括至少一个连接于第三通道的样品 (sample collection unit) 库和至少一个连接于第二通道的第二退液库。 CN1253625A CLAIM 45.一种微型流体装置，它包括：具有内部和外部的体结构；分布在内部的第一通道；与第一通道连通的至少第一样 (sample collection unit) 品预加样组件，该预加样组件包括：与第一通道相交于第一交叉口的第一进样通道，与第一进样通道连通的第一组多样品库；位于第一组多样品库和第一交叉口之间，与第一进样通道连通的第一预加样/退液库。 CN1253625A CLAIM 49.一种分析多份样品的方法，它包括：a)提供一种微型流体装置，它包括具有内部和外部的体结构；分布在内部的至少第一、第二和第三微细通道，第二通道与第一通道相交于第一交叉口，第三通道与第一通道相交于第二交叉口；分布在体结构内的多个样品库，各库均与第二通道连接；至少一个连接于第三通道的第一退液库；b)运送样品从所述多样品库中的第一库经过第二通道，经过第一和第二交叉口，进入第三通道，流向第一退液库；c)将第一 (programmable processor) 交叉口的该部分样品注入第一通道；d)沿第一通道运送该部分第一样品；和e)在分析通道内分析该部分第一样品。 CN1253625A CLAIM 68.一种微型流体装置，它包括：具有外部和内部的体结构；位于所述内部的一根分析通道；位于所述内部的第一和第二横向通道，所述的第一横 (bodily fluid) 向通道位于所述分析通道的第一侧并与之相交于第一交叉口，所述第二横向通道位于所述分析通道的第二侧并与之相交于第二交叉口；位于体结构内与所述第一横向通道连通的第一样品源；位于体结构内与所述第二横向通道连通的至少第二样品源；位于所述内部与所述第一横向通道相交于第三交叉口的第一退液通道；位于所述内部并与所述第二横向通道相交于第四交叉口的至少第二退液通道；样品引导系统，用于将样品从所述第一和第二样品源分别通过所述第一和第二横向通道传送至所述第一和第二退液库，将所述样品选择性地注入所述分析通道。
US8283155B2 CLAIM 9. The system of claim 1 wherein the sample collection unit (的样品, 第一样) collects a sample of bodily fluid (第一横) which is less than about 500 uL.	CN1253625A CLAIM 5.根据权利要求1所述的微型流体装置，它还包括至少一个连接于第三通道的样品 (sample collection unit) 库和至少一个连接于第二通道的第二退液库。 CN1253625A CLAIM 45.一种微型流体装置，它包括：具有内部和外部的体结构；分布在内部的第一通道；与第一通道连通的至少第一样 (sample collection unit) 品预加样组件，该预加样组件包括：与第一通道相交于第一交叉口的第一进样通道，与第一进样通道连通的第一组多样品库；位于第一组多样品库和第一交叉口之间，与第一进样通道连通的第一预加样/退液库。 CN1253625A CLAIM 68.一种微型流体装置，它包括：具有外部和内部的体结构；位于所述内部的一根分析通道；位于所述内部的第一和第二横向通道，所述的第一横 (bodily fluid) 向通道位于所述分析通道的第一侧并与之相交于第一交叉口，所述第二横向通道位于所述分析通道的第二侧并与之相交于第二交叉口；位于体结构内与所述第一横向通道连通的第一样品源；位于体结构内与所述第二横向通道连通的至少第二样品源；位于所述内部与所述第一横向通道相交于第三交叉口的第一退液通道；位于所述内部并与所述第二横向通道相交于第四交叉口的至少第二退液通道；样品引导系统，用于将样品从所述第一和第二样品源分别通过所述第一和第二横向通道传送至所述第一和第二退液库，将所述样品选择性地注入所述分析通道。
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid reagents (基丙烯酸甲酯) immobilized within the assay assembly.	CN1253625A CLAIM 15.根据权利要求14所述的微型流体装置，其中的聚合材料选自聚二甲基硅氧烷、聚甲基丙烯酸甲酯 (nucleic acid reagents) 、聚氨基甲酯、聚氯乙烯、聚苯乙烯、聚砜、聚碳酸酯、聚甲基戊烯、聚丙烯、聚乙烯、聚偏氟乙烯和丙烯腈-丁二烯-苯乙烯的共聚物。
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents (基丙烯酸甲酯) for said plurality of analytes.	CN1253625A CLAIM 15.根据权利要求14所述的微型流体装置，其中的聚合材料选自聚二甲基硅氧烷、聚甲基丙烯酸甲酯 (nucleic acid reagents) 、聚氨基甲酯、聚氯乙烯、聚苯乙烯、聚砜、聚碳酸酯、聚甲基戊烯、聚丙烯、聚乙烯、聚偏氟乙烯和丙烯腈-丁二烯-苯乙烯的共聚物。
US8283155B2 CLAIM 22. A method for detecting an analyte in a bodily fluid (第一横) of a subject, comprising: a) providing a system of claim 1 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	CN1253625A CLAIM 68.一种微型流体装置，它包括：具有外部和内部的体结构；位于所述内部的一根分析通道；位于所述内部的第一和第二横向通道，所述的第一横 (bodily fluid) 向通道位于所述分析通道的第一侧并与之相交于第一交叉口，所述第二横向通道位于所述分析通道的第二侧并与之相交于第二交叉口；位于体结构内与所述第一横向通道连通的第一样品源；位于体结构内与所述第二横向通道连通的至少第二样品源；位于所述内部与所述第一横向通道相交于第三交叉口的第一退液通道；位于所述内部并与所述第二横向通道相交于第四交叉口的至少第二退液通道；样品引导系统，用于将样品从所述第一和第二样品源分别通过所述第一和第二横向通道传送至所述第一和第二退液库，将所述样品选择性地注入所述分析通道。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid (第一横) from a subject, comprising: a) a reader assembly comprising a programmable processor (将第一) that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit (的样品, 第一样) configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	CN1253625A CLAIM 5.根据权利要求1所述的微型流体装置，它还包括至少一个连接于第三通道的样品 (sample collection unit) 库和至少一个连接于第二通道的第二退液库。 CN1253625A CLAIM 45.一种微型流体装置，它包括：具有内部和外部的体结构；分布在内部的第一通道；与第一通道连通的至少第一样 (sample collection unit) 品预加样组件，该预加样组件包括：与第一通道相交于第一交叉口的第一进样通道，与第一进样通道连通的第一组多样品库；位于第一组多样品库和第一交叉口之间，与第一进样通道连通的第一预加样/退液库。 CN1253625A CLAIM 49.一种分析多份样品的方法，它包括：a)提供一种微型流体装置，它包括具有内部和外部的体结构；分布在内部的至少第一、第二和第三微细通道，第二通道与第一通道相交于第一交叉口，第三通道与第一通道相交于第二交叉口；分布在体结构内的多个样品库，各库均与第二通道连接；至少一个连接于第三通道的第一退液库；b)运送样品从所述多样品库中的第一库经过第二通道，经过第一和第二交叉口，进入第三通道，流向第一退液库；c)将第一 (programmable processor) 交叉口的该部分样品注入第一通道；d)沿第一通道运送该部分第一样品；和e)在分析通道内分析该部分第一样品。 CN1253625A CLAIM 68.一种微型流体装置，它包括：具有外部和内部的体结构；位于所述内部的一根分析通道；位于所述内部的第一和第二横向通道，所述的第一横 (bodily fluid) 向通道位于所述分析通道的第一侧并与之相交于第一交叉口，所述第二横向通道位于所述分析通道的第二侧并与之相交于第二交叉口；位于体结构内与所述第一横向通道连通的第一样品源；位于体结构内与所述第二横向通道连通的至少第二样品源；位于所述内部与所述第一横向通道相交于第三交叉口的第一退液通道；位于所述内部并与所述第二横向通道相交于第四交叉口的至少第二退液通道；样品引导系统，用于将样品从所述第一和第二样品源分别通过所述第一和第二横向通道传送至所述第一和第二退液库，将所述样品选择性地注入所述分析通道。
US8283155B2 CLAIM 38. The system of claim 30 wherein the sample collection unit (的样品, 第一样) collects a sample of bodily fluid (第一横) which is less than about 500 uL.	CN1253625A CLAIM 5.根据权利要求1所述的微型流体装置，它还包括至少一个连接于第三通道的样品 (sample collection unit) 库和至少一个连接于第二通道的第二退液库。 CN1253625A CLAIM 45.一种微型流体装置，它包括：具有内部和外部的体结构；分布在内部的第一通道；与第一通道连通的至少第一样 (sample collection unit) 品预加样组件，该预加样组件包括：与第一通道相交于第一交叉口的第一进样通道，与第一进样通道连通的第一组多样品库；位于第一组多样品库和第一交叉口之间，与第一进样通道连通的第一预加样/退液库。 CN1253625A CLAIM 68.一种微型流体装置，它包括：具有外部和内部的体结构；位于所述内部的一根分析通道；位于所述内部的第一和第二横向通道，所述的第一横 (bodily fluid) 向通道位于所述分析通道的第一侧并与之相交于第一交叉口，所述第二横向通道位于所述分析通道的第二侧并与之相交于第二交叉口；位于体结构内与所述第一横向通道连通的第一样品源；位于体结构内与所述第二横向通道连通的至少第二样品源；位于所述内部与所述第一横向通道相交于第三交叉口的第一退液通道；位于所述内部并与所述第二横向通道相交于第四交叉口的至少第二退液通道；样品引导系统，用于将样品从所述第一和第二样品源分别通过所述第一和第二横向通道传送至所述第一和第二退液库，将所述样品选择性地注入所述分析通道。
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid reagents (基丙烯酸甲酯) immobilized within the assay assembly.	CN1253625A CLAIM 15.根据权利要求14所述的微型流体装置，其中的聚合材料选自聚二甲基硅氧烷、聚甲基丙烯酸甲酯 (nucleic acid reagents) 、聚氨基甲酯、聚氯乙烯、聚苯乙烯、聚砜、聚碳酸酯、聚甲基戊烯、聚丙烯、聚乙烯、聚偏氟乙烯和丙烯腈-丁二烯-苯乙烯的共聚物。
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents (基丙烯酸甲酯) for said plurality of analytes.	CN1253625A CLAIM 15.根据权利要求14所述的微型流体装置，其中的聚合材料选自聚二甲基硅氧烷、聚甲基丙烯酸甲酯 (nucleic acid reagents) 、聚氨基甲酯、聚氯乙烯、聚苯乙烯、聚砜、聚碳酸酯、聚甲基戊烯、聚丙烯、聚乙烯、聚偏氟乙烯和丙烯腈-丁二烯-苯乙烯的共聚物。
US8283155B2 CLAIM 45. The system of claim 30 further comprising a dilution chamber containing a diluents for diluting the sample of bodily fluid (第一横) according to said protocol transmitted by the external device and received by the reader assembly.	CN1253625A CLAIM 68.一种微型流体装置，它包括：具有外部和内部的体结构；位于所述内部的一根分析通道；位于所述内部的第一和第二横向通道，所述的第一横 (bodily fluid) 向通道位于所述分析通道的第一侧并与之相交于第一交叉口，所述第二横向通道位于所述分析通道的第二侧并与之相交于第二交叉口；位于体结构内与所述第一横向通道连通的第一样品源；位于体结构内与所述第二横向通道连通的至少第二样品源；位于所述内部与所述第一横向通道相交于第三交叉口的第一退液通道；位于所述内部并与所述第二横向通道相交于第四交叉口的至少第二退液通道；样品引导系统，用于将样品从所述第一和第二样品源分别通过所述第一和第二横向通道传送至所述第一和第二退液库，将所述样品选择性地注入所述分析通道。
US8283155B2 CLAIM 48. A method for detecting an analyte in a bodily fluid (第一横) of a subject, comprising: a) providing a system of claim 30 ; b) allowing a sample of bodily fluid to react with the reactants contained within said assay assembly to yield one or more detectable signal(s) indicative of the presence of said analyte; and c) detecting said detectable signal(s).	CN1253625A CLAIM 68.一种微型流体装置，它包括：具有外部和内部的体结构；位于所述内部的一根分析通道；位于所述内部的第一和第二横向通道，所述的第一横 (bodily fluid) 向通道位于所述分析通道的第一侧并与之相交于第一交叉口，所述第二横向通道位于所述分析通道的第二侧并与之相交于第二交叉口；位于体结构内与所述第一横向通道连通的第一样品源；位于体结构内与所述第二横向通道连通的至少第二样品源；位于所述内部与所述第一横向通道相交于第三交叉口的第一退液通道；位于所述内部并与所述第二横向通道相交于第四交叉口的至少第二退液通道；样品引导系统，用于将样品从所述第一和第二样品源分别通过所述第一和第二横向通道传送至所述第一和第二退液库，将所述样品选择性地注入所述分析通道。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	EP0962773A1 Filed: 1998-06-03 Issued: 1999-12-08 Electrochemical based assay processes instrument and labels (Original Assignee) Mark Howard Jones Mark Howard Jones
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	EP0962773A1 CLAIM 6 An assay as in claim 5 wherein both said binding species are selected from the following; antibody, antigen, nucleic acid (nucleic acid) , receptor, ligand, lectin, nucleic acid analogue, streptavidin, avidin.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	EP0962773A1 CLAIM 6 An assay as in claim 5 wherein both said binding species are selected from the following; antibody, antigen, nucleic acid (nucleic acid) , receptor, ligand, lectin, nucleic acid analogue, streptavidin, avidin.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	EP0962773A1 CLAIM 6 An assay as in claim 5 wherein both said binding species are selected from the following; antibody, antigen, nucleic acid (nucleic acid) , receptor, ligand, lectin, nucleic acid analogue, streptavidin, avidin.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	EP0962773A1 CLAIM 6 An assay as in claim 5 wherein both said binding species are selected from the following; antibody, antigen, nucleic acid (nucleic acid) , receptor, ligand, lectin, nucleic acid analogue, streptavidin, avidin.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JPH10305016A Filed: 1997-05-08 Issued: 1998-11-17 行動情報提供システム (Original Assignee) Casio Comput Co Ltd; カシオ計算機株式会社 Toru Yamakita, 徹山北
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method (検出手段) for detecting said signal, and wherein said reader further comprises a detection assembly (検出手段) for detecting said signal which is transmitted via said communication assembly to said external device.	JPH10305016A CLAIM 1 【請求項１】ユーザの生体に係わるデータを検出する生体データ検出手段 (detection method, detection assembly) と、上記ユーザの周囲の環境に係わるデータを検出する環境データ検出手段と、上記生体データ検出手段および環境データ検出手段により検出されたデータを上記ユーザの行動記録と対応づけて格納する格納手段と、該格納手段に格納されている情報に基づいて上記ユーザの行動についての情報を出力する行動情報出力手段と、を有する行動情報提供システム。
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method (検出手段) further comprises detecting an optical signal from the sample.	JPH10305016A CLAIM 1 【請求項１】ユーザの生体に係わるデータを検出する生体データ検出手段 (detection method, detection assembly) と、上記ユーザの周囲の環境に係わるデータを検出する環境データ検出手段と、上記生体データ検出手段および環境データ検出手段により検出されたデータを上記ユーザの行動記録と対応づけて格納する格納手段と、該格納手段に格納されている情報に基づいて上記ユーザの行動についての情報を出力する行動情報出力手段と、を有する行動情報提供システム。
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method (検出手段) includes collecting signals from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	JPH10305016A CLAIM 1 【請求項１】ユーザの生体に係わるデータを検出する生体データ検出手段 (detection method, detection assembly) と、上記ユーザの周囲の環境に係わるデータを検出する環境データ検出手段と、上記生体データ検出手段および環境データ検出手段により検出されたデータを上記ユーザの行動記録と対応づけて格納する格納手段と、該格納手段に格納されている情報に基づいて上記ユーザの行動についての情報を出力する行動情報出力手段と、を有する行動情報提供システム。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly (検出手段) for detecting said signal which is transmitted via said communication assembly to said external device.	JPH10305016A CLAIM 1 【請求項１】ユーザの生体に係わるデータを検出する生体データ検出手段 (detection method, detection assembly) と、上記ユーザの周囲の環境に係わるデータを検出する環境データ検出手段と、上記生体データ検出手段および環境データ検出手段により検出されたデータを上記ユーザの行動記録と対応づけて格納する格納手段と、該格納手段に格納されている情報に基づいて上記ユーザの行動についての情報を出力する行動情報出力手段と、を有する行動情報提供システム。

JPH10239240A

Filed: 1997-02-25 Issued: 1998-09-11

自動ｄｎａプローブ装置

(Original Assignee) Hitachi Ltd; 株式会社日立製作所

Tomoharu Kajiyama, Yuji Miyahara, 裕二宮原, 智晴梶山

US8283155B2
CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly (光検出) for detecting said signal which is transmitted via said communication assembly to said external device.

JPH10239240A
CLAIM 1 【請求項１】電気化学発光検出 (detection assembly) 器と独立に移動することが可能な作用電極と、測定項目に対応する既知配列のポリヌクレオチド１本鎖プローブの溶液と、電気化学発光反応を有する金属錯体溶液と、電気化学発光の還元試薬と、試料溶液に挿入並びに離脱が可能な外部電極と、予め決められた手順の電圧を作用電極と外部電極間に印加する電源と、電気化学発光検出器とで構成されることを特徴とする自動ＤＮＡプローブ装置。

US8283155B2
CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly (光検出) for detecting said signal which is transmitted via said communication assembly to said external device.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JPH1072628A Filed: 1997-07-09 Issued: 1998-03-17 エアバッグ用インフレーターの再利用 (Original Assignee) Autoliv Asp Inc; オートリブエーエスピー，インコーポレイティド Harry W Ii Miller, Jeff K Morley, ケイ．モーレイジェフ, ダブリュ．ミラーザセカンドハリー
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit (金属部品) configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	JPH1072628A CLAIM 1 【請求項１】非アルミニウム金属部品 (sample collection unit) に加え、ガスフィルターアッセンブリ及びガス発生剤物質を含む非金属部品を備える、アルミニウム合金ハウジングを具備するエアバッグ用インフレーターからの金属有価物の回収法であって、下記の工程を含む方法：エアバッグ用インフレーターに、せん断操作を施し、該インフレーターを微粉砕する工程；前記ガス発生剤物質を含む、せん断操作からの、様々な金属及び非金属材料を分離しかつ回収する工程；前述の分離かつ回収されたアルミニウム合金部品を、ガス燃料で燃焼された溶解炉に供給する工程；前記アルミニウム合金部品を、分離かつ回収されたガス発生剤物質の少なくとも一部を、流入(inflow)ガス燃料に供給することによって、該部品の溶融に十分な温度で加熱し、該アルミニウム合金部品の溶融に必要な加熱容量を提供する工程；及びアルミニウム合金を回収する工程。
US8283155B2 CLAIM 9. The system of claim 1 wherein the sample collection unit (金属部品) collects a sample of bodily fluid which is less than about 500 uL.	JPH1072628A CLAIM 1 【請求項１】非アルミニウム金属部品 (sample collection unit) に加え、ガスフィルターアッセンブリ及びガス発生剤物質を含む非金属部品を備える、アルミニウム合金ハウジングを具備するエアバッグ用インフレーターからの金属有価物の回収法であって、下記の工程を含む方法：エアバッグ用インフレーターに、せん断操作を施し、該インフレーターを微粉砕する工程；前記ガス発生剤物質を含む、せん断操作からの、様々な金属及び非金属材料を分離しかつ回収する工程；前述の分離かつ回収されたアルミニウム合金部品を、ガス燃料で燃焼された溶解炉に供給する工程；前記アルミニウム合金部品を、分離かつ回収されたガス発生剤物質の少なくとも一部を、流入(inflow)ガス燃料に供給することによって、該部品の溶融に十分な温度で加熱し、該アルミニウム合金部品の溶融に必要な加熱容量を提供する工程；及びアルミニウム合金を回収する工程。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit (金属部品) configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	JPH1072628A CLAIM 1 【請求項１】非アルミニウム金属部品 (sample collection unit) に加え、ガスフィルターアッセンブリ及びガス発生剤物質を含む非金属部品を備える、アルミニウム合金ハウジングを具備するエアバッグ用インフレーターからの金属有価物の回収法であって、下記の工程を含む方法：エアバッグ用インフレーターに、せん断操作を施し、該インフレーターを微粉砕する工程；前記ガス発生剤物質を含む、せん断操作からの、様々な金属及び非金属材料を分離しかつ回収する工程；前述の分離かつ回収されたアルミニウム合金部品を、ガス燃料で燃焼された溶解炉に供給する工程；前記アルミニウム合金部品を、分離かつ回収されたガス発生剤物質の少なくとも一部を、流入(inflow)ガス燃料に供給することによって、該部品の溶融に十分な温度で加熱し、該アルミニウム合金部品の溶融に必要な加熱容量を提供する工程；及びアルミニウム合金を回収する工程。
US8283155B2 CLAIM 38. The system of claim 30 wherein the sample collection unit (金属部品) collects a sample of bodily fluid which is less than about 500 uL.	JPH1072628A CLAIM 1 【請求項１】非アルミニウム金属部品 (sample collection unit) に加え、ガスフィルターアッセンブリ及びガス発生剤物質を含む非金属部品を備える、アルミニウム合金ハウジングを具備するエアバッグ用インフレーターからの金属有価物の回収法であって、下記の工程を含む方法：エアバッグ用インフレーターに、せん断操作を施し、該インフレーターを微粉砕する工程；前記ガス発生剤物質を含む、せん断操作からの、様々な金属及び非金属材料を分離しかつ回収する工程；前述の分離かつ回収されたアルミニウム合金部品を、ガス燃料で燃焼された溶解炉に供給する工程；前記アルミニウム合金部品を、分離かつ回収されたガス発生剤物質の少なくとも一部を、流入(inflow)ガス燃料に供給することによって、該部品の溶融に十分な温度で加熱し、該アルミニウム合金部品の溶融に必要な加熱容量を提供する工程；及びアルミニウム合金を回収する工程。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JPH09281078A Filed: 1996-04-09 Issued: 1997-10-31 Ｄｎａ塩基配列決定装置 (Original Assignee) Hitachi Electron Eng Co Ltd; 日立電子エンジニアリング株式会社 Yoshinori Mishina, Ryoji Nemoto, 喜典三品, 亮二根本
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method (検出手段, 光検出) for detecting said signal, and wherein said reader further comprises a detection assembly (検出手段, 光検出) for detecting said signal which is transmitted via said communication assembly to said external device.	JPH09281078A CLAIM 1 【請求項１】蛍光標識されたＤＮＡ断片用の多数の泳動路を有する、垂直に保持される平板型ゲル電気泳動手段、該電気泳動手段の泳動路に励起光を照射する励起光源、該励起光によって照射された蛍光標識ＤＮＡ断片から発生された蛍光を検出し電気信号に変換する蛍光検出 (detection method, detection assembly) 手段とからなるＤＮＡ塩基配列決定装置において、前記励起光源は高輝度発光ダイオード（ＬＥＤ）からなり、前記蛍光検出手段 (detection method, detection assembly) は屈折率分布型レンズアレー，フィルタおよびＣＣＤラインセンサから構成されており、前記高輝度発光ダイオードは電子冷熱器を有する温調回路に接続されていることを特徴とするＤＮＡ塩基配列決定装置。
US8283155B2 CLAIM 3. The system of claim 1 wherein the external device further comprises a means for receiving and aggregating a plurality of signals to effect trending (なるＤＮＡ) of the presence and/or concentration of said analyte taken at various time points over a given period of time.	JPH09281078A CLAIM 1 【請求項１】蛍光標識されたＤＮＡ断片用の多数の泳動路を有する、垂直に保持される平板型ゲル電気泳動手段、該電気泳動手段の泳動路に励起光を照射する励起光源、該励起光によって照射された蛍光標識ＤＮＡ断片から発生された蛍光を検出し電気信号に変換する蛍光検出手段とからなるＤＮＡ (effect trending) 塩基配列決定装置において、前記励起光源は高輝度発光ダイオード（ＬＥＤ）からなり、前記蛍光検出手段は屈折率分布型レンズアレー，フィルタおよびＣＣＤラインセンサから構成されており、前記高輝度発光ダイオードは電子冷熱器を有する温調回路に接続されていることを特徴とするＤＮＡ塩基配列決定装置。
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method (検出手段, 光検出) further comprises detecting an optical signal from the sample.	JPH09281078A CLAIM 1 【請求項１】蛍光標識されたＤＮＡ断片用の多数の泳動路を有する、垂直に保持される平板型ゲル電気泳動手段、該電気泳動手段の泳動路に励起光を照射する励起光源、該励起光によって照射された蛍光標識ＤＮＡ断片から発生された蛍光を検出し電気信号に変換する蛍光検出 (detection method, detection assembly) 手段とからなるＤＮＡ塩基配列決定装置において、前記励起光源は高輝度発光ダイオード（ＬＥＤ）からなり、前記蛍光検出手段 (detection method, detection assembly) は屈折率分布型レンズアレー，フィルタおよびＣＣＤラインセンサから構成されており、前記高輝度発光ダイオードは電子冷熱器を有する温調回路に接続されていることを特徴とするＤＮＡ塩基配列決定装置。
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method (検出手段, 光検出) includes collecting signals from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	JPH09281078A CLAIM 1 【請求項１】蛍光標識されたＤＮＡ断片用の多数の泳動路を有する、垂直に保持される平板型ゲル電気泳動手段、該電気泳動手段の泳動路に励起光を照射する励起光源、該励起光によって照射された蛍光標識ＤＮＡ断片から発生された蛍光を検出し電気信号に変換する蛍光検出 (detection method, detection assembly) 手段とからなるＤＮＡ塩基配列決定装置において、前記励起光源は高輝度発光ダイオード（ＬＥＤ）からなり、前記蛍光検出手段 (detection method, detection assembly) は屈折率分布型レンズアレー，フィルタおよびＣＣＤラインセンサから構成されており、前記高輝度発光ダイオードは電子冷熱器を有する温調回路に接続されていることを特徴とするＤＮＡ塩基配列決定装置。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly (検出手段, 光検出) for detecting said signal which is transmitted via said communication assembly to said external device.	JPH09281078A CLAIM 1 【請求項１】蛍光標識されたＤＮＡ断片用の多数の泳動路を有する、垂直に保持される平板型ゲル電気泳動手段、該電気泳動手段の泳動路に励起光を照射する励起光源、該励起光によって照射された蛍光標識ＤＮＡ断片から発生された蛍光を検出し電気信号に変換する蛍光検出 (detection method, detection assembly) 手段とからなるＤＮＡ塩基配列決定装置において、前記励起光源は高輝度発光ダイオード（ＬＥＤ）からなり、前記蛍光検出手段 (detection method, detection assembly) は屈折率分布型レンズアレー，フィルタおよびＣＣＤラインセンサから構成されており、前記高輝度発光ダイオードは電子冷熱器を有する温調回路に接続されていることを特徴とするＤＮＡ塩基配列決定装置。
US8283155B2 CLAIM 32. The system of claim 30 wherein the external device further comprises a means for receiving and aggregating a plurality of signals to effect trending (なるＤＮＡ) of the presence and/or concentration of said analyte taken at various time points over a given period of time.	JPH09281078A CLAIM 1 【請求項１】蛍光標識されたＤＮＡ断片用の多数の泳動路を有する、垂直に保持される平板型ゲル電気泳動手段、該電気泳動手段の泳動路に励起光を照射する励起光源、該励起光によって照射された蛍光標識ＤＮＡ断片から発生された蛍光を検出し電気信号に変換する蛍光検出手段とからなるＤＮＡ (effect trending) 塩基配列決定装置において、前記励起光源は高輝度発光ダイオード（ＬＥＤ）からなり、前記蛍光検出手段は屈折率分布型レンズアレー，フィルタおよびＣＣＤラインセンサから構成されており、前記高輝度発光ダイオードは電子冷熱器を有する温調回路に接続されていることを特徴とするＤＮＡ塩基配列決定装置。

JPH09253056A

Filed: 1996-03-27 Issued: 1997-09-30

患者監視装置及び患者監視システム

(Original Assignee) Nec Corp; 日本電気株式会社

Masayuki Takahashi, 正之高橋

US8283155B2
CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor (メモリ) that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.

JPH09253056A
CLAIM 1 【請求項１】患者の生体現象の計測値を監視する患者監視装置であって、この患者監視装置から離れた場所に置かれて血液分析を行う分析装置にネットワーク回線を介して接続された前記患者監視装置において、前記患者から血液サンプルを採取した時に操作されるイベントキー入力部と、このイベントキー入力部に接続され、該イベントキー入力部が操作された時に前記患者の生体現象の計測値として前記患者監視装置に入力されている前記患者の体温のデータを記憶するメモリ (programmable processor) と、前記分析装置が前記患者から採取した血液サンプルについて血液分析を行った分析結果データを、前記分析装置から前記ネットワーク回線を介して受け、この分析結果データを、前記メモリに記憶された前記患者の体温のデータを基に、演算補正し、補正された分析結果データを出力する演算補正回路とを有することを特徴とする患者監視装置。

US8283155B2
CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor (メモリ) that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JPH09244055A Filed: 1996-03-14 Issued: 1997-09-19 液晶表示装置 (Original Assignee) Hitachi Ltd; 株式会社日立製作所 Masayasu Eto, Takuo Kaito, Shigeki Kataoka, Shigeru Matsuyama, Satoshi Mihashi, Tamihito Nakagome, Masato Shimura, 里志三橋, 民仁中込, 正人志村, 茂松山, 正容江渡, 拓生海東, 茂樹片岡
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method (する合金) for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	JPH09244055A CLAIM 3 【請求項３】液晶を介して互いに対向配置される透明基板のうち一方の透明基板の液晶側の面の単位画素領域に、ゲート信号線からの走査信号の供給によってオンする薄膜トランジスタと、このオンされた薄膜トランジスタを介してドレイン信号線からの画素信号が供給される画素電極とが備えられ、前記薄膜トランジスタを構成する半導体層として多結晶シリコンを用いているものであって、他方の透明基板側に形成された共通電極を、導電体を介して、前記一方の透明基板側の導体層に引き出すように構成されている液晶表示装置において、前記導電体はその表面に突起部を複数有する形状となっているとともに、この導電体および前記導電層の各材料として、その一方がＡｌあるいはそれを主体とする合金 (detection method) で、他方がＣｒあるいはそれを主体する合金で形成されていることを特徴とする液晶表示装置。
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method (する合金) further comprises detecting an optical signal from the sample.	JPH09244055A CLAIM 3 【請求項３】液晶を介して互いに対向配置される透明基板のうち一方の透明基板の液晶側の面の単位画素領域に、ゲート信号線からの走査信号の供給によってオンする薄膜トランジスタと、このオンされた薄膜トランジスタを介してドレイン信号線からの画素信号が供給される画素電極とが備えられ、前記薄膜トランジスタを構成する半導体層として多結晶シリコンを用いているものであって、他方の透明基板側に形成された共通電極を、導電体を介して、前記一方の透明基板側の導体層に引き出すように構成されている液晶表示装置において、前記導電体はその表面に突起部を複数有する形状となっているとともに、この導電体および前記導電層の各材料として、その一方がＡｌあるいはそれを主体とする合金 (detection method) で、他方がＣｒあるいはそれを主体する合金で形成されていることを特徴とする液晶表示装置。
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method (する合金) includes collecting signals from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	JPH09244055A CLAIM 3 【請求項３】液晶を介して互いに対向配置される透明基板のうち一方の透明基板の液晶側の面の単位画素領域に、ゲート信号線からの走査信号の供給によってオンする薄膜トランジスタと、このオンされた薄膜トランジスタを介してドレイン信号線からの画素信号が供給される画素電極とが備えられ、前記薄膜トランジスタを構成する半導体層として多結晶シリコンを用いているものであって、他方の透明基板側に形成された共通電極を、導電体を介して、前記一方の透明基板側の導体層に引き出すように構成されている液晶表示装置において、前記導電体はその表面に突起部を複数有する形状となっているとともに、この導電体および前記導電層の各材料として、その一方がＡｌあるいはそれを主体とする合金 (detection method) で、他方がＣｒあるいはそれを主体する合金で形成されていることを特徴とする液晶表示装置。

JPH09192218A

Filed: 1996-01-16 Issued: 1997-07-29

血糖値管理システム

(Original Assignee) Hitachi Ltd; 株式会社日立製作所

Toshiko Fujii, Masao Kan, Yutaka Masuzawa, Yuji Miyahara, Osamu Ozawa, Tsuyoshi Sonehara, 裕二宮原, 理小沢, 剛志曽根原, 正男管, 稔子藤井, 裕鱒沢

US8283155B2
CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly (光検出) for detecting said signal which is transmitted via said communication assembly (少なくとも１) to said external device.

JPH09192218A
CLAIM 1 【請求項１】生体に直接光を照射する少なくとも１ (communication assembly) 個の光源と、生体から生ずる透過光，散乱光または光音響信号を検出する光検出 (detection assembly) 器または音響センサを有する生体物質濃度を測定する装置に、血糖値回復用液体の注入手段および液体注入量制御手段を設けたことを特徴とする血糖値管理システム。

US8283155B2
CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly (光検出) for detecting said signal which is transmitted via said communication assembly (少なくとも１) to said external device.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JPH09113511A Filed: 1995-10-18 Issued: 1997-05-02 グリコアルブミン測定用乾式試験片 (Original Assignee) Kdk Corp; 株式会社京都第一科学 Shigeru Doi, Masao Kono, Hiroshi Yamamoto, 茂土井, 博司山本, 昌雄河野
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (試験片) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	JPH09113511A CLAIM 1 【請求項１】展開液を用いて全血中のアルブミンとグリコアルブミンとを同時に測定するための乾式試験片 (test device) であって、支持体上に装着された展開膜へ、血球分離層と，アルブミンを着色する第一の色素とグリコアルブミンを着色する第二の色素を含む試薬層と，アルブミンとグリコアルブミンを捕捉するために両者に対する特異的結合性物質を固定化した測定層と，展開残液を吸収する残液吸収層の各層をこの順序で設けるグリコアルブミン測定用乾式試験片。
US8283155B2 CLAIM 8. The system of claim 1 wherein the test device (試験片) further comprises a microneedle useful for collecting the sample.	JPH09113511A CLAIM 1 【請求項１】展開液を用いて全血中のアルブミンとグリコアルブミンとを同時に測定するための乾式試験片 (test device) であって、支持体上に装着された展開膜へ、血球分離層と，アルブミンを着色する第一の色素とグリコアルブミンを着色する第二の色素を含む試薬層と，アルブミンとグリコアルブミンを捕捉するために両者に対する特異的結合性物質を固定化した測定層と，展開残液を吸収する残液吸収層の各層をこの順序で設けるグリコアルブミン測定用乾式試験片。
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device (試験片) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents for said plurality of analytes.	JPH09113511A CLAIM 1 【請求項１】展開液を用いて全血中のアルブミンとグリコアルブミンとを同時に測定するための乾式試験片 (test device) であって、支持体上に装着された展開膜へ、血球分離層と，アルブミンを着色する第一の色素とグリコアルブミンを着色する第二の色素を含む試薬層と，アルブミンとグリコアルブミンを捕捉するために両者に対する特異的結合性物質を固定化した測定層と，展開残液を吸収する残液吸収層の各層をこの順序で設けるグリコアルブミン測定用乾式試験片。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device (試験片) configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	JPH09113511A CLAIM 1 【請求項１】展開液を用いて全血中のアルブミンとグリコアルブミンとを同時に測定するための乾式試験片 (test device) であって、支持体上に装着された展開膜へ、血球分離層と，アルブミンを着色する第一の色素とグリコアルブミンを着色する第二の色素を含む試薬層と，アルブミンとグリコアルブミンを捕捉するために両者に対する特異的結合性物質を固定化した測定層と，展開残液を吸収する残液吸収層の各層をこの順序で設けるグリコアルブミン測定用乾式試験片。
US8283155B2 CLAIM 37. The system of claim 30 wherein the test device (試験片) further comprises a microneedle useful for collecting the sample.	JPH09113511A CLAIM 1 【請求項１】展開液を用いて全血中のアルブミンとグリコアルブミンとを同時に測定するための乾式試験片 (test device) であって、支持体上に装着された展開膜へ、血球分離層と，アルブミンを着色する第一の色素とグリコアルブミンを着色する第二の色素を含む試薬層と，アルブミンとグリコアルブミンを捕捉するために両者に対する特異的結合性物質を固定化した測定層と，展開残液を吸収する残液吸収層の各層をこの順序で設けるグリコアルブミン測定用乾式試験片。
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device (試験片) is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents for said plurality of analytes.	JPH09113511A CLAIM 1 【請求項１】展開液を用いて全血中のアルブミンとグリコアルブミンとを同時に測定するための乾式試験片 (test device) であって、支持体上に装着された展開膜へ、血球分離層と，アルブミンを着色する第一の色素とグリコアルブミンを着色する第二の色素を含む試薬層と，アルブミンとグリコアルブミンを捕捉するために両者に対する特異的結合性物質を固定化した測定層と，展開残液を吸収する残液吸収層の各層をこの順序で設けるグリコアルブミン測定用乾式試験片。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	CN1146017A Filed: 1996-01-18 Issued: 1997-03-26 毛细管阵列电泳系统 (Original Assignee) 株式会社日立制作所神原秀记, 高桥智, 穴泽隆, 山田尚志, 小原贤信
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit (的样品) configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	CN1146017A CLAIM 2.根据权利要求1的毛细管阵列电泳系统，其中所说的样品 (sample collection unit) 被洗提进入缓冲剂溶液流，所说的激励光照射所说缓冲剂溶液中洗提的样品。
US8283155B2 CLAIM 9. The system of claim 1 wherein the sample collection unit (的样品) collects a sample of bodily fluid which is less than about 500 uL.	CN1146017A CLAIM 2.根据权利要求1的毛细管阵列电泳系统，其中所说的样品 (sample collection unit) 被洗提进入缓冲剂溶液流，所说的激励光照射所说缓冲剂溶液中洗提的样品。
US8283155B2 CLAIM 23. The method of claim 22 further comprising quantifying the amount of said analyte present (一个毛细管) in said sample.	CN1146017A CLAIM 1.一个毛细管 (analyte present) 阵列电泳系统，包括：大量毛细管阵列层，每层具有排列在一行中的大量毛细管电泳道，所说的大量毛细管阵列层的末端，一层重叠在另一层顶上；一个激励光照射邻近的所说末端样品；及一个二维检测器，用来检测从所说样品所发射的荧光。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit (的样品) configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	CN1146017A CLAIM 2.根据权利要求1的毛细管阵列电泳系统，其中所说的样品 (sample collection unit) 被洗提进入缓冲剂溶液流，所说的激励光照射所说缓冲剂溶液中洗提的样品。
US8283155B2 CLAIM 38. The system of claim 30 wherein the sample collection unit (的样品) collects a sample of bodily fluid which is less than about 500 uL.	CN1146017A CLAIM 2.根据权利要求1的毛细管阵列电泳系统，其中所说的样品 (sample collection unit) 被洗提进入缓冲剂溶液流，所说的激励光照射所说缓冲剂溶液中洗提的样品。
US8283155B2 CLAIM 49. The method of claim 48 further comprising quantifying the amount of said analyte present (一个毛细管) in said sample.	CN1146017A CLAIM 1.一个毛细管 (analyte present) 阵列电泳系统，包括：大量毛细管阵列层，每层具有排列在一行中的大量毛细管电泳道，所说的大量毛细管阵列层的末端，一层重叠在另一层顶上；一个激励光照射邻近的所说末端样品；及一个二维检测器，用来检测从所说样品所发射的荧光。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JPH0968533A Filed: 1995-08-31 Issued: 1997-03-11 薬品投与量を表示可能な生化学物質測定装置 (Original Assignee) Brother Ind Ltd; ブラザー工業株式会社 Masaki Yamaguchi, 昌樹山口
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method (検出手段) for detecting said signal, and wherein said reader further comprises a detection assembly (検出手段) for detecting said signal which is transmitted via said communication assembly (少なくとも１) to said external device.	JPH0968533A CLAIM 1 【請求項１】収集された生体の分泌液に含まれる所定の生化学物質の濃度に関連する情報を検出する検出手段 (detection method, detection assembly) と、前記所定の生化学物質に関して前記分泌液中の濃度に関連する情報と血液中の濃度との対応情報を記憶する記憶手段と、前記検出手段により検出された前記生化学物質の濃度に関連する情報と前記記憶手段に記憶された対応情報とに基づき、血液中の前記生化学物質の濃度を算出する算出手段と、生体に投与すべき薬品の投与量を表示可能な表示手段と、前記算出手段により算出された前記生化学物質の濃度に応じて前記表示手段に前記薬品の投与量を表示させる表示制御手段とを備えたことを特徴とする薬品投与量を表示可能な生化学物質測定装置。 JPH0968533A CLAIM 5 【請求項５】前記検出手段は、前記生化学物質を反応させる少なくとも１ (communication assembly) 種類の酵素と、前記反応により生成される生成物の増減を検出するための電極とを備えたことを特徴とする請求項１乃至４のいずれかに記載の薬品投与量を表示可能な生化学物質測定装置。
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method (検出手段) further comprises detecting an optical signal from the sample.	JPH0968533A CLAIM 1 【請求項１】収集された生体の分泌液に含まれる所定の生化学物質の濃度に関連する情報を検出する検出手段 (detection method, detection assembly) と、前記所定の生化学物質に関して前記分泌液中の濃度に関連する情報と血液中の濃度との対応情報を記憶する記憶手段と、前記検出手段により検出された前記生化学物質の濃度に関連する情報と前記記憶手段に記憶された対応情報とに基づき、血液中の前記生化学物質の濃度を算出する算出手段と、生体に投与すべき薬品の投与量を表示可能な表示手段と、前記算出手段により算出された前記生化学物質の濃度に応じて前記表示手段に前記薬品の投与量を表示させる表示制御手段とを備えたことを特徴とする薬品投与量を表示可能な生化学物質測定装置。
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method (検出手段) includes collecting signals from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	JPH0968533A CLAIM 1 【請求項１】収集された生体の分泌液に含まれる所定の生化学物質の濃度に関連する情報を検出する検出手段 (detection method, detection assembly) と、前記所定の生化学物質に関して前記分泌液中の濃度に関連する情報と血液中の濃度との対応情報を記憶する記憶手段と、前記検出手段により検出された前記生化学物質の濃度に関連する情報と前記記憶手段に記憶された対応情報とに基づき、血液中の前記生化学物質の濃度を算出する算出手段と、生体に投与すべき薬品の投与量を表示可能な表示手段と、前記算出手段により算出された前記生化学物質の濃度に応じて前記表示手段に前記薬品の投与量を表示させる表示制御手段とを備えたことを特徴とする薬品投与量を表示可能な生化学物質測定装置。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly (検出手段) for detecting said signal which is transmitted via said communication assembly (少なくとも１) to said external device.	JPH0968533A CLAIM 1 【請求項１】収集された生体の分泌液に含まれる所定の生化学物質の濃度に関連する情報を検出する検出手段 (detection method, detection assembly) と、前記所定の生化学物質に関して前記分泌液中の濃度に関連する情報と血液中の濃度との対応情報を記憶する記憶手段と、前記検出手段により検出された前記生化学物質の濃度に関連する情報と前記記憶手段に記憶された対応情報とに基づき、血液中の前記生化学物質の濃度を算出する算出手段と、生体に投与すべき薬品の投与量を表示可能な表示手段と、前記算出手段により算出された前記生化学物質の濃度に応じて前記表示手段に前記薬品の投与量を表示させる表示制御手段とを備えたことを特徴とする薬品投与量を表示可能な生化学物質測定装置。 JPH0968533A CLAIM 5 【請求項５】前記検出手段は、前記生化学物質を反応させる少なくとも１ (communication assembly) 種類の酵素と、前記反応により生成される生成物の増減を検出するための電極とを備えたことを特徴とする請求項１乃至４のいずれかに記載の薬品投与量を表示可能な生化学物質測定装置。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	EP0734017A1 Filed: 1996-03-18 Issued: 1996-09-25 Storage device (Original Assignee) HP Inc (Current Assignee) HP Inc Gary Gibson, Theodore I. Kamins, Marvin S. Keshner, Steven L. Neberhuls, Craig M. Perlov, Chung Ching Yang
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method (constant current source) for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	EP0734017A1 CLAIM 4 A storage device as recited in claim 2, comprising: a constant current source (detection method, board calibration) (154) connected to the field emitter (102) operable to control the magnitude of the electron beam current (156).
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method (constant current source) further comprises detecting an optical signal from the sample.	EP0734017A1 CLAIM 4 A storage device as recited in claim 2, comprising: a constant current source (detection method, board calibration) (154) connected to the field emitter (102) operable to control the magnitude of the electron beam current (156).
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method (constant current source) includes collecting signals from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	EP0734017A1 CLAIM 4 A storage device as recited in claim 2, comprising: a constant current source (detection method, board calibration) (154) connected to the field emitter (102) operable to control the magnitude of the electron beam current (156).

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JPH07196314A Filed: 1993-12-28 Issued: 1995-08-01 チューブ状合成無機微粒子 (Original Assignee) Maruo Calcium Co Ltd; 丸尾カルシウム株式会社 Minoru Hanazaki, Kayoko Hashimoto, Shiro Motoyoshi, Hiroshi Shibata, 洋志柴田, 佳代子橋本, 嗣郎源吉, 実花崎
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly (少なくとも１) to said external device.	JPH07196314A CLAIM 3 【請求項３】合成無機微粒子が燐酸塩、フッ化塩、珪酸塩、硫酸塩、炭酸塩、ペロブスカイト塩（ＭＴｉＯ 3 、Ｍ＝２価の金属）、シュウ酸塩及び水酸化物であるアルカリ土類金属塩、燐酸塩、珪酸塩及び水酸化物であるアルミニウ塩、珪酸及び珪酸水和物からなる群から選ばれる少なくとも１ (communication assembly) 種で主として構成される請求項１又は２記載のチューブ状合成無機微粒子。
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid reagents (ヒドロキシアパタイト, １０００) immobilized within the assay assembly.	JPH07196314A CLAIM 1 【請求項１】針状及び／又は柱状の形状であり、内部に中空状空間が存在し、且つ、下記の式（ａ）〜（ｅ）の物性を満足する、チューブ状合成無機微粒子。（ａ）０．１≦ＤＳ１≦１０００ (nucleic acid reagents) （μｍ）（ｂ）０．０５≦ＤＳ２≦１００（μｍ）（ｃ）０．０２≦ＤＳ３≦９５（μｍ）（ｄ）ＤＳ１／ＤＳ２≧２（ｅ）０．０５≦ＤＳ３／ＤＳ２≦０．９５但し、ＤＳ１：電子顕微鏡写真により測定したチューブ状合成無機微粒子の長径の平均粒子径（μｍ）。ＤＳ２：電子顕微鏡写真により測定したチューブ状合成無機微粒子の外径（短径）の平均粒子径（μｍ）。ＤＳ３：電子顕微鏡写真により測定したチューブ状合成無機微粒子の内径の平均粒子径（μｍ）。ＤＳ１／ＤＳ２：チューブ状合成無機微粒子の長径と短径のアスペクト比を表す値。ＤＳ３／ＤＳ２：チューブ状合成無機微粒子の内径と外径の割合を表す値。 JPH07196314A CLAIM 5 【請求項５】ヒドロキシアパタイト (nucleic acid reagents) 及び／又はフルオロアパタイトで主として構成される請求項１又は２記載のチューブ状合成無機微粒子。
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents (ヒドロキシアパタイト, １０００) for said plurality of analytes.	JPH07196314A CLAIM 1 【請求項１】針状及び／又は柱状の形状であり、内部に中空状空間が存在し、且つ、下記の式（ａ）〜（ｅ）の物性を満足する、チューブ状合成無機微粒子。（ａ）０．１≦ＤＳ１≦１０００ (nucleic acid reagents) （μｍ）（ｂ）０．０５≦ＤＳ２≦１００（μｍ）（ｃ）０．０２≦ＤＳ３≦９５（μｍ）（ｄ）ＤＳ１／ＤＳ２≧２（ｅ）０．０５≦ＤＳ３／ＤＳ２≦０．９５但し、ＤＳ１：電子顕微鏡写真により測定したチューブ状合成無機微粒子の長径の平均粒子径（μｍ）。ＤＳ２：電子顕微鏡写真により測定したチューブ状合成無機微粒子の外径（短径）の平均粒子径（μｍ）。ＤＳ３：電子顕微鏡写真により測定したチューブ状合成無機微粒子の内径の平均粒子径（μｍ）。ＤＳ１／ＤＳ２：チューブ状合成無機微粒子の長径と短径のアスペクト比を表す値。ＤＳ３／ＤＳ２：チューブ状合成無機微粒子の内径と外径の割合を表す値。 JPH07196314A CLAIM 5 【請求項５】ヒドロキシアパタイト (nucleic acid reagents) 及び／又はフルオロアパタイトで主として構成される請求項１又は２記載のチューブ状合成無機微粒子。
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly (少なくとも１) to said external device.	JPH07196314A CLAIM 3 【請求項３】合成無機微粒子が燐酸塩、フッ化塩、珪酸塩、硫酸塩、炭酸塩、ペロブスカイト塩（ＭＴｉＯ 3 、Ｍ＝２価の金属）、シュウ酸塩及び水酸化物であるアルカリ土類金属塩、燐酸塩、珪酸塩及び水酸化物であるアルミニウ塩、珪酸及び珪酸水和物からなる群から選ばれる少なくとも１ (communication assembly) 種で主として構成される請求項１又は２記載のチューブ状合成無機微粒子。
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid reagents (ヒドロキシアパタイト, １０００) immobilized within the assay assembly.	JPH07196314A CLAIM 1 【請求項１】針状及び／又は柱状の形状であり、内部に中空状空間が存在し、且つ、下記の式（ａ）〜（ｅ）の物性を満足する、チューブ状合成無機微粒子。（ａ）０．１≦ＤＳ１≦１０００ (nucleic acid reagents) （μｍ）（ｂ）０．０５≦ＤＳ２≦１００（μｍ）（ｃ）０．０２≦ＤＳ３≦９５（μｍ）（ｄ）ＤＳ１／ＤＳ２≧２（ｅ）０．０５≦ＤＳ３／ＤＳ２≦０．９５但し、ＤＳ１：電子顕微鏡写真により測定したチューブ状合成無機微粒子の長径の平均粒子径（μｍ）。ＤＳ２：電子顕微鏡写真により測定したチューブ状合成無機微粒子の外径（短径）の平均粒子径（μｍ）。ＤＳ３：電子顕微鏡写真により測定したチューブ状合成無機微粒子の内径の平均粒子径（μｍ）。ＤＳ１／ＤＳ２：チューブ状合成無機微粒子の長径と短径のアスペクト比を表す値。ＤＳ３／ＤＳ２：チューブ状合成無機微粒子の内径と外径の割合を表す値。 JPH07196314A CLAIM 5 【請求項５】ヒドロキシアパタイト (nucleic acid reagents) 及び／又はフルオロアパタイトで主として構成される請求項１又は２記載のチューブ状合成無機微粒子。
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid reagents (ヒドロキシアパタイト, １０００) for said plurality of analytes.	JPH07196314A CLAIM 1 【請求項１】針状及び／又は柱状の形状であり、内部に中空状空間が存在し、且つ、下記の式（ａ）〜（ｅ）の物性を満足する、チューブ状合成無機微粒子。（ａ）０．１≦ＤＳ１≦１０００ (nucleic acid reagents) （μｍ）（ｂ）０．０５≦ＤＳ２≦１００（μｍ）（ｃ）０．０２≦ＤＳ３≦９５（μｍ）（ｄ）ＤＳ１／ＤＳ２≧２（ｅ）０．０５≦ＤＳ３／ＤＳ２≦０．９５但し、ＤＳ１：電子顕微鏡写真により測定したチューブ状合成無機微粒子の長径の平均粒子径（μｍ）。ＤＳ２：電子顕微鏡写真により測定したチューブ状合成無機微粒子の外径（短径）の平均粒子径（μｍ）。ＤＳ３：電子顕微鏡写真により測定したチューブ状合成無機微粒子の内径の平均粒子径（μｍ）。ＤＳ１／ＤＳ２：チューブ状合成無機微粒子の長径と短径のアスペクト比を表す値。ＤＳ３／ＤＳ２：チューブ状合成無機微粒子の内径と外径の割合を表す値。 JPH07196314A CLAIM 5 【請求項５】ヒドロキシアパタイト (nucleic acid reagents) 及び／又はフルオロアパタイトで主として構成される請求項１又は２記載のチューブ状合成無機微粒子。

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	JPH07151101A Filed: 1993-11-29 Issued: 1995-06-13 ダイヤフラム接触面が渦巻状の容器 (Original Assignee) Kazuo Sugimura; Nobuyuki Sugimura; Tomu Sugimura; 一夫杉村; 宣行杉村; 登夢杉村 Kazuo Sugimura, Nobuyuki Sugimura, Tomu Sugimura, 一夫杉村, 宣行杉村, 登夢杉村
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method (スタート) for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	JPH07151101A CLAIM 1 【請求項１】素材板中心円形部の周りに隣接して、その周方向均等分位の少なくとも２点からスタート (detection method) した同心の渦巻状波紋が形成された渦巻状ダイヤフラムが、凹所を有する二つの容器によって挟持され、前記渦巻状ダイヤフラムと相対する容器の凹所の壁面形状を、前記渦巻状ダイヤフラムが前記壁面に接触するときの変形形状に合致した形状に形成したダイヤフラム接触面が渦巻状の容器。
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method (スタート) further comprises detecting an optical signal from the sample.	JPH07151101A CLAIM 1 【請求項１】素材板中心円形部の周りに隣接して、その周方向均等分位の少なくとも２点からスタート (detection method) した同心の渦巻状波紋が形成された渦巻状ダイヤフラムが、凹所を有する二つの容器によって挟持され、前記渦巻状ダイヤフラムと相対する容器の凹所の壁面形状を、前記渦巻状ダイヤフラムが前記壁面に接触するときの変形形状に合致した形状に形成したダイヤフラム接触面が渦巻状の容器。
US8283155B2 CLAIM 19. The system of claim 1 wherein the detection method (スタート) includes collecting signals from sensors, which may be selected from one or more of the following: temperature, conductivity, potentiometric, or amperometric.	JPH07151101A CLAIM 1 【請求項１】素材板中心円形部の周りに隣接して、その周方向均等分位の少なくとも２点からスタート (detection method) した同心の渦巻状波紋が形成された渦巻状ダイヤフラムが、凹所を有する二つの容器によって挟持され、前記渦巻状ダイヤフラムと相対する容器の凹所の壁面形状を、前記渦巻状ダイヤフラムが前記壁面に接触するときの変形形状に合致した形状に形成したダイヤフラム接触面が渦巻状の容器。

JPH07120393A

Filed: 1993-10-13 Issued: 1995-05-12

蛍光検出法

(Original Assignee) Nippon Tectron Co Ltd; 日本テクトロン株式会社

Yoshio Kawai, 義雄河合

US8283155B2
CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly (光検出) for detecting said signal which is transmitted via said communication assembly to said external device.

JPH07120393A
CLAIM 1 【請求項１】多点の蛍光を測定するに当り、蛍光発光の場より光ファイバーを用いて少数の光検出 (detection assembly) 素子に導き、各点の励起光光源を順番に測定に必要な時間点灯させることにより測定点を順次切換えることにより、可動部分なしに多点の蛍光を測定することを特徴とする蛍光検出法。

US8283155B2
CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly (光検出) for detecting said signal which is transmitted via said communication assembly to said external device.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	EP0652600A1 Filed: 1994-11-02 Issued: 1995-05-10 Aggregate of semiconductor micro-needles and method of manufacturing the same, and semiconductor apparatus and method of manufacturing the same (Original Assignee) Panasonic Corp (Current Assignee) Panasonic Corp Koji Eriguchi, Masafumi Kubota, Masaaki Niwa, Noboru Nomura
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method further comprises detecting an optical signal (optical signal) from the sample.	EP0652600A1 CLAIM 11 A semiconductor apparatus according to claim 10, further comprising optical-signal generating means for generating a first optical signal (optical signal) so that the first signal is made incident upon said quantized region, wherein said first quantized region receives the first optical signal from said optical-signal generating means and generates a second optical signal.
US8283155B2 CLAIM 18. The system of claim 17 wherein the optical signal (optical signal) is a chemiluminscent signal.	EP0652600A1 CLAIM 11 A semiconductor apparatus according to claim 10, further comprising optical-signal generating means for generating a first optical signal (optical signal) so that the first signal is made incident upon said quantized region, wherein said first quantized region receives the first optical signal from said optical-signal generating means and generates a second optical signal.

JPH07103959A

Filed: 1993-10-05 Issued: 1995-04-21

クロマトグラム解析方法およびクロマトグラフ装置およびこれらに用いられるデータ処理装置

(Original Assignee) Hitachi Ltd; 株式会社日立製作所

Kisaburo Deguchi, Masato Ito, Junkichi Miura, 順吉三浦, 正人伊藤, 喜三郎出口

US8283155B2
CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor (メモリ) that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.

JPH07103959A
CLAIM 23 【請求項２３】Ａ／Ｄ変換部と、メモリ (programmable processor) 部と、制御部と、インタフエイース部と、出力機器等からなるクマトグラム解析方法およびクロマトグラフ装置に用いられるデ−タ処理装置において、前記クマトグラムの検出ピ−ク波形から拡がりを表わす関数ｈ（ｔ）を算出・出力し、検出ピ−ク波形および前記関数ｈ（ｔ）を用いて前記検出ピ−ク波形をディコンボリュ−ション処理し、ディコンボリュ−ション処理後のクロマトグラムを出力することを特徴とするクマトグラム解析方法およびクロマトグラフ装置に用いられるデ −タ処理装置。

US8283155B2
CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor (メモリ) that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	EP0640828A1 Filed: 1994-08-16 Issued: 1995-03-01 Monitoring multiple reactions simultaneously and analyzing same (Original Assignee) F Hoffmann La Roche AG (Current Assignee) Applera Corp Russell G. Higuchi, Robert M. Watson
US8283155B2 CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit (excitation light source) configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly containing reactants that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	EP0640828A1 CLAIM 13 An apparatus according to claim 12 wherein said dichroic mirror is transmissive to light having a wavelength corresponding to the wavelength of light generated by the excitation light source (sample collection unit) and reflective to light having a wavelength corresponding to the wavelength of fluorescence emitted from a nucleic acid amplification mixture when that mixture is disposed in one of said recesses and exposed to light from the light source.
US8283155B2 CLAIM 9. The system of claim 1 wherein the sample collection unit (excitation light source) collects a sample of bodily fluid which is less than about 500 uL.	EP0640828A1 CLAIM 13 An apparatus according to claim 12 wherein said dichroic mirror is transmissive to light having a wavelength corresponding to the wavelength of light generated by the excitation light source (sample collection unit) and reflective to light having a wavelength corresponding to the wavelength of fluorescence emitted from a nucleic acid amplification mixture when that mixture is disposed in one of said recesses and exposed to light from the light source.
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid amplification reaction) reagents immobilized within the assay assembly.	EP0640828A1 CLAIM 4 An apparatus according to claim 1 characterized in that it further comprises means for cycling the temperature of said heat conducting member according to a preselected temperature versus time profile for multiple cycles and multiple nucleic acid amplification reaction (nucleic acid, nucleic acid reagents) mixtures, each comprising a fluorescent binding agent, each mixture being disposed in a different one of said recesses; and in that said light source provides an essentially uniform light flux over a portion of said heat conducting member and a number of said reaction mixtures; and said sensor is optically coupled to said heat conducting member for detecting fluorescence emitted from each amplification reaction mixture excited by said light flux, simultaneously.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid amplification reaction) reagents for said plurality of analytes.	EP0640828A1 CLAIM 4 An apparatus according to claim 1 characterized in that it further comprises means for cycling the temperature of said heat conducting member according to a preselected temperature versus time profile for multiple cycles and multiple nucleic acid amplification reaction (nucleic acid, nucleic acid reagents) mixtures, each comprising a fluorescent binding agent, each mixture being disposed in a different one of said recesses; and in that said light source provides an essentially uniform light flux over a portion of said heat conducting member and a number of said reaction mixtures; and said sensor is optically coupled to said heat conducting member for detecting fluorescence emitted from each amplification reaction mixture excited by said light flux, simultaneously.
US8283155B2 CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly; b) an external device configured to transmit a protocol to the communication assembly; c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit (excitation light source) configured for collecting a sample of bodily fluid suspected to contain an analyte; ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte; and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier; wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.	EP0640828A1 CLAIM 13 An apparatus according to claim 12 wherein said dichroic mirror is transmissive to light having a wavelength corresponding to the wavelength of light generated by the excitation light source (sample collection unit) and reflective to light having a wavelength corresponding to the wavelength of fluorescence emitted from a nucleic acid amplification mixture when that mixture is disposed in one of said recesses and exposed to light from the light source.
US8283155B2 CLAIM 38. The system of claim 30 wherein the sample collection unit (excitation light source) collects a sample of bodily fluid which is less than about 500 uL.	EP0640828A1 CLAIM 13 An apparatus according to claim 12 wherein said dichroic mirror is transmissive to light having a wavelength corresponding to the wavelength of light generated by the excitation light source (sample collection unit) and reflective to light having a wavelength corresponding to the wavelength of fluorescence emitted from a nucleic acid amplification mixture when that mixture is disposed in one of said recesses and exposed to light from the light source.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid amplification reaction) reagents immobilized within the assay assembly.	EP0640828A1 CLAIM 4 An apparatus according to claim 1 characterized in that it further comprises means for cycling the temperature of said heat conducting member according to a preselected temperature versus time profile for multiple cycles and multiple nucleic acid amplification reaction (nucleic acid, nucleic acid reagents) mixtures, each comprising a fluorescent binding agent, each mixture being disposed in a different one of said recesses; and in that said light source provides an essentially uniform light flux over a portion of said heat conducting member and a number of said reaction mixtures; and said sensor is optically coupled to said heat conducting member for detecting fluorescence emitted from each amplification reaction mixture excited by said light flux, simultaneously.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid amplification reaction) reagents for said plurality of analytes.	EP0640828A1 CLAIM 4 An apparatus according to claim 1 characterized in that it further comprises means for cycling the temperature of said heat conducting member according to a preselected temperature versus time profile for multiple cycles and multiple nucleic acid amplification reaction (nucleic acid, nucleic acid reagents) mixtures, each comprising a fluorescent binding agent, each mixture being disposed in a different one of said recesses; and in that said light source provides an essentially uniform light flux over a portion of said heat conducting member and a number of said reaction mixtures; and said sensor is optically coupled to said heat conducting member for detecting fluorescence emitted from each amplification reaction mixture excited by said light flux, simultaneously.

EP0631137A2

Filed: 1994-05-31 Issued: 1994-12-28

Glucose related measurement method and apparatus

(Original Assignee) Edward W. Stark

Edward W. Stark

US8283155B2
CLAIM 1. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly containing reactants (second electrical signal) that react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects (1) a reaction in said assay assembly for generating said signal, and (2) selection of a detection method for detecting said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.

EP0631137A2
CLAIM 1 A method of determining stable and labile glycated compound levels in blood comprising the steps of: a) supplying a source of electromagnetic energy covering a multiplicity of wavelength bands within a wavelength range from 380 nm to 2500 nm; b) directing the electromagnetic energy from said source into a sample volume containing blood; c) collecting a first portion of said energy representative of said source energy; d) collecting a second portion of said energy after it has interacted with material within said sample volume, said second portion carrying information relating to the levels of labile and stable glycated compounds within said sample volume; e) converting said first portion into first electrical signals representative of intensity of said first portions in each of said multiplicity of wavelength bands; f) converting said second portion into second electrical signal (assay assembly containing reactants) s representative of intensity of said second portion in each of said multiplicity of wavelength bands; g) pretreating said electrical signals in accordance with known information to remove deviations from established reference conditions to form data signals that are a function of the fractional portion of the energy in each of said wavelength bands absorbed and scattered by said material in said measurement volume; h) processing selected groups of said data signals in accordance with chemometric models developed from analysis of such data signals together with known values of the analytes derived from measurements on a calibration set of samples larger in number than the number of wavelength bands included in the set of said selected groups of data signals to develop analyte signals representative of the amounts of glycated compounds for which chemometric models have been developed and utilized; and, i) storing and displaying said analyte signals in a form suitable for medical use.

US8283155B2
CLAIM 30. A two-way communication system for detecting an analyte in a bodily fluid from a subject, comprising: a) a reader assembly comprising a programmable processor that is operably linked to a communication assembly;

b) an external device configured to transmit a protocol to the communication assembly;

c) a test device configured to be inserted into the reader assembly, said test device comprising: i) a sample collection unit configured for collecting a sample of bodily fluid suspected to contain an analyte;

ii) an assay assembly configured to run a plurality of assays, said assay assembly containing reactants (second electrical signal) for conducting said plurality of assays, wherein said reactants react with said sample of bodily fluid based on the protocol transmitted from said external device to yield a detectable signal indicative of the presence and/or concentration of said analyte;

and iii) an identifier that is configured to provide the identity of said test device and is also configured to trigger the transmission of said protocol that is selected based on said identifier;

wherein the programmable processor of the reader assembly is configured to receive said protocol from said external device, wherein said protocol in turn effects a selection of at least one assay from said plurality of assays to be run with said assay assembly for generating said signal, and wherein said reader further comprises a detection assembly for detecting said signal which is transmitted via said communication assembly to said external device.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	EP0576602A1 Filed: 1992-02-18 Issued: 1994-01-05 A device and a method for separating liquid samples. (Original Assignee) 3M Co (Current Assignee) DIAGEN INSTITUT FUER MOLEKULARBIOLOGISCHE DIAGNOS ; 3M Co James E Aysta, Metin Colpan
US8283155B2 CLAIM 12. The system of claim 1 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	EP0576602A1 CLAIM 11. The device of claim 1 wherein said liquid sample comprises components selected from the class consisting of nucleic acid (nucleic acid) s or proteins of plant, animal or human cells and wherein said separation layer (28) comprises a material for selectively adsorbing at least one of said components in said liquid sample.
US8283155B2 CLAIM 13. The system of claim 1 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	EP0576602A1 CLAIM 11. The device of claim 1 wherein said liquid sample comprises components selected from the class consisting of nucleic acid (nucleic acid) s or proteins of plant, animal or human cells and wherein said separation layer (28) comprises a material for selectively adsorbing at least one of said components in said liquid sample.
US8283155B2 CLAIM 41. The system of claim 30 wherein said reactants comprise immunoassay or nucleic acid (nucleic acid) reagents immobilized within the assay assembly.	EP0576602A1 CLAIM 11. The device of claim 1 wherein said liquid sample comprises components selected from the class consisting of nucleic acid (nucleic acid) s or proteins of plant, animal or human cells and wherein said separation layer (28) comprises a material for selectively adsorbing at least one of said components in said liquid sample.
US8283155B2 CLAIM 42. The system of claim 30 wherein the test device is configured to detect a plurality of analytes and said test device comprises immunoassay or nucleic acid (nucleic acid) reagents for said plurality of analytes.	EP0576602A1 CLAIM 11. The device of claim 1 wherein said liquid sample comprises components selected from the class consisting of nucleic acid (nucleic acid) s or proteins of plant, animal or human cells and wherein said separation layer (28) comprises a material for selectively adsorbing at least one of said components in said liquid sample.

US8283155B2 Filed: 2005-05-09 Issued: 2012-10-09 Point-of-care fluidic systems and uses thereof (Original Assignee) Theranos Inc (Current Assignee) Theranos IP Co LLC Elizabeth A. Holmes, Shaunak Roy, John Howard, Chengwang Wang, Ian Gibbons, Timothy M. Kemp, Shize Daniel Qi	EP0571225A2 Filed: 1993-05-21 Issued: 1993-11-24 Measurement device and method of calibration (Original Assignee) Puritan Bennett Corp (Current Assignee) Puritan Bennett Corp Edwin B. Merrick, Amal Jeryes, Neal B. Dowling, Jr., Yuan Young, Larry Powell
US8283155B2 CLAIM 17. The system of claim 1 wherein the detection method further comprises detecting an optical signal (optical signal) from the sample.	EP0571225A2 CLAIM 3 The measurement apparatus of claim 1 or claim 2, wherein said sensor component generates an optical signal (optical signal) and wherein said first and said second memory means store calibration data electronically.
US8283155B2 CLAIM 18. The system of claim 17 wherein the optical signal (optical signal) is a chemiluminscent signal.	EP0571225A2 CLAIM 3 The measurement apparatus of claim 1 or claim 2, wherein said sensor component generates an optical signal (optical signal) and wherein said first and said second memory means store calibration data electronically.